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Introduction from the National Director of Finance
During 2006 the Primary Care Reimbursement 
Service (PCRS) continued to support the single 
largest reform project undertaken in the State, 
offering an unparalleled opportunity to modernise 
and improve health service provision to the public 
in support of the Health Service Executive’s overall 
strategy to make it easier for people to access 
appropriate healthcare services when and where they 
need them. 
The PCRS supports the delivery of primary health 
care by providing reimbursement services to primary 
care contractors for the provision of health services 
to members of the public in their own community. 
Every year almost everybody in Ireland uses one 
or more of the services provided by the Health 
Service Executive (HSE). In 2006 over 2.26 million 
persons used the services of primary care contractors 
for which reimbursement was provided by the 
PCRS. In 2006 the PCRS processed in excess of 60 
million transactions with associated expenditure of 
€2.1 billion. With the fastest growing population in 
the European Union, it is anticipated that expenditure 
will continue to grow.
In addition to the processing and making of payments 
on a national basis to key customers, including 
General Practitioners, Pharmacists, Dentists and 
Optometrists/Ophthalmologists, the PCRS compiles 
statistics and trend analyses which are provided 
to other areas within the HSE, the Government, 
customers, stakeholders and to members of the 
public. 
Throughout 2006 we have continued to work 
with our customers to improve the provision of 
services by combining appropriate technology with 
a professional service and efficient delivery. The 
PCRS has rolled out a number of new initiatives, 
further building on the electronic transmission of 
contractor claims and systems to provide additional 
information and client eligibility services to primary 
care contractors and others.
During the year the PCRS continued to play an 
important role in supporting the management 
of the various schemes, which are becoming 
increasingly complex, and assisted in rolling out 
new initiatives to support both the modernisation 
and the transformation agendas of the HSE. This 
Statistical Analysis Publication reflects the many and 
varied Schemes and Payment Systems currently in 
operation. 
I would like to take this opportunity to thank 
everybody in the organisation for their important 
individual contribution and commitment, and their 
team efforts in the delivery of these vital support 
services, which ultimately enable members of the 
public to access the health services that they need 
in their own community. I would also like to 
acknowledge the contribution of my fellow Directors 
and the support of the HSE Board throughout 
2006. Once again the goodwill and co-operation 
received from all of our customers, General 
Practitioners, Pharmacists, Dentists, Optometrists/
Ophthalmologists is very much appreciated. 
I look forward to continuing to build on our success 
and striving to improve the services to our customers 
even further. 
Liam Woods 
National Director of Finance
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Community Based Services – Payment Arrangements
Almost all payments for services provided in the 
community by General Practitioners, Community 
Pharmacies, Dentists and Optometrists/ 
Ophthalmologists are made by the Primary Care 
Reimbursement Service. Payments in the Year 2006 
were in excess of €2.07bn. Estimated payments by 
the Primary Care Reimbursement Service for 2007 
are €2.26bn.
Claim data is processed and payments are made by 
the Primary Care Reimbursement Service under the 
following Schemes/Payment Arrangements:
General Medical Services (GMS)
Persons who are unable without undue hardship to 
arrange general practitioner medical and surgical 
services for themselves and their dependants and all 
persons aged 70 years and over receive a free general 
medical service.
Drugs, medicines and appliances supplied under the 
Scheme are provided through retail pharmacies. In 
most cases the Doctor gives a completed prescription 
form to a person, who takes it to any pharmacy that 
has an agreement with the Health Service Executive 
to dispense GMS prescription forms. In rural areas 
the Doctor may dispense for those persons who opt 
to have their medicines dispensed by him/her. All 
GMS claims are processed and paid by the Primary 
Care Reimbursement Service. 
Drugs Payment Scheme (DPS)
Under the Drugs Payment Scheme persons who are 
ordinarily resident in the State and who do not have 
a current medical card can benefit - an individual 
or family has now to pay no more than €85 in 
a calendar month for approved drugs, medicines 
and appliances for themselves or their families. In 
order to benefit under this Scheme a person must 
register themselves and their dependants with their 
Local Health Office. Items currently reimbursable 
under the Drugs Payment Scheme are those listed 
in the GMS Code Book. Other items which were 
reimbursable under the DCS and Refund of Drugs 
Schemes continue, in certain circumstances, to be 
reimbursable under the Drugs Payment Scheme. 
DPS claims are processed and paid by the Primary 
Care Reimbursement Service. 
Long Term Illness Scheme (LTI)
On approval by the Health Service Executive 
persons who suffer from one or more of a schedule 
of illnesses are entitled to obtain, without charge, 
irrespective of income, necessary drugs/medicines 
and/or appliances under the LTI Scheme. All LTI 
claims are processed and paid by the Primary Care 
Reimbursement Service.
Dental Treatment Services Scheme (DTSS)
Under the Dental Treatment Services Scheme GMS 
eligible adults have access to a range of treatments 
and clinical procedures comprised of Routine 
Treatments and Full Upper and Lower Dentures. 
Routine Treatments are now available for all eligible 
persons. Dentists may also prescribe a range of 
medicines to eligible persons. All claims under the 
DTSS are processed and paid by the Primary Care 
Reimbursement Service. 
European Economic Area (EEA)
Residents from one of the other states of the 
European Economic Area, with established eligibility, 
who require emergency general practitioner services 
while on a temporary visit to the State are entitled 
to receive from a General Practitioner a GMS 
prescription form for necessary medication and 
to have such medication dispensed in a Pharmacy 
that has entered into an agreement with the Health 
Service Executive within the State. Students, posted 
workers and their dependants are entitled to full 
services on presentation of a valid Form E128. EEA 
claims are paid by the Primary Care Reimbursement 
Service. 
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High Tech Drugs (HTD)
Arrangements are in place for the supply and 
dispensing of High Tech medicines through 
Community Pharmacies. Such medicines are 
generally only prescribed or initiated in hospital 
and would include items such as anti-rejection 
drugs for transplant patients or medicines used 
in conjunction with chemotherapy or growth 
hormones. The medicines are purchased by the 
Health Service Executive and supplied through 
Community Pharmacies for which Pharmacists are 
paid a patient care fee: the cost of the medicines 
and patient care fees are paid by the Primary Care 
Reimbursement Service.
Primary Childhood Immunisation Scheme
A National Primary Childhood Immunisation 
Scheme provides for immunisation of the total 
child population with the aim of eliminating, as 
far as possible, such conditions as Diphtheria, 
Polio, Measles, Mumps, Rubella and more recently 
Meningococcal C Meningitis. Payments under this 
Scheme to Doctors in the Midland, Mid-Western, 
Southern and Western HSE Areas are made by the 
Primary Care Reimbursement Service.
Health (Amendment) Act 1996
Under the Health (Amendment) Act 1996 certain 
health services are made available without charge to 
persons who have contracted Hepatitis C directly or 
indirectly from the use of Human Immunoglobulin - 
Anti D or the receipt within the State of another blood 
product or blood transfusion. General Practitioner 
services, pharmaceutical services, dental services and 
optometric/ophthalmic services provided under the 
Act are paid for by the Primary Care Reimbursement 
Service.
Methadone Treatment Scheme
Methadone is prescribed and dispensed by Doctors 
and Pharmacists for approved clients under the 
Methadone Treatment Scheme - capitation fees 
payable to participating Doctors and Community 
Pharmacists and claims by pharmacies for the 
ingredient cost of the Methadone dispensed and the 
associated dispensing fees are processed and paid by 
the Primary Care Reimbursement Service.
Health Service Executive Community 
Ophthalmic Services Scheme (HSE-COS)
Under the Health Service Executive Community 
Ophthalmic Services Scheme, adult medical card 
holders and their dependants are entitled, free 
of charge, to eye examinations and necessary 
spectacles/appliances. Claims by Optometrists/ 
Ophthalmologists are paid by the Primary Care 
Reimbursement Service. Claims for spectacles 
provided under the Children’s Scheme are also paid 
by the Primary Care Reimbursement Service.
Immunisations for certain GMS Eligible 
Persons
Agreement was reached between the Department 
of Health & Children and the Irish Medical 
Organisation on fee rates to be applied to certain 
immunisations for GMS eligible persons. The 
immunisations encompassed by the agreement 
are:- Pneumococcal, Influenza, Hepatitis B and 
the combined Pneumococcal/Influenza. The Health 
Service Executive facilitated claiming for any of 
these immunisations by extending the range of codes 
for ‘Special Items of Service’.
General Practitioner Visit Card (GPVC)
Certain people in Ireland who do not qualify for 
a medical card may apply to the Health Service 
Executive for a GP Visit Card. GP Visit Cards 
allow individuals and families who qualify, to 
visit their General Practitioner for free. All GP 
claims are processed and paid by the Primary Care 
Reimbursement Service.
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Summary Statement of Activity During the Year
● Payments in the Year were in excess of 
€2,075.16m.
● Claim data is processed and payments are made 
by the PCRS under the following Schemes:
■ General Medical Services (GMS);
■ Drugs Payment (DP); 
■ Long Term Illness (LTI);
■ Dental Treatment Services (DTS);
■ European Economic Area (EEA);
■ High Tech Drugs (HTD);
■ Primary Childhood Immunisation;
■ Health (Amendment) Act 1996;
■ Methadone Treatment;
■ Health Service Executive Community 
Ophthalmic Services (HSE-COS).
● At year end there were more than 2.91m 
persons registered as being eligible to benefit 
under the General Medical Services, Drugs 
Payment, Long Term Illness, Dental Treatment 
and Health Service Executive Community 
Ophthalmic Services Schemes.
● More than 95% of eligible GMS persons 
availed of GP, Pharmaceutical, Dental or 
Ophthalmic services provided by more than 
5,811 Doctors, Pharmacists, Dentists and 
Optometrists/Ophthalmologists.
● More than 55m prescription items were paid 
for by the PCRS - an increase of over 4.7m 
items on 2005.
● Fees and allowances paid to Doctors totalled 
€404.72m.
● Payments to Pharmacies totalled €1,365.17m:
■ GMS €940.22m;
■ DP €285.79m;
■ LTI €115.46m;
■ EEA €2.11m;
■ Patient Care Fees under the HTD Scheme 
€10.51m;
■ The Health (Amendment) Act 1996, 
Methadone Treatment Scheme, DTS 
prescriptions and Pharmacy Training 
Grants €11.08m.
● Payments to Dentists under the DTS totalled 
€55.50m.
● Payments to Optometrists/Ophthalmologists 
under the HSE-COS totalled €18m.
● Payments to Wholesalers under the HTD 
Scheme totalled €207.25m.
● Administration costs in the accounting period 
of 2006 were €14.46m.
● Claims processed are in respect of services 
provided in the community and availed of by 
almost 53.41% of the population.
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The Year 2006
Doctors Fees 282.25m
 Allowances 122.47m
Pharmacists Fees and Mark-Up  321.74m
 Drugs and Medicines 1,032.92m
Dentists  55.50m
High Tech Drugs Scheme Payment to Wholesalers 207.25m 
Patient Care Fees paid to Pharmacists 10.51m
Optometrists/Ophthalmologists 18.00m
Administration  14.46m
Investment in General Practice Development 10.06m
Total of Payments for the year €2,075.16m
● Fees to Doctors include an amount of €7.01m in 
respect of the Primary Childhood Immunisation 
Scheme, €0.22m in respect of the Health 
(Amendment) Act 1996, €4.88m in respect of 
the Methadone Treatment Scheme.
● Allowances paid to Doctors include an amount 
of €6.38m paid as superannuation to Retired 
District Medical Officers and their dependants.
● Payments to Pharmacists include an amount of 
€1.66m in respect of drugs/medicines dispensed 
under the Health (Amendment) Act 1996, an 
amount of €8.50m in respect of the cost of 
Methadone dispensed under the Methadone 
Treatment Scheme and an amount of €0.72m  
in respect of DTS prescriptions.
● Payments to Dentists include an amount of 
€51,832 in respect of treatments under the 
Health (Amendment) Act 1996.
● Payments to Optometrists/Ophthalmologists 
include an amount of €51,154 in respect of 
treatments under the Health (Amendment) Act 
1996.
● The corresponding figures for 2005 are – 
■ Total of Payments €1,881.3m.
■ Doctors’ Fees €291.33m and Doctors’ 
Allowances €122.70m.
■ Pharmacists’ Fees and Mark-Up €283.82m, 
Drugs and Medicines €905.59m.
■ Payments to Dentists under the DTS Scheme 
were €54.46m.
■ Payments to Optometrists/Ophthalmologists 
€17m.
■ Investment in General Practice Development 
was €11.93m.
■ High Tech Drugs Scheme – Payment to 
Wholesalers €168.76m, Patient Care Fees 
€8.73m.
■ Administration €17.01m.
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Number of Agreements
2,315 Doctors 1,414 Dentists 552 Optometrists1,530 Pharmacists
The number of agreements between Health Service Executive and General Practitioners for the provision of services to GMS 
persons reflects the policy position agreed between the Department of Health & Children and the Irish Medical Organisation on 
entry to the GMS. In December 2006 there were 2,315 such agreements. 
Number of Agreements as at 31st December 2006
*220 GPs who do not hold GMS agreements and who were registered as providing services under the Primary Childhood Immunisation Scheme, the Health 
(Amendment) Act 1996, Heartwatch and the Methadone Treatment Scheme at year end are included above.
#12 Pharmacies who do not hold GMS agreements and who were registered as providing services under non GMS Schemes at year end are included above.
+201 Dentists who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.
Health Service Executive Doctors Pharmacists Dentists Optometrists
East Coast Area  2   5  0  45
South West Area  0  20   89  85
Northern Area  256  72  48  45
Midland  5  86  7  45
Mid-Western  28  46  4  44
North Eastern  64  6  2  56
North Western  7  88  6  
South Eastern  225  65  29  54
Southern  409  28    74
Western  257  54  74  7
National  *2,315  #1,530  +1,414  552
Corresponding figures for 2005 2,257 ,40 ,94 5
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Persons Eligible for Services
Persons who are unable without undue hardship to arrange General 
Practitioner medical and surgical services plus dental and optometric 
services for themselves and their dependants are provided with such 
services free of charge under the GMS Scheme. An eligible person 
is entitled to select a Doctor of his/her choice, from among those 
Doctors who have entered into agreements with the Health Service 
Executive. Drugs, medicines and appliances prescribed by participating 
Doctors for their GMS patients are provided through Community 
Pharmacies. Dental and ophthalmic services are provided by Dentists 
and Optometrists/Ophthalmologists who have contracted with the 
Health Service Executive. GMS prescription forms may be dispensed in 
any Pharmacy that has an agreement with the Health Service Executive 
to dispense GMS prescription forms. In rural areas, where a Doctor has 
a centre of practice three miles or more from the nearest retail Pharmacy 
participating in the Scheme, the Doctor dispenses for those persons 
served from the centre who opt to have their medicines dispensed by 
him/her. The number of eligible GMS persons at year end included 
54,257 persons who were entitled and had opted to have their medicines 
dispensed by their GPs.
Under the terms of the Drugs Payment Scheme persons who do not 
have a medical card may apply for a Drugs Payment Scheme card on 
an individual or on a family unit basis. Prescribed medicines, which are 
reimbursable under the GMS, costing in excess of a specified amount per 
month, currently €85 per family, is claimed by the Pharmacy and is paid 
by the Primary Care Reimbursement Service.
On approval by the Health Service Executive persons who suffer from 
one or more of a schedule of illnesses are entitled to obtain, without 
charge, irrespective of income, necessary drugs/medicines and/or 
appliances under the LTI Scheme. The Primary Care Reimbursement 
Service makes payments on behalf of the Health Service Executive for 
LTI claims submitted by Pharmacies.
GMS 1,221,695 
Number of Eligible Persons as at 31st December 2006
Health Service Executive
Eastern Areas  60,840  8,49  54,984   54,859
Midland 74,9 4,29  95,227  5,888
Mid-Western 08,97 ,289  60,867  7,42 
North Eastern 07,75 6,50  7,8 8,622
North Western 02,652  4,885  64,47 5,96
South Eastern 46,968 8,020  57,480 0,852
Southern 8,52 9,78  254,70 7,507
Western 8,680 7,0  40,84 5,220
National 1,221,695 51,760 1,525,657  106,307
% of Population 28.85%  1.22%  36.03%  2.51%
Corresponding figures for 2005 ,55,727 5,079 ,478,650  99,280
GMS - General Medical Services Scheme. GPVC - GP Visit Card Scheme. DP - Drugs Payment Scheme. LTI - Long Term Illness Scheme.
GPVC 51,760 DP 1,525,657 LTI 106,307
GMS GPVC DP LTI
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Payments to Doctors
Payments to General Practitioners are categorised as fees and/or 
allowances. For the majority of GPs who operate under the 1989 
agreement the principle fee is the capitation per person which is weighted 
for gender, age and distance from Doctor’s centre of practice - capitation 
fees totalled €195,007,011 in 2006 – a decrease of €11,091,579 on 2005. 
Fees totalling €1,427,644 were paid to 13 GPs who continue to provide 
services under the Fee-Per-Item of service agreements.
Apart from ‘Out-of-Hours’ fees and fees for a range of special services 
the cost of services provided in normal hours by GPs for GMS persons, 
including the prescribing of necessary medicines, is encompassed by the 
capitation fee. All GMS persons can avail of full GP services and in many 
cases they can benefit from specialist clinics provided by GPs for issues 
such as Women’s Health, Family Planning and Asthma.
In addition to a capitation fee an outside normal hours fee is payable for 
non routine consultations when an eligible GMS person is seen by their 
GP or another GP acting on his/her behalf from 5pm in the evening 
to 9am on the following morning (Monday to Friday) and all hours on 
Saturdays, Sundays and Bank Holidays. The number of ‘Out-of-Hours’ 
claims increased to 639,573 in 2006 compared with 576,885 in 2005 - 
and the cost of such claims increased to €34,717,410 from €33,506,917 
in 2005. Special fees are payable for a range of 18 services such as 
excisions, suturing, vaccinations, catheterization, family planning etc. the 
most frequent claimed special service in 2006 was Influenza Vaccination 
(299,769) followed by Excisions (75,248) and E.C.G. treatments (56,847) 
- there was a total of more than 592,928 special services provided in 2006 
- special fees totalling €21,627,306 were paid in 2006.
Annual and Study Leave together with locum, nursing and secretarial 
support plus other practice support payments account for most of the 
€122,474,346 allowances paid in the year. The total paid in 2005 was 
€122,697,221.
 Fees 282.25m Allowances 122.47m
Total of Payments to Doctors by Health Service Executive
Health Service Executive 2006
East Coast Area  €29,478,759 
South West Area  €45,684,4
Northern Area  €9,589,54
Midland  €25,544,62 Dublin North East €75,744,85 
Mid-Western €5,69,905 Dublin Mid-Leinster  €00,707,8
North Eastern  €6,55,2 South  €,59,42
North Western  €,47,809 West  €4,682,85
South Eastern €47,96,42
Southern  €65,677,000
Western €47,894,67
National €404,728,474
Corresponding figure for 2005  €44,025,06
The total of payments to Doctors includes payments of: €7,012,935 under the Primary Childhood Immunisation Scheme; €223,970 to Doctors who provided services 
under the Health (Amendment) Act 1996; Heartwatch €1,578,286;  Trainers/Trainee Grants €2,393,516 and €4,884,035 under the Methadone Treatment Scheme.
Total Payments accumulated  
by Regional Health Area
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Volume of Claims by Doctors
Fee-Per-Item 91,086
Special Type 209,705
Special Service 592,928
Out-of-Hours 639,573
National – Number of Claims – 2006
Number of Claims in each Health Service Executive Area
Health Service Executive Fee-Per-Item Special Type Special Service Out-of-Hours
East Coast Area – 0,047 5,87 26,82
South West Area 24,452 9,94 55,90 65,8
Northern Area 2,42 6,24 48,867 49,97
Midland – 5,94 8,876 42,2
Mid-Western ,25 24,680 47,695 48,450
North Eastern – 2,079 46,250 8,759
North Western – 2,96 59,27 55,764
South Eastern 9,02 6,98 78,2 9,774
Southern 22,928 5,49 02,040 55,70
Western – 29,96 80,40 95,40
National 91,086 209,705 592,928 639,573
Corresponding figures for 2005 0,608 96,44 580,722 576,885
A majority of Doctors are paid an annual capitation fee for each eligible 
person - the rate of payment is determined by the age/gender of the 
person and distance between each person’s residence and the centre of 
practice of their Doctor-of-Choice. A minority of Doctors (13) who 
have continued to provide services under the Fee-Per-Item of Service 
agreement are paid a fee for each Doctor/Patient contact. 
A Special Type Consultation (STC) fee is payable when a GMS eligible 
person is unable to contact their registered Doctor and is seen as an 
emergency case by another. General Practitioners qualify for payment of 
‘special fees’ for the special items of service separately identified under 
the Capitation agreement and the Fee-Per-Item agreement.
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4 5
Payments to Pharmacies
A GMS person who is provided with a properly completed GMS 
prescription form by his/her GP can choose to have such prescription 
forms dispensed in any of the Pharmacies who have entered into 
agreements with the Health Service Executive for the provision of 
services under Section 59 of the Health Act, 1970.
In 2006 there were 13.9m prescription forms containing 41m prescription 
items dispensed at a cost of over €940,224,576 i.e. an average cost of 
€22.80 per dispensed item. More than 95% of all eligible GMS persons 
were prescribed for in the year. The average cost of medicines per GMS 
person in 2006 was €809.04.
Payments made to Pharmacies under the GMS and DTS Schemes are 
inclusive of the ingredient cost of medicines, dispensing fees and VAT.
Under DP, LTI and EEA Schemes Pharmacies are reimbursed the 
ingredient cost of items dispensed; dispensing fees and VAT; a markup of 
up to 50% on the ingredient cost of items dispensed is also paid.
The cost of the High Tech Drugs Scheme was €217.76m - at year end 
there were 36,460 persons registered under this Scheme - Patient Care 
Fees totalled €10.51m and payments for drugs and medicines totalled 
€207.25m.
In the year the Primary Care Reimbursement Service processed claims 
valued at €368.03m on drugs acting on the ‘cardiovascular system’ (GMS 
€228.67m, DP €115.00m and LTI €24.36m). The second highest cost 
category was drugs acting on the ‘nervous system’ €270.43m (GMS 
€187.98m, DP €66.37m, LTI €16.08m). The third highest amount 
paid was for drugs acting on the alimentary tract and metabolism system 
€240.08m (GMS €142.82m, DP €64.62m, LTI €32.64m).
 GMS €940.22m DP €285.79m  LTI €115.46m EEA €2.11m
Total of Payments to Pharmacies by Health Service Executive
Health Service Executive GMS  DP  LTI  *EEA 
East Coast Area  66,49,4 26,767,97 ,460,956 76,6
South Western Area 06,80,99 48,25,84 9,8,460 25,248
Northern Area 04,54,962 4,296,280 7,46,25 68,75
Midland 64,627,065 6,722,99 6,686,599 87,44
Mid-Western 86,89,94 2,046,697 7,44,77 26,909
North Eastern 8,747,42 2,460,72 0,50,05 4,78
North Western 60,265,46 9,906,0 6,99,72 276,94
South Eastern 6,97,29 27,855,8 ,99,855 25,77
Southern 5,075,586 4,856,55 ,572,52 484,687
Western 0,956,664 2,942,62 7,60,20 65,545
National e940,224,576 e283,108,115 e115,461,340 e2,113,911
Corresponding figures for 2005 e8,442,62 e244,485,98 e00,546,64 e,879,609
* EEA – Payment to Pharmacies to cover the cost of GMS prescriptions dispensed for residents from the European Economic Area.
Pharmacies were also paid in respect of the drugs/medicines dispensed under: Health (Amendment) Act 1996 - €1,662,371; Methadone Treatment Scheme - 
€8,498,432; DTS Scheme - €718,604; Pharmacy Training Grant - €189,592 and Patient Care Fees totalling €10,511,147 under the High Tech Drugs Scheme. 
(Payments to Wholesalers under the High Tech Drugs Scheme amounted to €207,247,071).
In 2006 The National Maternity Hospital was paid €953,868 and The Rotunda Hospital was paid €1,730,743 in respect of Fertility Treatment. These figures are not 
included in the above table.
   
  GMS  DP  LTI  *EEA 
Dublin North East 86,262,94 64,756,452 27,964,250 20,49
Dublin Mid-Leinster 27,57,97 9,744,274 9,959,05 288,908 
South 267,992,75 7,7,968 25,566,87  75,864
West 248,62,070 54,895,42 2,97,688 878,648
Total Payments accumulated by Regional Health Area
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4 5
Volume of Claims by Pharmacies
EEA 0.09m
HTD 0.25m
Other 0.36m
LTI 2.17m
DP 11.87m
GMS 40.57m
National – Number of Items – 2006
GMS prescription forms processed for payment in the year totalled 13.9m 
- the total of prescribed items was more than 40.5m - these accounted 
for approximately 73% of all items paid for by the Primary Care 
Reimbursement Service in 2006.
Approximately 38.32% of GMS forms contained a single item: more 
than 19.84% contained 2 items - the average number of items per form 
was 2.91 (2005 – 2.83).
GMS dispensed items paid for by the Primary Care Reimbursement 
Service in 2006 increased by more than 3,141,568 - the increase in the 
number of DP items was more than 1,290,528 - the overall increase 
in the number of pharmacy claims processed by the Primary Care 
Reimbursement Service in the year was more than 4.7m.
Number of Items in each Health Service Executive Area
Health Service Executive GMS DP LTI EEA HTD *Other
East Coast Area 2,92,08 ,54,78 245,9 ,94 22,976 4,65
South West Area 4,770,974 ,85,976 6,906 5,267 6,20 6,874
Northern Area 4,4,096 ,626,508 22,2 2,855 28,822 92,55
Midland 2,747,55 749,8 28,57 ,727 6,05 0,984
Mid-Western ,80,272 ,0,75 5,966 0,049 8,576 7,240
North Eastern ,59,48 ,06,509 95,75 5,896 2,495 7,582
North Western 2,570,902 40,705 28,89 ,467 8,566 7,245
South Eastern 5,055,269 ,274,099 26,47 0,295 28,77 20,624
Southern 6,564,57 ,824,097 25,280 20,427 4,557 25,020
Western 4,78,4 94,4 8,86 5,65 27,087 4,876
National 40,569,342 11,872,217 2,165,300 88,742 252,692 356,965
Corresponding Figures for 2005 7,427,774 0,58,689 ,929, 8,965 206,64 28,9
* This group includes: 53,348 claim items in respect of the Health (Amendment) Act 1996; 217,699 items under the Methadone Treatment Scheme and 85,918 prescription items under the DTS Scheme.
GMS – General Medical Services Scheme. DP – Drugs Payment Scheme. LTI – Long Term Illness Scheme. EEA – European Economic Area. HTD – High Tech Drugs Scheme. 
Other – Methadone Treatment Scheme, Health (Amendment) Act 1996 and Dental Treatment Services Scheme.
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6 7
Payments to Dentists
Dentists were paid a total of €55,448,432 in 2006, in respect of 
treatments provided for more than 256,263 GMS persons under the 
DTS Scheme.
The following treatments were available to all eligible GMS persons.
ROUTINE: Routine treatments are categorised as either ‘Above the 
Line’ or ‘Below the Line’; 
 ‘Above the Line’ treatments are uncomplicated 
procedures viz. Amalgam; Extractions; 
 ‘Below the Line’ treatments are advanced procedures 
viz. Protracted Periodontal; Prosthetics.
‘Below the Line’ treatments - prior Health Service Executive approval 
for a specific course of treatment under this category is required. Full 
denture treatment is available, with prior Health Service Executive 
approval, to all edentulous GMS persons over 16 years. 
 Above the line €36.29m Below the line €19.15m
Payments to Dentists in each Health Service Executive Area
Health Service Executive 2006
Eastern Areas €4,668,790 
Midland €,006,78 
Mid-Western €4,950,524 Dublin North East €0,69,059
North Eastern €4,82,847 Dublin Mid-Leinster €,868,756 
North Western €,744,95 South €6,98,228
South Eastern €6,980,460 West €6,022,89
Southern €9,957,768
Western €7,26,950
National €55,448,432
Corresponding figure for 2005 e54,402,90
Dentists were also paid a total of €51,832 in 2006 in respect of treatments under the Health (Amendment) Act 1996.
Total Payments accumulated  
by Regional Health Area
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6 7
Volume of Claims by Dentists
Above the Line  987,149
Below the Line 108,770
National – Volume of Treatments – 2006
Volume of Treatments by Dentists in each Health Service Executive Area
Health Service Executive +Above the Line +Below the Line No. of persons treated  
   under DTS 
Eastern Areas  274,054  25,705  67,578
Midland  5,46  6,704  4,49
Mid-Western  87,444  ,54  2,574
North Eastern  84,87  0,20   22,408
North Western   72,26  5,452   8,652
South Eastern  7,457  5,0   ,94
Southern  8,470  8,408   47,96
Western  6,928  5,607   ,2
National 987,149 108,770 256,263
Corresponding figures for 2005 962,96 06,466 242,865
ROUTINE – Routine treatments are categorised as either ‘Above the Line’ or ‘Below the Line’:
 ‘Above the Line’ (ATL) treatments are uncomplicated procedures;
 ‘Below the Line’ (BTL) treatments are advanced procedures.
+ The most frequently used ATL service was Amalgam Restoration, which was used by 96,805 patients followed by Oral Examination. In the BTL category the most 
frequently used service was Prosthetics followed by Protracted Periodontal and Radiographs.
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8 9
Under the Health Service Executive Community Ophthalmic Services 
Scheme, Optometric/Ophthalmic services are provided to adult 
medical cardholders, which include free eye examinations and necessary 
spectacles/appliances.
Payments in respect of spectacles provided under the Children’s Scheme 
are also made by the Board on behalf of the majority of Health Service 
Executive Areas.
Payments in respect of eye examinations and necessary spectacles/
appliances are provided under the Teenager’s Scheme for eligible medical 
card holders on behalf of certain Health Service Executive Areas.
In the 12-month period to the end of December 2006 claims were 
received on behalf of 192,619 GMS persons for 464,623 treatments 
costing €16,927,104. 
Eye examinations by Optometrists/Ophthalmologists totalled 190,263 
- complete spectacles (distance, reading and bi-focals) provided under 
the Scheme totalled 274,360. The balance of treatments included 
replacement lenses and frames, tinted lenses, prisms and contact lenses. 
A breakdown of treatments and payments in each Health Service 
Executive Area is shown hereunder.
Payments to Optometrists/Ophthalmologists in each Health Service Executive Area
Health Service Executive 2006
Eastern Areas €4,980,99
Midland €,0,709
Mid-Western €,6,79 Dublin North East €2,928,2
North Eastern €,289,8 Dublin Mid-Leinster €4,452,576
North Western €,27,90 South €4,528,666
South Eastern €2,7,466 West €5,07,629
Southern €2,644,6
Western €,645,584
National €16,927,104
Corresponding figure for 2005 €5,8,940
Opticians were also paid in respect of: Health (Amendment) Act 1996 €51,154; Optical services for Teenagers €105,252; Optical services for Children €919,093.
Payments to Optometrists/Ophthalmologists
Total Payments accumulated  
by Regional Health Area
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8 9
Volume of Treatments by Optometrists/Ophthalmologists
Eye Exams 190,263
Appliances 274,360
GMS `1,123.89
LTI `2,175.15
DP `473.56
DTS `216.37
HSE-COS `87.88
C - 25.97%
A - 14.59%
N - 14.98%
R - 11.27%
V - 3.43%
Other - 29.76%
C - 24.32%
N - 19.99%
A - 15.19%
R - 8.93%
V - 7.85%
Other - 23.72%
V - 29.85%
A - 28.27%
C - 21.09%
N -13.93%
Other - 6.86%
National – Volume of Treatments – 2006 
Volume of Treatments by Optometrists/Ophthalmologists in each Health Service Executive Area
Health Service Executive Eye Exams Appliances Volume of  No. of Persons 
   Treatments  Treated 
Eastern Areas 56,269 78,7 4,442 56,27
Midland 2,060 7,5 29,75 2,66
Mid-Western 7,067 27,289 44,56 8,02
North Eastern 4,57 2,2 5,802 4,627
North Western 5,9 2,64 6,48 5,678
South Eastern 26,227 40,20 66,457 27,54
Southern 0,09 4,70 72,09 29,5
Western 8,44 27,228 45,669 8,654
National 190,263 274,360 464,623 192,619
Corresponding figures for 2005 68,400 249, 47,5 75,09
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20 2
Cost per Person in each Health Service Executive Area
   GMS  LTI DP DTS HSE-COS
Health Service  Doctor Pharmacy Total Pharmacy Net Cost Per Person Per Adult
Executive Cost Cost Cost Cost Per Claimant Treated Treated
  e e e e e e e
Eastern Areas 0.29 785.64 ,086.9 2,248.2 562.70 27.06 88.74
Midland  8.22 894.65 ,22.87 2,69.56 428.6 22.47 89.82
Mid-Western  299.82 88.20 ,8.02 ,8.60 422.84 20.00 89.0
North Eastern 24.6 80.08 ,54.7 2,206.56 45.26 24.78 88.4
North Western 299.98 674.46 974.44 2,289.02 446.74 200.78 8.
South Eastern 8.87 87.98 ,6.85 2,48.67 442.58 222.5 86.20
Southern 40.05 862.7 ,202.76 2,67.44 48.7 20.0 89.54
Western 26.2 796.08 ,22.40 2,0.8 92.68 25.50 88.22
National e314.85 e809.04 e1,123.89 e2,175.15 e473.56 e216.37 e87.88
Corresponding  
figures for 2005 e4.5 e750.04 e,09.9 e,896.89 e464.76 e25.89 e90.4
The Doctor cost above does not include superannuation paid to retired DMOs.
The Doctor cost for 2005 includes arrears paid resulting from the implementation of the 2005 LRC Agreement.
The above table shows the actual cost per person in respect of those who availed of services under each Scheme in 2006.
Medical and pharmaceutical services delivered to GMS persons increased in cost from €1,093.39 in 2005 to €1,123.89 in 2006 an increase of €30.50 per person - the 
cost of medical services per person decreased in cost from €343.35 in 2005 to €314.85 a decrease of 8.3% - the cost per person of pharmaceutical services increased 
from €750.04 in 2005 to €809.04 in 2006 an increase of 7.87%.
Cost per Person
National 2006
Eye Exams 190,263
Appliances 274,360
GMS `1,123.89
LTI `2,175.15
DP `473.56
DTS `216.37
HSE-COS `87.88
C - 25.97%
A - 14.59%
N - 14.98%
R - 11.27%
V - 3.43%
Other - 29.76%
C - 24.32%
N - 19.99%
A - 15.19%
R - 8.93%
V - 7.85%
Other - 23.72%
V - 29.85%
A - 28.27%
C - 21.09%
N -13.93%
Other - 6.86%
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Major Therapeutic Classification     em   %
A Alimentary Tract and Metabolism 142.82  15.19 
B Blood and Blood Forming Organs 42.4 4.50 
C Cardiovascular System  228.67 24.32
D Dermatologicals 7.79 .89
G Genito Urinary System and Sex Hormones  4.90  .7
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 9.08 0.97
J Anti-infectives for Systemic Use 4.0 .62
L Antineoplastic and Immunomodulating Agents 8.67 0.92
M Musculo-Skeletal System  58.65  6.24
N Nervous System 187.98  19.99
P Antiparasitic Products, Insecticides and Repellents 0.7  0.08
R Respiratory System  83.92 8.93 
S Sensory Organs  6.88 .79
V Clinical Nutritional Products 5.00 .72 
 Diagnostic Products  6.6 .77 
 Ostomy Appliances 9.64 .0 
 Urinary Appliances 4.0  0.4 
 Needles/Syringes/Lancets 2.95  0. 
 Other Therapeutic Products 2.05 0.22 
 Dressings .60 0.7 
 Miscellaneous .85  0.20
 Total e940.22m 100%
Major Therapeutic Classification of Drugs, Medicines and Appliances - General Medical Services Scheme
National 2006
Eye Exams 190,263
Appliances 274,360
GMS `1,123.89
LTI `2,175.15
DP `473.56
DTS `216.37
HSE-COS `87.88
C - 25.97%
A - 14.59%
N - 14.98%
R - 11.27%
V - 3.43%
Other - 29.76%
C - 24.32%
N - 19.99%
A - 15.19%
R - 8.93%
V - 7.85%
Other - 23.72%
V - 29.85%
A - 28.27%
C - 21.09%
N -13.93%
Other - 6.86%
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22 2
Major Therapeutic Classification     em   %
A Alimentary Tract and Metabolism 64.62 14.59
B Blood and Blood Forming Organs 4.26  .22
C Cardiovascular System 115.00 25.97
D Dermatologicals 9.9 4.8
G Genito Urinary System and Sex Hormones  .5  7.5
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins .99  0.90
J Anti-infectives for Systemic Use 20. 4.59
L Antineoplastic and Immunomodulating Agents 6.7 .44
M Musculo-Skeletal System 27.97 6.
N Nervous System 66.37 14.98
P Antiparasitic Products, Insecticides and Repellents .46 0.
R Respiratory System 49.90 11.27
S Sensory Organs 4.7 .06
V Clinical Nutritional Products 6.70  .5 
 Ostomy Appliances 4.55  .0 
 Urinary Appliances .4  0.2 
 Diagnostic Products .04  0.24 
 Dressings 0.4 0.09 
 Needles/Syringes/Lancets 0.22 0.05 
 Other Therapeutic Products 0.47  0. 
 Miscellaneous 0.8  0.08
 Total e422.92m  100%
Major Therapeutic Classification of Drugs, Medicines and Appliances - Drugs Payment Scheme
National 2006
Note: The above costs are inclusive of the monthly payment of €85 payable to the Pharmacy by the individual or family.
Eye Exams 190,263
Appliances 274,360
GMS `1,123.89
LTI `2,175.15
DP `473.56
DTS `216.37
HSE-COS `87.88
C - 25.97%
A - 14.59%
N - 14.98%
R - 11.27%
V - 3.43%
Other - 29.76%
C - 24.32%
N - 19.99%
A - 15.19%
R - 8.93%
V - 7.85%
Other - 23.72%
V - 29.85%
A - 28.27%
C - 21.09%
N -13.93%
Other - 6.86%
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22 2
Major Therapeutic Classification     em   %
A Alimentary Tract and Metabolism 32.64 28.27 
B Blood and Blood Forming Organs 2.45 2.2 
C Cardiovascular System 24.36 21.09 
D Dermatologicals 0.20 0.7
G Genito Urinary System and Sex Hormones .2 0.97
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 0.76  0.66
J Anti-infectives for Systemic Use .85 .60
L Antineoplastic and Immunomodulating Agents 0.09 0.08
M Musculo-Skeletal System 0.66 0.58
N Nervous System 16.08 13.93
P Antiparasitic Products, Insecticides and Repellents 0.00 0.00
R Respiratory System 0.59 0.5
S Sensory Organs 0.20 0.7
V Diagnostic Products 22.45 9.45 
 Clinical Nutritional Products 5.24 4.54 
 Needles/Syringes/Lancets/Swabs 4.70 4.06 
 Urinary Appliances 0.90 0.78 
 Nutritional/Ancillary Devices 0.56 0.49 
 Dressings 0.5 0. 
 Ostomy Appliances 0.7 0.5 
 Other Therapeutic Products 0.07 0.06 
 Miscellaneous 0.22 0.9
 Total e115.46m 100%
Major Therapeutic Classification of Drugs, Medicines and Appliances – Long Term Illness Scheme
National 2006
Eye Exams 190,263
Appliances 274,360
GMS `1,123.89
LTI `2,175.15
DP `473.56
DTS `216.37
HSE-COS `87.88
C - 25.97%
A - 14.59%
N - 14.98%
R - 11.27%
V - 3.43%
Other - 29.76%
C - 24.32%
N - 19.99%
A - 15.19%
R - 8.93%
V - 7.85%
Other - 23.72%
V - 29.85%
A - 28.27%
C - 21.09%
N -13.93%
Other - 6.86%
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Summary of Statistical Information relating to the GMS Scheme for each of the five years 2002-2006
2006 2005 2004 2003 2002
Number of Eligible Persons in December ,22,695 ,55,727 ,48,94 ,58,4 ,68,745
Doctors (000’s) (000’s) (000’s) (000’s) (000’s)
Total Payments €9,029 €40,07 €06,250 €286,80 €27,99
Doctors’ Payment per Person €4.85 €4.5 €26.5 €247.66 €22.5
Pharmacies (000’s) (000’s) (000’s) (000’s) (000’s)
Total Cost of Prescriptions €924,995 €86,04 €747,905 €66,566 €57,874
Ingredient Cost €74,94 €65,25 €585,22 €50,578 €42,269
Dispensing Fee €6,57 €47,860 €49,08 €2,5 €04,827
VAT €7,56 €5,9 €,702 €,87 €9,778
Number of Forms ,92 ,227 2,794 2,24 ,55
Number of Items 40,569 7,428 5,00 2,24 29,500
Cost per Form €66.9 €6.7 €58.46 €5.99 €46.57
Cost per Item €22.80 €2.8 €2.5 €9.74 €8.24
Ingredient Cost per Item €8.4 €7.45 €6.70 €5.62 €4.5
Items per Form 2.9 2.8 2.74 2.6 2.55
(000’s) (000’s) (000’s) (000’s) (000’s)
Total Cost of Stock Orders €5,20 €5,9 €5,4 €4,096 €,08
Ingredient Cost €,777 €,74 €,944 €0,904 €0,059
Pharmacy Fees €2,944 €2,927 €2,986 €2,726 €2,55
VAT €509 €498 €48 €466 €444
(000’s) (000’s) (000’s) (000’s) (000’s)
Overall Cost of Medicines €940,225 €8,44 €76,8 €650,662 €550,892
*Pharmacy Payment per Person €809.04 €750.04 €692.7 €595.6
Overall Payments €1,331,254 €1,234,514 €1,069,568 €937,493 €822,831
*Overall Payment per Person €1,123.89 €1,093.39 €954.26 €842.82
Doctors’ payment per person is exclusive of superannuation paid to retired DMOs.
*Since 2003 these figures are based on the actual number of persons who availed of services.
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Summary of Statistical Information relating to the LTI/DP Schemes for each of the five years 2002-2006
*Since 2003 these figures are based on the actual number of persons who availed of services under each Scheme.
2006 2005 2004 2003 2002
LTI Scheme
Number of Eligible Persons in December 06,07 99,280 9,504 97,84 92,745
*Number of Claimants 5,082 5,006 50,526 48,05
(000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items 2,65 ,929 ,675 ,464 ,280
Total Cost €5,46 €00,547 €85,55 €7,48 €6,66
Cost per Item €5.2 €52.2 €5.08 €50. €48.5
*Cost per Claimant €2,75.5 €,896.89 €,69.2 €,526.40
DP Scheme
Number of Eligible Persons in December ,525,657 ,478,650 ,469,25 ,96,8 ,9,95
*Number of Claimants 597,85 526,052 499,664 474,4
(000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items ,872 0,582 9,9 9, 9,06
Gross Cost €442,924 €88,02 €5,44 €5,82 €287,489
Net Cost €28,08 €244,486 €22,959 €204,422 €92,66
Gross Cost per Item €7. €6.67 €5.5 €.92 €.72
*Net Cost per Claimant €47.56 €464.76 €448.22 €40.90
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Fees and Allowances under Capitation Agreement as at 31st December 2006
Above rates inclusive of supplementary Out-of-Hours Fee.
Up to 3 Miles 3-5 Miles 5-7 Miles 7-10 Miles  Over 10 Miles
Ages Male € Female € Male € Female € Male € Female € Male € Female €  Male € Female €
Under 5 years 8.89 79.97 86.04 84.4 92.6 90. 98.2 96.7 05.74 0.86
5 – 5 49. 49.65 50.85 5.7 5.8 5.96 55.8 56.7 58.9 59.9
6 – 44 6.66 98.4 6.89 00.64 67.9 0.92 70.4 06.6 74.40 .
45 – 64 9.5 0.77 24.70 6.2 2.6 44.0 40.9 5.8 50.09 6.47
65 – 69 25.5 9.60 40.4 54.50 62.52 76.58 84.2 98.0 2.20 225.0
70 and over 6.85 5.5 52.8 66.72 75.02 89.54 97.42 2.96 225.28 29.84
The Capitation rate is €627.13 per annum for persons aged 70 years and over in the community issued with a medical card for the first time 
regardless of income. A Capitation rate of €908.88 per annum will apply to anyone aged 70 years and over in a private nursing home (approved by 
the Health Service Executive) for continuous periods in excess of five weeks. 
Out-of-Hours Payment  
Surgery €47.26 
Domiciliary
Up to  miles €47.26
 - 5 miles €6.06
5 - 7 miles €70.99
7 - 0 miles €78.79
Over 0 miles €94.57 
Additional Fee €6.89
*Special Items of Service
(i) to (ix) €29.56
(x) and (xi) €44.5
(xii) €7.9
(xiii) €49.75
(xiv) €79.6
(xv) and (xvi) €9.89 
(xvii) €59.8
(xviii) €4.8
 +Mileage
Temporary Residents 
Surgery €47.26
Domiciliary
Up to  miles €47.26
 - 5 miles €6.06
5 - 7 miles €70.99
7 - 0 miles €78.79
Over 0 miles €94.57 
Rural Dispensing Fee €4.8
Fee for Second Medical Opinion €.5
Practice Payments for Rural Areas
Rural Practice Allowance  
Per Annum €9,27.70
Practice Support
Allowance for Practice Secretary  
up to a maximum Per Annum of €25,957.54 
Allowance for Practice Nurse up  
to a maximum Per Annum of €40,790.4
Contributions to Locum Expenses
(Subject to the conditions of the Agreement)
Annual Leave  Up to a maximum of 
Sick Leave €,645.56 per week
Study Leave  Up to a maximum of 
Maternity Leave  €25.08 per day
Paternity Leave
Contributions to Medical  
Indemnity Insurance
Calculation of contribution is related  
to GMS panel numbers and net premium.
Asylum Seekers
A one off superannuable registration fee of
€8.8 per relevant patient will be paid to
Doctors in respect of each such patient on 
their GMS Scheme panels.
* Special Items of Service. 
(i) Excisions/Cryotherapy/ 
Diathermy of Skin Lesions.
(ii) Suturing of Cuts and Lacerations.
(iii) Draining of Hydroceles.
(iv) Treatment and Plugging  
of Dental and Nasal 
Haemorrhages.
(v) Recognised Vein Treatment.
(vi) ECG Tests and their 
Interpretation.
(vii) Instruction in the fitting 
of a Diaphragm.
(viii) Removal of Adherent 
Foreign Bodies from the 
Conjunctival Surface of the Eye.
(ix) Removal of Lodged or Impacted 
Foreign Bodies from the Ear, 
Nose and Throat.
(x) Nebuliser Treatment  
in the case of Acute Asthmatic 
Attack. 
(xi) Bladder Catheterization.
(xii) Attendance at case conferences 
(in cases where such are 
convened by the HSE).
(xiii) Advice and Fitting  
of a Diaphragm.
(xiv) Counselling and  
Fitting of an IUCD.
(xv) Pneumococcal Vaccination.
(xvi) Influenza Vaccination.
(xvii) Pneumococcal/Influenza 
Vaccination.
(xviii) Hepatitis B Vaccination.
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Fees and Allowances under the Fee-Per-Item Agreement and Fees under the Immunisation Scheme, 
Health (Amendment) Act 1996 and Methadone Treatment Scheme as at 31st December 2006
Surgery Consultations
Day Normal Hours €.02 
Late Outside Normal Hours other than (Night) €8.5 
Night Midnight to 8.00 a.m. €6.6
Domiciliary Consultations
Day Normal Hours  
 Urban €9.20 
 Up to  miles €9.20 
  - 5 miles €25.5 
 5 - 7 miles €.78 
 7 - 0 miles €42.6 
 Over 0 miles €52.97
Late Outside Normal Hours  
 Urban €25.5 
 Up to  miles €25.5 
  - 5 miles €2.54 
 5 - 7 miles €42.6 
 7 - 0 miles €56.27 
 Over 0 miles €65.99
Night Midnight to 8.00 a.m.  
 Urban €49. 
 Up to  miles €49. 
  - 5 miles €6.8 
 5 - 7 miles €80.7 
 7 - 0 miles €89.46 
 Over 0 miles €97.2
Emergency Fee/EEA Fee (Additional to Standard Fee) €4.24
Dispensing Fee €4.24
Rural Practitioner’s Allowance 
Per Annum €8,94.5
Locum and Practice Expense Allowance 
Per Annum €,64.6
Sessional Rate - Homes for the Aged 
Per  Hour Session €87.2
* Special Items of Service 
(i) to (vii) €26.7 
(viii) and (ix) €9.89 
(x)  €59.8 
(xi)   €4.8
Immunisation Fees 
(i) Registration of child with a GP €8. 
(ii) Complete course of immunisation   
 against PT/DT; Hib; Polio and MMR  €26.98 
(iii) 95% uptake bonus €6.6
Health (Amendment) Act 1996 
Surgery Fee €6.8 
Domiciliary Fee €47.98
Methadone Treatment Scheme 
Level  Contractor €49.28 
Level 2 Contractor €64.64
* Special Items of Service. 
(i) Excisions/Cryotherapy/ 
Diathermy of Skin Lesions.
(ii) Suturing of Cuts and 
Lacerations.
(iii) Draining of Hydroceles.
(iv) Treatment and Plugging 
of Dental and Nasal 
Haemorrhages.
(v) Recognised Vein Treatment.
(vi) ECG Tests and their 
Interpretation.
(vii) Instruction in the fitting of a 
Diaphragm.
(viii) Pneumococcal Vaccination.
(ix) Influenza Vaccination.
(x) Pneumococcal/Influenza 
Vaccination.
(xi) Hepatitis B Vaccination.
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Scale of Fees Payable to Participating Pharmacists as at 31st December 2006
High Tech Medicines Scheme
Reimbursement of ingredient cost plus 50% mark-up on ingredient cost plus Standard Fee - €2.86 (Note 1)
20% mark-up on Incontinence Products and Dressings under DP Scheme
Extemporaneously dispensed preparations are reimbursed at current private prescription rates. In the case of the Drugs Payment Scheme  
the PCRS makes payments to Pharmacies in respect of authorised Patients whose monthly costs of prescribed drugs and medicines are  
in excess of the specified monthly amount (currently 85) payable to the Pharmacy by an individual or family.
Note 1 The standard fee is an all inclusive fee which includes container and broken bulk allowance.
Patient Care Fee: e54.82 per month.
Methadone Treatment Scheme 
Patient Care Fee: Up to a Maximum of e54.80 per month.
DP/LTI/EEA Schemes and Health (Amendment) Act 1996
GMS Scheme E
Standard Fee-Per-Item (Note 1) .26
Extemporaneous Fee 6.28
Extemporaneous dispensing and compounding of 
- Powders  8.8 
- Ointments and Creams 2.56
Controlled Drugs 5.07
Non-Dispensing - exercise of professional judgement .4
Phased Dispensing - each part of phased dispensing .4
Urgent/Late Dispensing 
Additional fee for Urgent/Late dispensing other than between midnight and 8.00 a.m. (Note 2) 8.8
Additional fee for Urgent/Late dispensing between midnight and 8.00 a.m. 8.24
Note 1 e2.78 basic fee and e0.48 allowance for containers, obsolescence etc.
Note 2 Urgent fee prescriptions are those so specified by the prescriber and necessarily dispensed outside normal hours.  
  Late fee prescriptions are those which, though not marked urgent, are in exceptional circumstances necessarily dispensed outside normal hours by  
  the Pharmacist, having regard to the person’s requirements.
Note 3 A Standard Fee-Per-Item is also payable on prescription forms issued by Dentists under the DTS Scheme.
Note 4 A Fee-Per-Item of €4.21 is also payable on prescription forms in respect of persons aged 70 years and over issued with a medical card for 
  the first time regardless of income.
Supplies to Dispensing Doctors 
Pharmacies supplying Dispensing Doctors are reimbursed on the basis of the basic trade price with the addition of 25% on cost.
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Scale of Fees Payable under the Dental Treatment Services Scheme as at 31st December 2006
Treatment Type Routine 
  E
Oral Examination 0.78
Prophylaxis  28.9
Restoration (Amalgam) 46.52
Restoration (Composite) 6 anterior teeth only 48.22
Exodontics (Extraction under local anaesthetic) 6.76
Surgical Extraction - Maximum  units:  
 Fee payable for each 5 minute unit  2.7
 Maximum 98.9
st Stage Endodontic Treatment (Anterior teeth only) 5.25
Denture Repairs 
 st Item of Repair 42.4
 Each Subsequent Item  .57
 Maximum 69.49
Apicectomy/Amputation of Roots  *Dentist Estimate
Endodontics (Anterior teeth only) *Dentist Estimate
Protracted Periodontal Treatment *Dentist Estimate
Radiographs  
  Film 2.0
 2 or more Films 4.8
 Panoramic 8.55
Miscellaneous   
 (e.g. Abcess, Haemorrhage, Dressings etc.)  2.05
Prosthetics 
 Full Upper or Lower Denture  288.6
 (Other than Edentulous Persons) 
 Partial Upper or Lower Acrylic Denture  2.7
 Complete Upper or Lower Reline 5.55
 Complete Upper and Lower Reline 92.
Full Upper and Lower Denture (Edentulous Persons Only)  42.58
*Dentist Estimates are subject to agreement between a Dentist and the Health Service Executive Area.
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Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme
As as 31st December 2006 E
Examinations  
Eye Examination Ophthalmic Optician 22.28 
Eye Examination Ophthalmologist/  
Ophthalmic Medical Practitioner 25.29 
Medical Eye Examination by Ophthalmologist 50.58 
Eye Examination for Contact Lenses (Grant) 67.7 (H)
Eye Examination Ophthalmic (Dilation) 44.56 
Appliances  
Single Vision Complete Appliances  
Spectacles - Distance 45.59 
Spectacles - Reading 45.59 
Spectacles - Uncollected 2.4 
Contact Lenses (Pair) 45.60 
Contact Lenses Standard or Disposable per pair (Grant) 69.89 (H)
Single Vision Spectacles - with Glass Lenses Distance 5.9 (H)
Single Vision Spectacles - with Glass Lenses Reading 5.9 (H)
Single Vision Spectacles - with Plastic Lenses Distance 45.28 (H)
Single Vision Spectacles - with Plastic Lenses Reading 45.28 (H)
Single Vision Lenses to Own Frame  
Replacement Distance Lens () to own frame 7.7 
Replacement Distance Lenses (2) to own frame 5.4 
Replacement Reading Lens () to own frame 7.7 
Replacement Reading Lenses (2) to own frame 5.4 
Single Vision Lenses to Non-Standard Frame  
Single Vision Lens () (Glass) Distance  25.68 (H)
Single Vision Lenses (2) (Glass) Distance  5.5 (H)
Single Vision Lens () (Glass) Reading 25.68 (H)
Single Vision Lenses (2) (Glass) Reading   5.5 (H)
Single Vision Lens () (Plastic) Distance   29.00 (H)
Single Vision Lenses (2) (Plastic) Distance  58.0 (H)
Single Vision Lens () (Plastic) Reading 29.00 (H)
Single Vision Lenses (2) (Plastic) Reading 58.0 (H) 
Additional Specification for Lenses to All Spectacle Types
Special grant towards additional specification for lens ()  
– applies to all spectacle types 84.65 (H)
Special grant towards additional specification for lenses (2) 
– applies to all spectacle types  69.0 (H)
Other Items - Single Vision  
Lenticular Lens ( Surface) 2.08 
Lenticular Lenses (2 Surfaces) 24.5 
Lenticular Lenses ( Surfaces) 6.2 
Lenticular Lenses (4 Surfaces) 48.0 
Tinted Lens () 7.97 
Tinted Lenses (2) 5.94 
Tinted Lenses () 2.92 
Tinted Lenses (4) .90 
Prism () 6.5 
Prisms (2) .07 
Prisms () 9.60 
Prisms (4) 26.4 
Prisms (5) 2.67 
Prisms (6) 9.20 
Prisms (7) 45.74 
Prisms (8) 52.27 
Dioptric powers higher than 8.00 () Lens 6.5 
Dioptric powers higher than 8.00 (2) Lenses 2.29 
Dioptric powers higher than 8.00 () Lenses 8.44 
Dioptric powers higher than 8.00 (4) Lenses 24.59 
Anti-Reflective Coating on Plastic Lens () 8.6 (H) 
  E
(H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.
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Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme continued
As as 31st December 2006 E
Anti-Reflective Coating on Plastic Lenses (2) 7.22 (H)
Dioptric powers higher than 6.00 (Plastic) () Lens 5.7 
Dioptric powers higher than 6.00 (Plastic) (2) Lenses 0.7 
Dioptric powers higher than 6.00 (Plastic) () Lenses 46.0 
Dioptric powers higher than 6.00 (Plastic) (4) Lenses 6.47 
Plastic Lens () for children as prescribed 5.0 
Plastic Lenses (2) for children as prescribed 0.07 
Plastic Lens () Adult 4.95 (H)
Plastic Lenses (2) Adult 9.90 (H)
Bifocals   
Spectacles Bifocal Complete 92. 
Fused Bifocal Spectacles 80.94 (H)
Varifocals Spectacles - Glass or Plastic  268.8 (H)
  
Bifocal Lenses  
Replacement Bifocal Lens () to own frame 4.02 
Replacement Bifocal Lenses (2) to own frame 82.04 
Bifocal Lens () to Non-Standard Frames  52.99 (H)
Bifocal Lenses (2) to Non-Standard Frames  05.97 (H)
Varifocal Lens () (Grant) 00.78 (H)
Varifocal Lenses (2) (Grant) 20.56 (H)
Other Items - Bifocals € 
Sphere over 6.00 and up to 9.00 extra charge () Lens 4.5 
Sphere over 6.00 and up to 9.00 extra charge (2) Lenses 8.0 
Sphere over 9.00 extra charge () Lens 9.22 
Sphere over 9.00 extra charge (2) Lenses 8.44 
Tinted Lens () 8.75 
Tinted Lenses (2) 7.47 
Prism () 9.24 
Prisms (2) 8.49 
  
Repairs  
Replacement Frame to own lenses .4 
Replacement Front to own lenses 5.8 
Replacement Side () to own frame 2.45 
Replacement Sides (2) to own frame 4.90 
Complete New Frames 97.75 (H)
  E
(H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.
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DETAILED STATISTICAL ANALYSIS OF 
CLAIMS AND PAYMENTS 2006
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Table 1 GMS: Summary of Statistical Information for each of the Five Years 2002 - 2006 
Year ended December:- 2006 2005 2004 2003 2002 Year ended December:- 2006 2005 2004 2003 2002
Number of Eligible  ,22,695 ,55,727 ,48,94 ,58,4 ,68,745  Number of Doctor Contracts 2,5 2,257 2,20 2,8 2,4
Persons in December      Number of Pharmacist Contracts ,50 ,40 , ,292 ,249
DOCTORS (000’s) (000’s) (000’s) (000’s) (000’s)   (000’s) (000’s) (000’s) (000’s) (000’s)
           
Total Payments 8391,029 8403,071 8306,250 8286,830 8271,939 Total Cost of Stock Orders 815,230 815,139 815,413 814,096 813,018
        Ingredient Cost 8,777 8,74 8,944 80,904 80,059
Doctors’ Payment  8314.85 8343.35 8261.53 8247.66 8221.15  Pharmacy Fees 82,944 82,927 82,986 82,726 82,55
per Person       VAT 8509 8498 848 8466 8444
PHARMACIES
Total Cost of  8924,995 8816,304 8747,905 8636,566 8537,874 Overall Cost of Medicines 8940,225 8831,443 8763,318 8650,662 8550,892
Prescriptions
 Ingredient Cost 874,94 865,25 8585,22 850,578 842,269 *Pharmacy Payment  8809.04 8750.04 8692.73 8595.16
 Dispensing Fee 86,57 847,860 849,08 82,5 804,827 per Person
 VAT 87,56 85,9 8,702 8,87 89,778
Number of Forms ,92 ,227 2,794 2,24 ,55
Number of Items 40,569 7,428 5,00 2,24 29,500 Overall Payments 81,331,254 81,234,514 81,069,568 8937,493 8822,831
Cost per Form 866.9 86.7 858.46 85.99 846.57 *Overall Payment  81,123.89 81,093.39 8954.26 8842.82
       per Person
Cost per Item 822.80 82.8 82.5 89.74 88.24
Ingredient Cost per Item 88.4 87.45 86.70 85.62 84.5
Items per Form 2.9 2.8 2.74 2.6 2.55
Note: Doctors payment per person is exclusive of superannuation paid to retired DMOs.
 *Since 2003 these figures are based on the actual number of persons who availed of services.
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Table 1.1 LTI/DP: Summary of Statistical Information for each of the Five Years 2002 - 2006
Year ended December:- 2006 2005 2004 2003  2002  Year ended December:- 2006 2005 2004 2003  2002
LTI Scheme      DP Scheme
Number of Eligible       Number of Eligible Persons  
Persons in December 06,07 99,280 9,504 97,84  92,745  in December ,525,657 ,478,650 ,469,25 ,96,8  ,9,95 
*Number of Claimants 5,082 5,006 50,526 48,05  *Number of Claimants 597,85 526,052 499,664 474,4
  (000’s)  (000’s) (000’s) (000’s)  (000’s)   (000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items 2,65 ,929 ,675 ,464 ,280 Number of Items ,872 0,582 9,9 9, 9,06 
            
Total Cost 85,46 800,547 885,55 87,48 86,66 Gross Cost 8442,924 888,02 85,44 85,82 8287,489
            
Cost per Item 85.2 852.2 85.08 850. 848.5 Net Cost 828,08 8244,486 822,959 8204,422 892,66
*Cost per Claimant 82,75.5 8,896.89 8,69.2 8,526.40  Gross Cost per Item 87. 86.67 85.5 8.92 8.72
       *Net Cost per Claimant 847.56 8464.76 8448.22 840.90
*Since 2003 these figures are based on the actual number of persons who availed of services under each Scheme.
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Table 2 Number of Agreements
Note:  (i) Where Doctors have panels numbers drawn from more than one HSE Area, the Area wherein the majority of such persons reside is deemed to be the Doctors HSE Area.
 (ii) 220 Doctors who do not have agreements under the GMS Scheme and who provide services under the Primary Childhood Immunisation Scheme, the Health (Amendment) Act 1996, 
Heartwatch, Palliative Care and the Methadone Treatment Scheme are included in the above.
 (iii) 201 Dentists (198 - 2005) who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.
 (iv) 12 Pharmacies who do not hold GMS agreements and who were registered as providing non GMS Schemes at year-end are included above. 
 (v) Above figures relate to the position as at 31st December 2006.
Health Service  
Executive
Doctors Pharmacists Dentists Optometrists
2006  2005 2006 2005  2006  2005  2006  2005  
East Coast Area 2 22 5 26 0 02 45 45 
South Western Area 0 0 20 96 89 205 85 78 
Northern Area 256 242 72 6 48 54 45 42 
Midland 5 26 86 82 7 68 45 4 
Mid-Western 28 24 46 7 4 02 44 42 
North Eastern 64 62 6 26 2 0 56 50 
North Western 7 4 88 79 6 64  0 
South Eastern 225 222 65 5 29 2 54 5 
Southern 409 89 28 227  04 74 79 
Western 257 25 54 4 74 60 7 69 
National 2,315 2,257 1,530 1,430 1,414 1,394 552 531 
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Table 3 GMS: Payments to Doctors 
   2006 2005
   2 2
FEES - Item of Service Contract ,427,644 ,80,460
 - Capitation 95,007,0 206,098,590
 - Special Claims/Services ,567,070 4,64,854
 - Out-of-Hours 4,77,40 ,506,97
 - Dispensing 2,567,255 2,75,426
 - Asylum Seekers ,598,662 ,484,255
 - GP Visit Cards ,669,850 92,65
ALLOWANCES - Annual Leave 8,28,80 8,508,7
 - Locum and Practice Expenses 6,5 ,25
 - Sick Leave ,20,00 ,54,79
 - Maternity Leave 694,044 52,758
 - Rural Practice ,566,52 4,974,708
 - Secretarial/Nursing 55,,9 59,48,7
 - Study Leave ,472,90 ,560,225
 - Medical Indemnity Insurance 2,6,422 ,99,026
 - Rostering/Out-of-Hours 0,929,872 6,548,29
 - Practice Development 4,5,85 4,65,469
 - Practice Support Grant 2,67,706 2,668,68
 - IMO Agreements:
     One-in-one rotas 64,869 64,869
     Third year Trainees 4,92 28,882
     Trainer Grants ,27,255 89,60
SALARIES - Former District Medical Officers 2,55,074 ,807,47
 - Benefits to retired DMOs and their dependants 6,75,56 6,249,48
SUPERANNUATION FUND - Contribution 20,5,950 20,807,94 
TOTAL   €391,029,248 €403,071,088
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Table 4 GMS: Cost of Prescriptions 
Health 
Service  
Executive
Ingredient Cost Dispensing Fee VAT Total
2006  
e
2005 
e
2006  
e
2005 
e
2006  
e
2005 
e
2006  
e
2005 
e
East Coast Area 52,604,778 46,496,56 2,207,696 ,6,95 ,28,9 ,4,29 66,09,59 58,772,807 
South Western 
Area 85,9,05 75,4,20 8,962,984 7,289,04 2,6,588 ,864,426 06,28,877 94,586,690 
Northern Area 84,240,528 7,247,60 8,7,09 6,70,06 ,957,6 ,689,822 04,70,75 9,07,58 
Midland 5,582,6 45,478,996 ,254,647 0,096,069 ,205,29 ,047,9 64,042,57 56,622,978 
Mid-Western 68,55,698 60,5,877 5,0,8 ,66,854 ,66,878 ,9,282 85,200,409 75,207,0 
North Eastern 64,42,026 56,5,85 4,74,9 2,84,200 ,58,627 ,08,787 80,05,046 70,656,822 
North Western 46,64,9 40,948,98 0,095,7 9,40,657 ,07,007 944,60 57,80, 5,04,24 
South Eastern 90,478,95 79,072,272 20,529,625 8,258,25 2,229,792 ,945,504 ,27,62 99,276,0 
Southern 2,545,20 06,,4 26,27,67 2,8,500 2,78,095 2,68,59 50,545,46 2,492,99 
 Western 78,82,20 69,57,87 6,889,727 5,254,274 ,76,22 ,58,77 97,449,78 86,46,468 
National €743,942,527 €653,250,513 €163,536,536 €147,859,882 €17,515,736 €15,193,166 €924,994,799 €816,303,561
Note: Cost of medicines supplied by pharmacies to Dispensing Doctors is given in Table 5.
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Health 
Service 
Executive
Ingredient Cost *Pharmacy Fee VAT Total
2006  
e
2005 
e
2006  
e
2005 
e
2006  
e
2005 
e
2006  
e
2005 
e
East Coast Area 74,0 60,88 4,58 40,22 7,909 2,08 255,820 2,22 
South Western 
Area 07,99 04,04 26,802 26,004 28,04 27, 62,042 57,7 
Northern Area 97,02 54,250 24,255 ,568 22,940 ,944 44,227 8,762 
Midland 447,50 47,946 ,870 09,495 25,9 22,9 584,492 570,54 
Mid-Western 94,7 88,22 228,68 220,799 46,40 47,686 ,89,54 ,5,77 
North Eastern ,28,40 ,206,28 2,06 0,566 52,20 52,459 ,72,86 ,560,06 
North Western ,927,446 2,098,402 48,86 52,98 54,84 58,82 2,464,50 2,68,208 
South Eastern 2,869,462 2,797,52 77,5 699,284 92,702 90,747 ,679,57 ,587,8 
Southern 80,678 407,894 95,64 0,978 54,28 58,0 50,2 568,82 
Western ,50,08 ,564,090 882,85 890,05 94,99 9,772 4,507,486 4,547,967 
National €11,776,611 €11,714,162 €2,943,988 €2,927,005 €509,178 €497,895 €15,229,777 €15,139,062
Table 5 GMS: Cost of Stock Order Forms 
Note: (i) Stock Order Forms are provided by HSE Areas for the use of Dispensing Doctors to obtain Medicines and Appliances from retail pharmacies for dispensing to persons who are 
entitled to be dispensed to.
 (ii) *Pharmacies are reimbursed for stock order items on the basis of the basic trade price, with the addition of 25% on cost.
 (iii) The above figures include needles, syringes and dressings which are available for Doctors use.
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Table 6 DTS: Payments to Dentists
Note: Dentists were also paid a total €51,832 in 2006 (€55,922 in 2005) in respect of fees under Health (Amendment) Act 1996.
Health Service  
Executive
Above the Line Below the Line Total
2006 
€
2005 
€
2006 
€
2005 
€
2006 
€
2005 
€
Eastern Areas 0,068,965 9,899,747 4,599,825 4,572,584 4,668,790 4,472, 
Midland ,856,58 ,874,45 ,50,020 ,26,662 ,006,78 ,00,007 
Mid-Western ,94,49 ,02,569 ,756,085 ,76,677 4,950,524 4,787,246 
North Eastern ,076,7 2,840,442 ,76,4 ,607,576 4,82,847 4,448,08 
North Western 2,585,220 2,698,869 ,59,695 ,0,069 ,744,95 ,808,98 
South Eastern 4,290,799 4,22,062 2,689,66 2,55,877 6,980,460 6,774,99 
Southern 6,806,550 6,59,095 ,5,28 ,096,867 9,957,768 9,689,962 
Western 4,45,202 4,477,946 2,9,748 2,942,54 7,26,950 7,420,460 
National €36,294,066 €35,629,075 €19,154,366 €18,773,826 €55,448,432 €54,402,901
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Table 7 GMS: Payment per Person 
Health Service 
Executive
2006 2005
Doctors
e
Pharmacies
e
Total
e
Doctors
e
Pharmacies
e
Total
e
Eastern Areas 0.29 785.64 ,086.9 2.9 727.2 ,060.05
Midland 8.22 894.65 ,22.87 5.48 8.55 ,87.0
Mid-Western 299.82 88.20 ,8.02 2.44 776.40 ,08.84
North Eastern 24.6 80.08 ,54.7 8.74 775.9 ,.9
North Western 299.98 674.46 974.44 22.96 629.0 95.97
South Eastern 8.87 87.98 ,6.85 49.6 764.57 ,4.8
Southern 40.05 862.7 ,202.76 6.87 789.96 ,5.8
Western 26.2 796.08 ,22.40 60.7 79.60 ,00.
National €314.85 €809.04 €1,123.89 €343.35 €750.04 €1,093.39
Note:  The payment per person is inclusive of total payments to Doctors (Table 3) excluding superannuation benefits to retired DMOs and their dependants and total payments to 
pharmacies (Tables 4 and 5) in respect of the actual cost per person who availed of services.
42101 HSE AR06 Eng.indd   41 9/20/07   6:03:46 PM
42 4
Table 8 GMS: Number of Doctors in Eligible Person Cost Categories
Number of Doctors with an annual cost per eligible person of:-
Health Service 
Executive Up to e300 e301-e350 e351-e400 e401-e450 e451-e500 e501-e550 e551-e600 e601-e650 e651-e700 e701&Over
Eastern Areas 6 (7) 2 (8)  () 9 (5) 8 (0) 2 (2) 2 (6) 4 (0)  () 49 (49)
Midland 2 () -  () - - () - 2 (-)  () - () 97 (96)
Mid-Western 2 ()  () - - () 2 ()  (2) 2 ()  (2) 9 (7) 48 (47)
North Eastern - (4) - (2)  (2) 2 ()  () 5 () 5 (2) 2 (5) 4 (2) 28 ()
North Western - (2) 2 (2)  (-)  (2) 2 (2)  (4)  () 4 (6) 9 (9) 06 (00)
South Eastern 5 (2) - ()  (-) - (2) - 2 () 4 (4) 7 (2) 5 (4) 9 (94)
Southern - (2) -  (-) - () - ()  (4) 2 (4)  (2) 9 (5) 00 (0)
Western - (5) 2 (2)  (-) 2 (-) 2 () 2 (4)  () 6 () 8 (7) 98 (202)
National 15 (36) 7 (18) 9 (6) 16 (22) 15 (21) 28 (28) 40 (29) 40 (31) 55 (46) 1,659 (1,668)
Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from this table.
 (ii) The annual cost per eligible person is the total payment for the Doctor and the total prescribing/dispensing costs in respect of the number of persons on the panel as at December 2006.
 (iii) Doctors payment is exclusive of superannuation paid to retired DMOs.
2006 (2005 in brackets)
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Table 9 GMS: Number of Eligible Persons
Health Service 
Executive
Number of persons (including dependants)  
and % of population* eligible in Health Service 
Executive
Number of persons (including dependants)  
and % of population* eligible in
December 2006 December 2005 December 2006 December 2005
No.  % No.  % No.  % No.  %
EASTERN AREA NORTH WESTERN
Dublin 289,790 24.4 274,245 24.42 Donegal 7,058 48.5 68,80 49.70
Kildare 4,6 22.0 7,790 2.05 Leitrim ,68 40.6 ,044 40.92
Wicklow 29,94 2.70 27,62 24.08 Sligo 9,956 2.76 9,49 .49
TOTAL 60,840 24.08 9,647 24.24 TOTAL 02,652 4.8 98,95 44.40
MIDLAND SOUTH EASTERN
Laois 8,7 27.2 6,99 28.9 Carlow 6,840 .7 5,44 .56
Longford ,09 8.0 2,545 40.8 Kilkenny 20,885 2.90 9,802 24.65
Offaly 20,726 29.6 9,597 0.78 Tipperary S.R. 29,50 5.0 28,6 6.6
Westmeath 22,29 28.2 20,990 29.2 Waterford 7,44 4.66 5,744 5.20
TOTAL 74,9 29.56 70,2 .2 Wexford 42,679 2.4 40,020 4.2
TOTAL 46,968 .92 9,620 2.96
MID-WESTERN
Clare ,556 0.29 ,55 0.6 SOUTHERN
Limerick 54,242 29.50 49,92 28.48 Cork 8,720 28.85 2,65 29.56
Tipperary N.R. 2,75 2.09 9,40 .80 Kerry 42,792 0.65 4,22 .0
TOTAL 08,97 0.22 00,688 29.65 TOTAL 8,52 29.25 7,586 29.9
NORTH EASTERN WESTERN
Cavan 20,99 2.74 8,958 4.25 Galway 68,45 29.6 65,758 .45
Louth 7,809 4.09 5,4 4.5 Mayo 48,944 9.58 47,588 40.52
Meath 2,476 9.97 29,69 2.92 Roscommon 2,285 6.26 20,26 7.6
Monaghan 6,527 29.6 6,05 0.62 TOTAL 8,680 .55 ,582 5.
TOTAL 07,75 27.40 99,566 28.96 NATIONAL 1,221,695 28.85 1,155,727 29.50
Note: (i) *The population figures for each county are taken from the Census of Population 2006. The most recent Official C.S.O. estimate of national population as at October 2006 is 4,234,925.
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Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups
Health 
Service 
Executive
Age Classification
As at December 2006
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 Years
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas ,98 4,864 28,847 8,28 9,5 7,64 8,675 9,28 7,80 6,66 9,76 26,79 22,820 ,94 4,24 9,006 ,497 2,50
Midland 2,594 2,686 5,280 ,7 ,82 7,554 2,009 2,04 4,052 ,75 2,55 6,288 4,02 2,8 6,4 ,928 2,898 6,826
Mid-Western ,420 ,56 6,96 4,9 5,204 0,5 2,76 2,699 5,45 5,442 4,20 9,562 5,852 ,75 9,60 5,66 4,47 0,089
North Eastern ,5 ,784 7,295 5,264 5,544 0,808 2,722 2,840 5,562 5,880 4,060 9,940 6,00 ,76 9,726 5,629 4,87 0,06
North Western ,5 ,99 6,552 4,828 5,299 0,27 2,692 2,90 5,622 6,98 4,66 0,86 5,468 ,655 9,2 5,668 4,72 0,400
South Eastern 4,76 4,974 9,690 6,69 7,00 ,99 ,689 ,889 7,578 6,987 4,458 ,445 8,74 4,926 ,00 7,824 6,02 ,86
Southern 5,5 5,726 ,04 7,4 7,920 5,5 4,048 4,26 8,284 8,52 5,86 4,88 9,565 6,09 5,584 9,284 7,27 6,557
Western ,760 4,22 7,882 5,9 6,47 2,278 ,566 ,596 7,62 6,969 5,280 2,249 6,64 4,27 0,970 6,979 5,747 2,726
National 40,452 4,07 8,52 57,040 60,788 7,828 0,7 ,6 6,478 60,244 40,668 00,92 68,555 40,06 08,66 6,94 49,09 2,95
% of Eligible 
Persons .% .5% 6.84% 4.67% 4.98% 9.64% 2.47% 2.57% 5.0% 4.9% .% 8.26% 5.6% .28% 8.89% 5.2% 4.0% 9.25%
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Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued
Health 
Service 
Executive
Age Classification
As at December 2006
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years and Over All
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 5,096 ,560 26,656 7,408 ,97 0,805 0,558 7,625 8,8 2,7 7,66 8,95 4,556 25,07 68,86 207,65 5,475 60,840
Midland ,44 2,97 6,405 4,209 ,47 7,626 2,204 ,75 ,957 ,660 ,474 7,4 7,592 5,264 2,856 4,7 ,82 74,9
Mid-Western 5,57 4,556 9,7 6,44 5,50 ,847 ,96 2,87 6,269 5,4 5,69 0,582 ,08 7,54 8,822 59,595 49,78 08,97
North Eastern 4,897 4,277 9,74 5,967 5,4 ,0 ,40 2,54 5,654 5,74 4,782 9,956 ,20 7,8 8,59 59,95 48,56 07,75
North Western 5,250 4,952 0,202 5,976 5,696 ,672 2,847 2,7 5,578 ,80 ,745 7,546 8,777 6,92 4,969 54,658 47,994 02,652
South Eastern 7,22 6,29 ,54 8,884 7,68 6,502 4,80 4,72 8,982 7,277 6,78 ,995 4,422 9,98 24,60 80,64 66,4 46,968
Southern 8,977 7,840 6,87 0,952 9,28 20,280 6,207 5,075 ,282 9,85 8,924 8,79 20,294 ,09 ,87 00,242 8,270 8,52
Western 7,05 6,697 ,72 8,087 7,89 5,926 4,27 ,906 8,2 6,24 6,28 2,569 4,84 0,9 24,95 74,52 64,28 8,680
National 57,058 49,82 06,240 67,827 57,92 25,759 7,489 0,649 68,8 62,698 56,776 9,474 ,964 84,765 26,729 677,78 544,7 ,22,695
% of Eligible 
Persons 4.67% 4.0% 8.70% 5.55% 4.74% 0.29% .07% 2.5% 5.58% 5.% 4.65% 9.78% 0.80% 6.94% 7.74% 55.45% 44.55% 00.00%
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Table 9.2 GMS: Percentage of Eligible Persons by Mileage Allocation
Health Service 
Executive
Mileage Classification
As at December 2006
Up to 3 Miles 3 - 5 Miles 5 - 7 Miles 7 - 10 Miles Over 10 Miles
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 5.58 7.9 89.5 . 2.4 5.52 .80 .8 .8 0.62 0.5 . 0.6 0.0 0.66
Midland 4.6 27.40 6.76 6.6 5.6 2.26 .00 0.50 2.50 .4 .09 2.42 0.02 0.0 0.06
Mid-Western 6.8 0. 67.2 6.59 5.48 2.06 9.9 8. 8.22 .0 0.9 2.0 0.29 0.28 0.56
North Eastern 4.98 27.98 62.96 7.79 6.60 4.9 .5 9.28 20.4 .02 0.86 .89 0.7 0.5 0.
North Western 26.6 22.52 48.88 9.4 8.57 8.00 2.40 .6 2.56 .74 .29 7.0 .2 .22 2.5
South Eastern 6.56 29.80 66.6 6.8 5.82 2.6 9.87 8.7 8.04 .4 .8 2.6 0.20 0.6 0.6
Southern 5.50 28.2 6.7 6.92 5.8 2.72 9.52 7.84 7.6 .95 .74 .69 . .8 2.52
Western 28.00 2.2 5.2 8.9 7.54 5.92 .2 0.4 2.46 4. .99 8. .60 .49 .08
National 38.76 30.35 69.11 6.19 5.26 11.45 8.12 6.84 14.96 1.72 1.51 3.22 0.66 0.60 1.26
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Table 9.3 GPVC: Number of Eligible Persons
Health Service 
Executive
Number of persons (including dependants)  
and % of population* eligible in Health Service 
Executive
Number of persons (including dependants)  
and % of population* eligible in
December 2006 December 2005 December 2006 December 2005
No.  % No.  % No.  % No.  %
EASTERN AREA NORTH WESTERN
Dublin 5,688 0.48 565 0.05 Donegal ,62 2.29 525 0.8
Kildare ,40 0.72 7 0.04 Leitrim 540 .87 92 0.4
Wicklow ,2 0.89 0 0. Sligo 98 .62 06 0.8
TOTAL 8,49 0.54 768 0.05 TOTAL 4,885 2.06 72 0.2
MIDLAND SOUTH EASTERN
Laois ,02 .64 55 0.09 Carlow ,2 2.62 70 0.7
Longford 677 .97 26 0.08 Kilkenny ,264 .45 64 0.20
Offaly , .86 6 0.0 Tipperary S.R. ,78 2.09 67 0.2
Westmeath ,47 .44 2 0.0 Waterford ,494 .8 200 0.20
TOTAL 4,29 .69 65 0.07 Wexford 2,20 .67 262 0.22
TOTAL 8,020 .74 96 0.2
MID-WESTERN
Clare 968 0.87 29 0.2 SOUTHERN
Limerick ,590 0.86  0.06 Cork 7,647 .59 99 0.2
Tipperary N.R. 7 . 2 0.0 Kerry 2,07 .48 26 0.25
TOTAL ,289 0.9 26 0.08 TOTAL 9,78 .57 ,245 0.2
NORTH EASTERN WESTERN
Cavan ,268 .98 4 0.2 Galway ,597 .56 20 0.06
Louth ,90 .72 8 0.8 Mayo 2,6 .9 80 0.5
Meath 2,02 .42 20 0.6 Roscommon ,52 .96 7 0.0
Monaghan 877 .57 4 0.27 TOTAL 7,0 .72 07 0.08
TOTAL 6,50 .6 648 0.9 NATIONAL 51,760 1.22 5,080 0.13
Note:  (i) *The population figures for each county are taken from the Census of Population 2006. The most recent Official C.S.O. estimate of national population as at October 2006 is 4,234,925.
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Table 9.4 GPVC: Number of Eligible Persons by Gender within Age Groups
Health Service 
Executive
Age Classification
As at December 2006
Under 5 Years 5 - 11 Years 12 - 15 Years 16 - 24 Years 25 - 34 Years
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 486 558 ,044 66 6 ,296 00 0 60 295 75 470 652 87 ,09
Midland 270 02 572 49 42 69 7 77 48 9 40  5 226 579
Mid-Western 95 227 422 259 27 52 26 4 267 75 28 0 266 8 449
North Eastern 46 45 887 50 584 ,087 97 205 402 06 9 497 584 8 902
North Western 255 274 529 74 85 759 80 22 92 25 25 560 50 248 598
South Eastern 470 486 956 647 66 ,08 6 298 64 460 275 75 79 456 ,95
Southern 597 642 ,29 756 705 ,46 2 4 666 527 9 866 799 5 ,0
Western 45 46 96 55 57 ,26 255 266 52 47 252 599 595 49 944
National ,62 ,40 6,565 4,04 4,56 8,260 ,877 ,94 ,8 2,626 ,75 4,6 4,8 2,678 7,06
% of Eligible 
Persons 6.% 6.57% 2.68% 7.9% 8.0% 5.96% .6% .74% 7.6% 5.07% .5% 8.4% 8.8% 5.7% .55%
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Table 9.4 GPVC: Number of Eligible Persons by Gender within Age Groups continued
Health Service  
Executive
Age Classification
As at December 2006
35 - 44 Years 45 - 54 Years 55 - 64 Years 65 - 69 Years All
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 85 70 ,552 476 75 85 478 24 802 224 270 494 4,425 ,724 8,49
Midland 45 5 766 26 209 445 80 78 58 60 89 49 2,225 2,04 4,29
Mid-Western 46 22 668 88 76 64  04 27 24 4 67 ,692 ,597 ,289
North Eastern 6 625 ,256  276 587 270 225 495 99 8 27 ,7 ,0 6,50
North Western 46 407 870 6 288 604 27 227 444 5 78 29 2,5 2,54 4,885
South Eastern 788 668 ,456 4 99 82 84 9 72 87 4 20 4,24 ,696 8,020
Southern 964 92 ,885 605 490 ,095 496 407 90 26 67 29 5,202 4,56 9,78
Western 686 640 ,26 464 47 90  07 68 6 98 59 ,725 ,85 7,0
National 5,44 4,65 9,779 ,029 2,650 5,679 2,449 2, 4,560 72 997 ,729 27,46 24,299 5,760
% of Eligible 
Persons 9.94% 8.95% 8.89% 5.85% 5.2% 0.97% 4.7% 4.08% 8.8% .4% .9% .4% 5.05% 46.95% 00.00%
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Table 10 GMS: Size of Panels of Doctors
Health Service 
Executive
 Number of Doctors with panels of:-
Up to 250 251 - 500 501 - 1,000 1,001 - 1,500 1,501 - 2,000 2,001 - 2,500
East Coast Area 49 (59) 54 (49) 6 (6) 5 () - -
South Western Area 4 (64) 47 (47) 89 (8) 44 (42) 7 (4)  ()
Northern Area 4 (5) 40 (42) 69 (7) 6 (28) 9 (0) 2 ()
Midland 8 () 8 (22) 45 (47) 27 (2)  (-) -
Mid-Western 29 (7) 4 () 78 (77) 20 (8) 7 (4) -
North Eastern 4 (24) 29 (0) 87 (8) 2 (9) 4 () -
North Western  (7) 2 (2) 52 (47) 4 (6)  (7) -
South Eastern 2 (26) 6 (9) 8 () 8 (28) 5 (5) -
Southern 80 (75) 77 (79) 46 (6) 4 (0) 4 (2)  ()
Western 7 (44) 56 (55) 02 (0) 8 (29)  () -
National 347 (394) 421 (417) 847 (815) 299 (254) 49 (34) 6 (5)
 As at December 2006 (2005 in brackets)
42101 HSE AR06 Eng.indd   50 9/20/07   6:03:51 PM
50 5
Table 11  GMS: Payments to Doctors in each Health Service Executive Area
Health Service  
Executive
2006
e
2005
e
East Coast Area 28,642,65 29,687,792
South Western Area 4,78,54 45,029,29
Northern Area 8,009,490 9,92,489
Midland 24,078,44 25,206,856
Mid-Western ,48,257 4,22,427
North Eastern 5,662,55 4,409,257
North Western ,26,24 2,470,288
South Eastern 47,70,689 49,75,964
Southern 62,870,862 6,954,440
Western 46,96,755 49,8,284
National €391,029,248 €403,071,088
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Table 12 GMS: Number of Special Type Consultations and Out-of-Hours Claims
Health Service 
Executive
No. of  Temporary 
Resident Claims
No. of EEA  
Visitor Claims
No. of Emergency 
Claims
Second Medical 
Opinion Claims
No. of Out-of-
Hours Claims
Total No. of 
Claims
2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005
East Coast Area 4,42 ,29 2,696 2,850 2,99 2,588 9 2 26,82 2,779 6,868 2,548
South Western 
Area
8,700 7,959 4,857 4,470 5,827 5,542 0  65,8 55,608 85,227 7,592
Northern Area 6,707 6,545 2,5 2,26 7,94 5, 7  - 49,97 4,76 65,442 57,902
Midland 0,64 8,26 2,280 2,88 ,482 7,908 8  42,2 7,70 58,066 56,55
Mid-Western 4,20 ,248 5,27 5,97 4,604 ,05 602 9 48,450 4,87 7,0 6,456
North Eastern* 7,78 5,202 ,029 ,0 ,668 ,442 4  8,759 9,254 20,88 8,92
North Western ,229 ,226 8,000 7,9 ,709 ,67 2 2 55,764 47,054 68,725 59,98
South Eastern 8, 8,04 5,588 5,902 ,207 ,629 0 6 9,774 8,075 08,72 98,65
Southern ,444 24,96 ,42 ,6 5,469 5,666 ,57 ,052 55,70 4,694 207,96 86,29
Western 5,20 5,04 9,229 0,0 5,55 5,440 4 29 95,40 95,09 25,076 25,9
National 109,501 95,115 56,508 57,795 41,832 42,254 1,864 1,279 639,573 576,885 849,280 773,328
* HSE North Eastern Area figures do not include statistics from North East Doc.
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Table 12.1 GMS: Payment to Doctors for Special Type Consultations and Out-of-Hours Claims 
* HSE North Eastern Area figures do not include statistics from North East Doc.
Health 
Service 
Executive
Cost of  Temporary 
Resident Claims
Cost of EEA  
Visitor Claims
Cost of Emergency 
Claims
Cost of Second Medical 
Opinion Claims
Cost of Out-of-Hours 
Claims
Total Cost of  
Claims
2006 
€
2005 
€
2006 
€
2005 
€
2006 
€
2005 
€
2006 
€
2005 
€
2006 
€
2005 
€
2006 
€
2005 
€
East Coast Area 2,827 9,52 2,976 0,29 ,55 04,8 22 50 ,240,752 94,094 ,708,22 ,295,298 
South Western 
Area
45,90 9,992 29,76 7,628 268,69 226,568 94 28 ,66,74 2,276,275 4,07,409 2,994,79 
Northern Area 04,96 254,06 96,885 87,002 4,952 204,96 0  - 2,25,859 ,698,684 2,990,962 2,244,665 
Midland 47,649 29,697 0,90 8,722 60,950 06,24 00 84 2,04,85 ,540,667 2,770,274 2,260,84 
Mid-Western 65,98 55,529 28,662 99,258 22,026 7,96 8,2 ,659 2,09,40 ,707,605 ,40,4 2,54,987 
North Eastern * 7,8 22,675 6,779 6,2 78,659 57,8 65 75 42,676 7,07 965,597 759,27 
North Western 46,559 25,577 64,42 04,88 78,58 65,668 77 84 2,688,070 ,9,68 ,278,6 2,40,55 
South Eastern 70,40 0,472 25,852 225,544 45,802 40,528 67 50 4,0,22 ,26,288 5,080,66 ,97,982 
Southern ,552,499 ,005,042 607,849 524,74 250,0 22,9 5,25 26,9 7,47,8 5,740,09 9,88,75 7,520,085 
Western 707,82 594,490 48,42 95,88 255,652 2,902 ,52 7 4,606,907 ,898,54 5,990,55 5,0,547 
National €5,70,90 €,807,060 €2,56,800 €2,29,02 €,98,876 €,660,792 €57,550 €2,822 €0,460,68 €2,70,850 €40,69,524 €,090,545
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Table 13 GMS: Analysis of Special Items of Service
 Type of Service Number of Claims Cost of Claims
2006 2005 2006
€
2005
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 75,248 68,52 2,22,742 ,65,049 
(ii) Suturing: Cuts and Lacerations 0,48 27,574 858,09 662,6 
(iii) Hydroceles: Draining of ,6 ,005 2,75 24,26 
(iv) Haemorrhages: Dental/Nasal 2,00 ,587 56,75 8,20 
(v) Veins: Recognised treatment 2,95 2,74 8,290 65,59 
(vi) ECG: Tests and interpretation 56,847 49,929 ,604,22 ,98,888 
(vii) Diaphragm: Instruction in the fitting of ,044 85 29,446 20,454 
(viii) Eye: Removal of Adherent foreign body 9,209 7,929 259,796 90,06 
(ix) Ear/Nose/Throat: Removal of foreign body 2,44 8,78 605,07 44,448 
(x) Nebuliser: Treatment in the case of acute asthmatic attack 50,496 47,775 2,9,50 ,726,807 
(xi) Bladder: Catheterization 6,022 5,47 254,955 97,4 
(xii) Case Conference: Convened by HSE 92 70 ,5 0,6 
(xiii) Diaphragm: Advice and fitting of 740 56 5,094 2,44 
(xiv) IUCD: Counselling and fitting of 6,44 4,94 489,040 26,024 
(xv) Pneumococcal: Vaccination 2,9 20,7 474,46 699,646 
(xvi) Influenza: Vaccination 299,769 299,094 ,582,655 9,989,8 
(xvii) Pneumococcal/Influenza: Vaccination 6,286 2,885 942, ,204,778 
(xviii) Hepatitis B: Vaccination 2 90 4,890 46,2 
National 592,928 580,722 \21,627,306 \18,499,824
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Table 13.1 GMS: Analysis of Special Items of Service by HSE Area
 Type of Service East Coast Area South Western Area
Number  
of Claims
Cost of Claims
€
Number of 
Claims
Cost of Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions ,980 2,40 7,087 99,967
(ii) Suturing: Cuts and Lacerations 79 22,0 ,984 55,942 
(iii) Hydroceles: Draining of 55 ,556 7 2,045 
(iv) Haemorrhages: Dental/Nasal 44 ,29  ,4 
(v) Veins: Recognised treatment 29 85 8 9,59 
(vi) ECG: Tests and interpretation 2,759 77,79 ,5 99,540 
(vii) Diaphragm: Instruction in the fitting of  870 96 ,69 
(viii) Eye: Removal of Adherent foreign body 2 6,578 47 9,790 
(ix) Ear/Nose/Throat: Removal of foreign body 824 2,24 2,080 58,68 
(x) Nebuliser: Treatment in the case of acute asthmatic attack ,9 48,84 ,50 48,64 
(xi) Bladder: Catheterization 67 7,065 85 7,846 
(xii) Case Conference: Convened by HSE 9 6  772 
(xiii) Diaphragm: Advice and fitting of 29 ,80 06 5,029 
(xiv) IUCD: Counselling and fitting of 460 4,97 709 5,875 
(xv) Pneumococcal: Vaccination 8 ,27 ,26 46,706 
(xvi) Influenza: Vaccination 2,05 89,08 ,664 ,22,40 
(xvii) Pneumococcal/Influenza: Vaccination ,45 77,898 2,000 5,70 
(xviii) Hepatitis B: Vaccination 7 955 4 5,59 
Total 35,818 €1,342,149 55,389 €2,055,371
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Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued
Type of Service Mid-Western North Eastern
Number  
of Claims
Cost of Claims
€
Number  
of Claims
Cost of Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 4,52 27,56 5,847 65,085
(ii) Suturing: Cuts and Lacerations 2,457 69,267 ,76 48,45 
(iii) Hydroceles: Draining of 79 2,29 62 ,754 
(iv) Haemorrhages: Dental/Nasal 95 2,68 54 ,524 
(v) Veins: Recognised treatment 45 ,68 27 7,69 
(vi)  ECG: Tests and interpretation ,72 05,048 ,999 2,94 
(vii) Diaphragm: Instruction in the fitting of 48 ,56 78 2,20 
(viii) Eye: Removal of Adherent foreign body 44 ,675 8 9,548 
(ix) Ear/Nose/Throat: Removal of foreign body ,274 5,976 ,46 40,502 
(x) Nebuliser: Treatment in the case of acute asthmatic attack ,04 29,05 ,264 8,269 
(xi) Bladder: Catheterization 506 2,86 60 25,808 
(xii) Case Conference: Convened by HSE 2 ,627 4 282 
(xiii) Diaphragm: Advice and fitting of 55 2,68 2 5,87 
(xiv) IUCD: Counselling and fitting of 457 4,785 620 47,095 
(xv) Pneumococcal: Vaccination ,228 47,222 999 8,24 
(xvi) Influenza: Vaccination 27,99 ,080,4 25,250 975,46 
(xvii) Pneumococcal/Influenza: Vaccination ,78 79,879 ,56 90,48 
(xviii) Hepatitis B: Vaccination 29 ,995 6 2,97 
Total 47,695 €1,768,347 46,250 €1,713,106
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Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued
Type of Service Northern Area Midland
Number  
of Claims
Cost of Claims
€
Number  
of Claims
Cost of Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 4,79 ,6 ,802 07,62
(ii) Suturing: Cuts and Lacerations ,688 47,685 2,659 75,072 
(iii) Hydroceles: Draining of 26 74 40 ,6 
(iv) Haemorrhages: Dental/Nasal 26 ,550 40 ,552 
(v) Veins: Recognised treatment 7 479 4 4,04 
(vi)  ECG: Tests and interpretation 2,049 57,82 5,27 44,74 
(vii) Diaphragm: Instruction in the fitting of 4 ,55 20 565 
(viii) Eye: Removal of Adherent foreign body 879 24,858 746 2,048 
(ix) Ear/Nose/Throat: Removal of foreign body ,748 49,7 ,505 42,76 
(x) Nebuliser: Treatment in the case of acute asthmatic attack ,827 77,450 4,768 20,978 
(xi) Bladder: Catheterization 57 2,409 99 6,897 
(xii) Case Conference: Convened by HSE 4 996  92 
(xiii) Diaphragm: Advice and fitting of 52 2,464 8 85 
(xiv) IUCD: Counselling and fitting of 650 49,442 428 2,500 
(xv) Pneumococcal: Vaccination ,54 52,04 840 2,274 
(xvi) Influenza: Vaccination ,8 ,229,462 6,884 652,549 
(xvii) Pneumococcal/Influenza: Vaccination ,777 02,865 ,056 6,005 
(xviii) Hepatitis B: Vaccination 2 4,90 8 2,459 
Total 48,867 €1,840,283 38,876 €1,409,075
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Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued
Type of Service North Western South Eastern
Number  
of Claims
Cost of Claims
€
Number  
of Claims
Cost of Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 8,49 29,66 9,799 276,444
(ii) Suturing: Cuts and Lacerations ,669 0,487 5,057 42,595 
(iii) Hydroceles: Draining of 58 4,449 2 ,47 
(iv) Haemorrhages: Dental/Nasal 8 9,04 258 7,277 
(v) Veins: Recognised treatment 29 87 69 7,508 
(vi)  ECG: Tests and interpretation 9,046 255,22 8,88 250,507 
(vii) Diaphragm: Instruction in the fitting of 95 2,69 79 2,220 
(viii) Eye: Removal of Adherent foreign body ,49 8,047 8 22,874 
(ix) Ear/Nose/Throat: Removal of foreign body 2,886 8,478 2,40 67,82 
(x) Nebuliser: Treatment in the case of acute asthmatic attack 7,89 ,65 7,475 6,680 
(xi) Bladder: Catheterization 898 8,0 928 9,284 
(xii) Case Conference: Convened by HSE 2 ,488 5 2,46 
(xiii) Diaphragm: Advice and fitting of 62 2,94 58 2,755 
(xiv) IUCD: Counselling and fitting of 565 42,860 ,77 89,499 
(xv) Pneumococcal: Vaccination ,025 9,479 ,295 49,804 
(xvi) Influenza: Vaccination 2,8 826,44 7,645 ,454,485 
(xvii) Pneumococcal/Influenza: Vaccination ,42 82,8 ,657 95,80 
(xviii) Hepatitis B: Vaccination 4 ,99 9 2,59 
Total 59,271 €2,102,019 78,321 €2,844,079
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Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued
Type of Service Southern Western
Number  
of Claims
Cost of Claims
€
Number  
of Claims
Cost of Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 4,26 402,07 2,726 59,286
(ii) Suturing: Cuts and Lacerations 5,849 64,895 4,548 28,87 
(iii) Hydroceles: Draining of 20 5,920 5 9,4 
(iv) Haemorrhages: Dental/Nasal 80 5,085 44 ,697 
(v) Veins: Recognised treatment 958 27,092 0 ,670 
(vi)  ECG: Tests and interpretation 8,45 28,560 9,277 26,856 
(vii) Diaphragm: Instruction in the fitting of 96 5,528 60 ,69 
(viii) Eye: Removal of Adherent foreign body 2,962 8,485 ,0 ,89 
(ix) Ear/Nose/Throat: Removal of foreign body 4,46 25,20 2,849 80,494 
(x) Nebuliser: Treatment in the case of acute asthmatic attack 8,406 56,529 9,225 9,04 
(xi) Bladder: Catheterization ,27 47,74 ,45 48,506 
(xii) Case Conference: Convened by HSE 4 2,996 9 ,5 
(xiii) Diaphragm: Advice and fitting of 97 9,44 40 ,89 
(xiv) IUCD: Counselling and fitting of ,064 80,950 04 2,097 
(xv) Pneumococcal: Vaccination ,69 62,74 ,952 75,0 
(xvi) Influenza: Vaccination 49,69 ,96,90 4,47 ,,454 
(xvii) Pneumococcal/Influenza: Vaccination 2,9 5,22 ,750 0,04 
(xviii) Hepatitis B: Vaccination 9 6,25 26 ,540 
 Total 102,040 €3,685,230 80,401 €2,867,647
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Table 14 GMS: Visiting Rate Categories for Doctors on Fee-Per-Item of Service
NATIONAL
2006 (2005 in brackets)
Doctors with 
panels of:-
 Visiting Rate:-*
6 - 6.9 7 - 7.9 8 - 8.9 9 - 9.9 10 - 10.9 11 - 11.9 12 and Over
 00-249 - - ()  (-)  (-) - - ()  ()
 250-499 - - 2 () - () - -  ()
 500-999  (2)  (-) - - - - () -
 ,000-,499 - - () - - - -  ()
 Over ,500 - - - -  (-) - () -
 TOTAL 1 (2) 1 (2) 3 (1) 1 (1) 1 (-) - (3) 3 (3)
Note: (i) The overall visiting rate in 2006 of the Doctors who continued on a Fee-Per-Item of service contract was 10.59 (Surgery: 9.88 Domiciliary: 0.71),  
(2005 - Total: 10.56 Surgery: 9.50 Domiciliary: 1.06). 
 (ii) Only Doctors with panels of 100 persons or over are included in the above table.
 (iii) *Visiting Rate is the total number of consultations divided by the total number of persons on panel.
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Table 15 GMS: Cost of Medicines by Gender within Age Groups 
Health 
Service 
Executive
Age Classification
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 Years
Female
e
Male
e
Total
e
Female
e
Male
e
Total
e
Female
e
Male
e
Total
e
Female
e
Male
e
Total
e
Female
e
Male
e
Total
e
Female
e
Male
e
Total
e
Eastern Areas 8.56 9.99 88.94 60.66 7.87 67.45 75.08 69.2 72.07 20.68 26.85 225.59 06.0 70. 27.48 452.45 46.46 457.02 
Midland 98.8 08.92 0.96 84.0 78.54 8.9 75.0 92.0 8.77 285.28 284.65 285.02 76.47 489.48 47.78 560.5 586.85 57.60 
Mid-Western 25.68 28. 27.0 8.7 .94 97.07 00.70 2.00 .8 277.40 25.28 267.00 80.8 455.24 409.50 5.5 580.9 54.40 
North Eastern 85.2 85.79 85.47 67.77 84.70 76.45 94.0 78. 86.0 222.6 20.86 24.5 9.54 68.72 8. 46.9 444.4 440.09 
North Western 58.0 85.0 72.6 58.68 64.99 6.98 65.77 8.8 74. 7.09 57.90 66.57 259.26 250.48 255.74 49.48 5.9 4. 
South Eastern 94.42 0.7 99.9 6.47 87.46 75.08 89.47 07.65 98.80 26.64 284.27 270.45 28.05 405.7 57.26 50.4 508.40 505.54 
Southern 08.28 25.2 7.07 99.5 .68 05.79 09.5 9.70 4.7 282. 29.82 286.24 79.48 489.9 42.9 556.8 66.0 582.86 
Western .60 0.9 07.59 7.06 7.46 72.0 67. 97.8 82.6 22.9 227.56 20.9 5.08 46.92 95.59 460.85 57.54 486.45 
National €9.9 €02.52 €98.0 €70.72 €84.5 €77.65 €8.75 €92.2 €88.07 €242.52 €26.05 €29.9 €.2 €406.40 €58.96 €476.25 €50.9 €487.9
% of National 
Average
2.% .2% 2.75% 9.9% 0.9% 0.09% 0.88% .98% .44% .5% 0.67% .7% 4.04% 52.8% 46.64% 6.88% 65.22% 6.%
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Health 
Service 
Executive
Age Classification
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years & Over Total
Female
e
Male
e
Total
e
Female
e
Male
e
Total
e
Female
e
Male
e
Total
e
Female
e
Male
e
Total
e
Female
e
Male
e
Total
e
Female
e
Male
e
Total
e
Eastern Areas 829.54 8.07 82.5 ,49.7 ,92.87 ,68.29 ,58.5 ,75.5 ,65.6 ,20.08 ,248.98 ,287.89 ,592.78 ,558.77 ,580.28 804.0 78.6 776.25
Midland 967.6 99.44 945.0 ,29.87 ,2.76 ,06.6 ,455.20 ,595.02 ,57.4 ,50.95 ,489.9 ,497.2 ,858. ,80.50 ,88.7 90.54 876.85 890.52
Mid-Western 80.24 778.8 795.5 ,0.99 ,4.5 ,2.7 ,287.26 ,275.8 ,28.8 ,2.08 ,249.2 ,285.98 ,54.89 ,55.26 ,542.2 804.69 77.7 790.50
North Eastern 7.00 77.56 74.06 ,0.54 ,065.8 ,07.52 ,24.4 ,285.95 ,262.7 ,28.9 ,282.86 ,282.7 ,5. ,576.07 ,550.22 79.78 77.9 729.64
North Western 564.07 544.67 554.65 862.6 82.5 84.40 ,050.7 ,050.55 ,050.46 ,22.80 ,8.75 ,20.79 ,76.5 ,24.5 ,54.72 595.8 557.60 577.96
South Eastern 804.8 80.08 807.27 ,02.96 ,0.99 ,5.90 ,02.26 ,06.0 ,04.4 ,40.9 ,4.56 ,27.99 ,60.58 ,568.97 ,59.6 799.66 776.55 789.2
Southern 865.5 860.2 862.8 ,94.6 ,82.47 ,89.04 ,5.86 ,88.6 ,59.59 ,82.5 ,9.5 ,52.5 ,529.77 ,55.64 ,524.2 864.60 82.72 850.2
Western 7.65 679.99 706.46 96.0 924.90 90.69 ,9.0 ,0.86 ,.8 ,227.78 ,5.6 ,90. ,427.70 ,85.70 ,40.64 74.6 697.88 77.59
National €79.60 €77.26 €78.26 €,095.08 €,099.4 €,097.08 €,285.96 €,00.47 €,292.49 €,8.68 €,266.4 €,29.7 €,557.7 €,52.2 €,547.49 €788.42 €746.9 €769.6
% of National 
Average
0.2% 00.2% 0.77% 42.29% 42.86% 42.55% 67.09% 68.98% 67.94% 7.4% 64.52% 68.0% 202.6% 99.08% 20.08% 02.45% 96.96% 00.00%
Table 15 GMS: Cost of Medicines by Gender within Age Groups continued
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Table 16 GMS: Number of Prescription Forms and Items 
Health Service 
Executive
Number of Forms Number of Items Items per Form
2006 2005 2006 2005 2006 2005
East Coast Area 955,567 9,277 2,92,08 2,700,20 .06 2.96
South Western Area ,66, ,546,259 4,770,974 4,47,74 2.95 2.86
Northern Area ,47,22 ,94,802 4,4,096 4,066,787 .0 2.92
Midland 97,7 875,4 2,747,55 2,5,68 2.99 2.89
Mid-Western ,29,45 ,22,8 ,80,272 ,508,6 2.95 2.87
North Eastern ,209,68 ,44,99 ,59,48 ,256,4 2.9 2.85
North Western 980,06 924,074 2,570,902 2,67,62 2.62 2.56
South Eastern ,746,598 ,654,962 5,055,269 4,629, 2.89 2.80
Southern 2,262,96 2,50,99 6,564,57 6,080,556 2.90 2.8
Western ,479, ,40,790 4,78,4 ,869,66 2.82 2.76
National 13,932,341 13,227,483 40,569,342 37,427,774 2.91 2.83
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Table 16.1 GMS: Payment to Pharmacists in Respect of Prescriptions
Health Service 
Executive
Cost Cost per Form Cost per Item Ingredient Cost  
per Item
2006  
e
2005  
e
2006  
e
2005  
e
2006  
e
2005  
e
2006  
e
2005  
e
East Coast Area 66,09,59 58,772,807 69.7 64.49 22.62 2.77 8.0 7.22
South Western Area 06,28,877 94,586,690 65.72 6.7 22.26 2.4 7.85 7.08
Northern Area 04,70,75 9,07,58 70.85 65.46 2.55 22.45 9.0 8.0
Midland 64,042,57 56,622,978 69.8 64.70 2. 22.7 8.78 7.96
Mid-Western 85,200,409 75,207,0 65.97 6.55 22.6 2.44 7.99 7.5
North Eastern 80,05,046 70,656,822 66.6 6.74 22.74 2.70 8.28 7.6
North Western 57,80, 5,04,24 58.96 55.2 22.48 2.56 8.4 7.0
South Eastern ,27,62 99,276,0 64.8 59.99 22.40 2.45 7.90 7.08
Southern 50,545,46 2,492,99 66.5 6.60 22.9 2.79 8.52 7.48
Western 97,449,78 86,46,468 65.88 6.5 2.2 22. 8.86 7.98
National €924,994,799 €816,303,561 €66.39 €61.71 €22.80 €21.81 €18.34 €17.45
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Table 16.2 GMS: Number of Items on Prescription Forms
Prescription forms having:-
2006 2005
No. of Forms % of  Total No. of Forms % of  Total
One Item 5,42,68 8.2 5,4,900 8.8
Two Items 2,766,47 9.84 2,668,577 20.5
Three Items ,602,99 .49 ,555,997 .75
Four Items ,4,28 7.99 ,074,998 8.2
Five Items 89,95 6.4 849,40 6.4
Six Items 805,925 5.78 74,87 5.62
Seven Items 89,042 6.9 794,6 6.00
Eight or more Items 527,20 .78 4,29 .2
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Table 16.3 DP: Number of Items on Claim Forms
Claim forms having:-
2006 2005
No. of Forms % of  Total No. of Forms % of  Total
One Item 2,084,274 4.78 ,859,7 4.6
Two Items ,0,609 2.25 908,87 2.2
Three Items 599,84 2.59 54,544 2.75
Four Items 9,966 8.2 54,705 8.2
Five Items 255,97 5.8 20,24 5.40
Six Items 62,2 .4 4,48 .7
Seven Items 00,00 2. 88,445 2.08
Eight or more Items 54,906 .25 ,694 .4
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Table 16.4 LTI: Number of Items on Claim Forms  
Claim forms having:-
2006 2005
No. of Forms % of  Total No. of Forms % of  Total
One Item 288,808 7.66 279,0 9.8
Two Items 46,459 9.0 42,00 9.96
Three Items 96,048 2.5 90,294 2.67
Four Items 74,748 9.75 67,28 9.44
Five Items 58,4 7.60 50,49 7.0
Six Items 4,592 5.42 5,2 4.95
Seven Items 27,58 .59 22,55 .4
Eight or more Items ,22 4.5 25,95 .64
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Table 17 GMS: Number of Dispensing Doctors* and Persons for whom they Dispense
Health Service Executive 2006 2005  
No. of Doctors No. of Persons No. of Doctors No. of Persons
Eastern Areas -                  -   55 
Midland 9 4,58  4,94 
Mid-Western 2 2,840 0 2,58 
North Eastern 5 ,4 6 ,75 
North Western 6 6,588 5 6,592 
South Eastern 2 8,742 24 8,7 
Southern  ,6  ,266 
Western 5 9,025 7 7,859 
National 129 54,257 135 53,808 
 * In rural areas where a Doctor has a centre of practice 3 miles or more from the nearest retail pharmacy the Doctor dispenses for persons served from that centre who opt to be dispensed to. 
The Doctor is paid a dispensing fee for each such person.  A Doctor’s medicine requirements are obtained on a Stock Order from a retail pharmacy - the stock ordered is approved in advance 
by a HSE Area.
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Table 18 GMS: Advance Payments to Pharmacists
Health Service Executive
Amount Advanced to Pharmacists as at 31st December:-
2006  
1
2005  
1
Eastern Areas ,728,97 ,946,702
Midland 87,07 97,85
Mid-Western ,87,858 ,204,48
North Eastern ,496,578 ,66,09
North Western ,74,5 ,252,4
South Eastern ,902,969 ,972,56
Southern 2,,547 2,260,880
Western ,87,466 ,980,845
National 114,313,785 115,171,582
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Table 19 GMS: Notes on Some of the More Commonly Prescribed Products
AMOXICILLIN 
AMOXICILLIN AND  
ENZYME INHIBITOR
FUROSEMIDE 
FUROSEMIDE WITH 
POTASSIUM SPARING 
DIURETICS
SALBUTAMOL
DICLOFENAC
ATORVASTATIN AND 
PRAVASTATIN
Amoxicillin, alone or potentiated by an 
inhibitor of bacterial enzymes is a broad 
spectrum Penicillin antibiotic indicated 
for the treatment of a wide range of 
infections. 
Salbutamol is a beta-adrenergic 
stimulant used mainly in the treatment 
of chronic asthma and chronic 
bronchitis.
Diclofenac is a Non-Steroidal Anti-
inflammatory Drug (NSAID) mainly 
used to treat pain and inflammation 
associated with muscular conditions 
and rheumatoid arthritis.
Atorvastatin and Pravastatin are 
indicated, in combination with dietary 
measures, for lowering cholesterol 
levels.
The diuretic Furosemide, alone 
or in combination with potassium 
- sparing diuretics, is used to treat 
hypertension.
OMEPRAZOLE
LANSOPRAZOLE
BECLOMETASONE
AMLODIPINE
ACETYLSALICYLIC ACID 
- ASPIRIN
ATENOLOL
Beclometasone is a potent steroid 
having an anti-inflammatory action 
within the lungs. It is used mainly 
by inhalation for the treatment of 
bronchial asthma.
Amlodipine is a calcium - channel 
blocker (similar to nifedipine) 
with peripheral and coronary 
vasodilator properties. It is given 
by mouth in the management 
of hypertension and of angina 
pectoris.
Acetylsalicylic Acid - Aspirin has 
anti-inflammatory and additionally 
analgesic and antipyretic (body 
temperature lowering) action. 
Acetylsalicylic Acid - Aspirin also has 
action against thrombosis or clot 
formation by inhibition of platelet 
cell aggregretion in the blood.
Atenolol is a beta blocker. 
Members of this class of drugs 
are used in the treatment of 
hypertension, angina pectoris and 
cardiac arrythmias.
Omeprazole and Lansoprazole 
are proton pump inhibitors which 
prevent secretion of gastric acid. 
They are used in the treatment 
of reflux oesophagitis and peptic 
ulceration.
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Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
 Acetylsalicylic Acid-Aspirin (Antithrombotic) 2,6,596 5.20 4,642,578 0.6
2 Atorvastatin ,2,665 2.98 47,454,284 6.28
 Levothyroxine Sodium 67,74 .65 ,9,86 0.8
4 Salbutamol (Inhaled) 65,809 .5 ,44,4 0.46
5 Amlodipine 59,997 .45 ,697,564 .55
6 Pravastatin 579,685 .42 2,8,666 .5
7 Calcium, Combinations 57,902 .4 4,642,06 0.6
8 Amoxicillin and Enzyme Inhibitor 566,908 .9 5,27,264 0.70
9 Atenolol 560,729 .8 2,969,27 0.9
0 Bisoprolol 554,82 .6 5,67,0 0.74
 Ramipril 549,27 .5 8,695,6 .5
2 Furosemide 549,47 .5 65,055 0.09
 Paracetamol 547,24 .4 755,82 0.0
4 Warfarin 540,599 . ,40,282 0.9
5 Omeprazole 56,64 .27 25,9,646 .
6 Lansoprazole 487,054 .20 8,640,0 2.47
7 Clinical Nutritional Products 449,7 .0 ,27,7 4.8
8 Diclofenac (Systemic) 44,86 .07 5,52,46 0.68
9 Diazepam 429,46 .06 295,059 0.04
20 Prednisolone (Systemic) 404,065 0.99 ,9,006 0.8
2 Bendroflumethiazide 40,069 0.99 6,00 0.08
22 Esomeprazole 89,74 0.96 6,475,85 2.8
2 Nimesulide 70, 0.9 6,27,4 0.8
24 Amoxicillin 6,989 0.89 ,77,99 0.2
25 Zopiclone 5,872 0.86 ,57,806 0.47
26 Perindopril 42,564 0.84 6,798,825 0.90
27 Metformin 40,82 0.84 ,,506 0.5
28 Clopidogrel 4,874 0.77 7,76,002 2.27
29 Alprazolam 2,45 0.77 ,220,675 0.6
0 Diagnostic Products 0,6 0.76 2,496,696 .65
 Salmeterol and other drugs for obstructive airway diseases 00,669 0.74 2,6,22 2.8
2 Pantoprazole 298,25 0.7 0,0,99 .4
 Digoxin 297,8 0.7 254,749 0.0
4 Paracetamol, Combs. excl. Psycholeptics 297,760 0.7 ,68,2 0.22
5 Alendronic Acid 290,855 0.72 0,24,98 .6
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Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
6 Codeine, Combs. excl. Psycholeptics 277,25 0.68 2,4,096 0.2
7 Lactulose 27,759 0.67 ,580,889 0.2
8 Tramadol 269,70 0.66 ,965,275 0.52
9 Doxazosin 265,006 0.65 8,64,4 .
40 Carbocisteine 264,25 0.65 ,40,828 0.9
4 Salbutamol and other drugs for obstructive airway diseases 26,744 0.65 7,66,886 0.98
42 Beclometasone (Inhaled) 258,49 0.64 4,996,99 0.66
4 Bendroflumethiazide and Potassium 258,98 0.6 545,074 0.07
44 Zolpidem 257,564 0.6 ,768,672 0.2
45 Alginic Acid 250,576 0.62 ,69,72 0.8
46 Gliclazide 248,760 0.6 2,69,766 0.5
47 Citalopram 24,052 0.60 6,249,56 0.8
48 Lisinopril 240,0 0.59 ,764,555 0.50
49 Furosemide and Potassium-Sparing Agents 24,204 0.58 ,94,548 0.6
50 Isosorbide Mononitrate 2,870 0.57 ,88,62 0.42
5 Artificial tears and other indifferent preparations 20,00 0.57 ,040,29 0.4
52 Diclofenac (Topical) 228,557 0.56 ,424,606 0.9
5 Folic Acid 222,096 0.55 222,272 0.0
54 Temazepam 22,28 0.54 456,86 0.06
55 Venlafaxine 29,28 0.54 9,452,476 .25
56 Ferrous Fumarate 2,92 0.5 84,457 0.05
57 Domperidone 22,49 0.52 ,46,72 0.5
58 Clarithromycin 20,506 0.50 ,96,90 0.52
59 Rosuvastatin 95,775 0.48 5,76,497 0.76
60 Escitalopram 90,09 0.47 5,724,22 0.76
6 Flurazepam 75,50 0.4 ,8,79 0.6
62 Tiotropium Bromide 62,057 0.40 8,070,205 .07
6 Ibuprofen 59,00 0.9 592,57 0.08
64 Mefenamic Acid 57,46 0.9 79,59 0.0
65 Metoprolol 56,562 0.8 500,25 0.07
66 Olanzapine 54,59 0.8 8,058,90 2.9
67 Glyceryl Trinitrate 52,59 0.7 ,60,55 0.2
68 Allopurinol 50,997 0.7 ,056,886 0.4
69 Risedronic Acid 44,96 0.6 5,269,49 0.70
70 Simvastatin 44,5 0.6 5,042,507 0.67
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Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
7 Needles/Syringes/Lancets 4,597 0.5 ,905,248 0.25
72 Rabeprazole 4,59 0.5 4,4,85 0.59
7 Glucosamine 42,709 0.5 4,469,00 0.59
74 Tolterodine 42,449 0.5 6,656,507 0.88
75 Cefaclor 40,765 0.5 ,69,50 0.5
76 Betamethasone (Topical) 40,669 0.5 640,9 0.08
77 Flucloxacillin 9,472 0.4 ,264,459 0.7
78 Tamsulosin 5,79 0. ,978,0 0.5
79 Betahistine ,894 0. 2,06,45 0.27
80 Losartan 2,477 0. ,68,9 0.48
8 Latanoprost 29,097 0.2 ,08,850 0.4
82 Drospirenone and Estrogen 28,88 0.2 889,777 0.2
8 Fluoxetine 28,6 0.2 ,772,07 0.50
84 Carbamazepine 27,90 0. 895,80 0.2
85 Risperidone 26,486 0. 8,7,282 .
86 Valsartan 26,77 0. ,005,005 0.40
87 Amitriptyline 25,445 0. 9,5 0.02
88 Diltiazem 2,667 0.0 ,796,95 0.24
89 Valproic Acid 2,4 0.0 ,40,9 0.8
90 Other Osmotically Acting Laxatives 2,089 0.0 ,945,444 0.26
9 Bromazepam 9,29 0.29 656,90 0.09
92 Paroxetine 9,87 0.29 ,77,92 0.49
9 Prochlorperazine 7,596 0.29 2,255 0.04
94 Sertraline 0,66 0.27 5,209,4 0.69
95 Levonorgestrel and Estrogen (Fixed Comb. Contraceptives) 0,69 0.27 446,467 0.06
96 Mirtazapine 09,7 0.27 ,202,622 0.42
97 Ispaghula (Psylla Seeds) 08,952 0.27 469,244 0.06
98 Acetylsalicylic Acid-Aspirin (Anti-inflammatory) 08,42 0.27 40,7 0.02
99 Nifedipine 07,65 0.26 ,9,22 0.8
00 Ranitidine 02,0 0.25 2,540,97 0.4
Total 29,234,316 71.83% e513,347,670 67.93%
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Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost 
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency  % of Scheme Total 
 Atorvastatin 47,454,284 6.28 ,2,665 2.98
2 Clinical Nutritional Products ,27,7 4.8 449,7 .0
 Omeprazole 25,9,646 . 56,64 .27
4 Pravastatin 2,8,666 .5 579,685 .42
5 Salmeterol and other drugs for obstructive airway diseases 2,6,22 2.8 00,669 0.74
6 Lansoprazole 8,640,0 2.47 487,054 .20
7 Olanzapine 8,058,90 2.9 54,59 0.8
8 Clopidogrel 7,76,002 2.27 4,874 0.77
9 Esomeprazole 6,475,85 2.8 89,74 0.96
0 Diagnostic Products 2,496,696 .65 0,6 0.76
 Amlodipine ,697,564 .55 59,997 .45
2 Alendronic Acid 0,24,98 .6 290,855 0.72
 Pantoprazole 0,0,99 .4 298,25 0.7
4 Donepezil 0,02,967 . 84,92 0.2
5 Venlafaxine 9,452,476 .25 29,28 0.54
6 Ostomy Appliances 9,27, .2 86,089 0.2
7 Ramipril 8,695,6 .5 549,27 .5
8 Risperidone 8,7,282 . 26,486 0.
9 Doxazosin 8,64,4 . 265,006 0.65
20 Tiotropium Bromide 8,070,205 .07 62,057 0.40
2 Salbutamol and other drugs for obstructive airway diseases 7,66,886 0.98 26,744 0.65
22 Perindopril 6,798,825 0.90 42,564 0.84
2 Tolterodine 6,656,507 0.88 42,449 0.5
24 Citalopram 6,249,56 0.8 24,052 0.60
25 Nimesulide 6,27,4 0.8 70, 0.9
26 Rosuvastatin 5,76,497 0.76 95,775 0.48
27 Escitalopram 5,724,22 0.76 90,09 0.47
28 Formoterol and other drugs for obstructive airway diseases 5,64,828 0.75 96,66 0.24
29 Bisoprolol 5,67,0 0.74 554,82 .6
0 Budesonide (Inhaled) 5,422,594 0.72 7,902 0.8
 Amoxicillin and Enzyme Inhibitor 5,27,264 0.70 566,908 .9
2 Risedronic Acid 5,269,49 0.70 44,96 0.6
 Sertraline 5,209,4 0.69 0,66 0.27
4 Diclofenac (Systemic) 5,52,46 0.68 44,86 .07
5 Pregabalin 5,096,2 0.67 54,98 0.4
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Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency % of Scheme Total 
6 Simvastatin 5,042,507 0.67 44,5 0.6
7 Beclometasone (Inhaled) 4,996,99 0.66 258,49 0.64
8 Fentanyl 4,920,668 0.65 4,984 0.09
9 Quetiapine 4,644,54 0.6 74,660 0.8
40 Acetylsalicylic Acid-Aspirin (Antithrombotic) 4,642,578 0.6 2,6,596 5.20
4 Calcium, Combinations 4,642,06 0.6 57,902 .4
42 Lamotrigine 4,52,095 0.60 77,74 0.9
4 Glucosamine 4,469,00 0.59 42,709 0.5
44 Rabeprazole 4,4,85 0.59 4,59 0.5
45 Tamsulosin ,978,0 0.5 5,79 0.
46 Tramadol ,965,275 0.52 269,70 0.66
47 Clarithromycin ,96,90 0.52 20,506 0.50
48 Gabapentin ,802,790 0.50 75,428 0.9
49 Urinary Appliances ,800,56 0.50 48,555 0.2
50 Fluoxetine ,772,07 0.50 28,6 0.2
5 Lisinopril ,764,555 0.50 240,0 0.59
52 Paroxetine ,77,92 0.49 9,87 0.29
5 Losartan ,68,9 0.48 2,477 0.
54 Zopiclone ,57,806 0.47 5,872 0.86
55 Anastrozole ,57,476 0.47 ,48 0.08
56 Salbutamol (Inhaled) ,44,4 0.46 65,809 .5
57 Mirtazapine ,202,622 0.42 09,7 0.27
58 Isosorbide Mononitrate ,88,62 0.42 2,870 0.57
59 Latanoprost ,08,850 0.4 29,097 0.2
60 Nicotine (Replacement Therapy) ,049,205 0.40 98,2 0.24
6 Valsartan ,005,005 0.40 26,77 0.
62 Fluticasone (Inhaled) 2,99,5 0.40 49,74 0.2
6 Atenolol 2,969,27 0.9 560,729 .8
64 Montelukast 2,88,25 0.8 72,779 0.8
65 Gliclazide 2,69,766 0.5 248,760 0.6
66 Ranitidine 2,540,97 0.4 02,0 0.25
67 Codeine, Combs. excl. Psycholeptics 2,4,096 0.2 277,25 0.68
68 Sildenafil 2,405,622 0.2 66,772 0.6
69 Levetiracetam 2,54,86 0. 24,77 0.06
70 Insulin Glargine, Long Acting 2,299,576 0.0 0,686 0.08
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Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency % of Scheme Total 
7 Mesalazine 2,20,89 0.29 5,649 0.09
72 Candesartan 2,4,586 0.28 9,5 0.22
7 Ondansetron 2,9,054 0.28 2,69 0.0
74 Orlistat 2,9,05 0.28 2,49 0.08
75 Rosiglitazone 2,5,784 0.28 8,887 0.0
76 Betahistine 2,06,45 0.27 ,894 0.
77 Alfuzosin ,969,990 0.26 65,52 0.6
78 Other Osmotically Acting Laxatives ,945,444 0.26 2,089 0.0
79 Valsartan and Diuretics ,97,08 0.26 75,722 0.9
80 Needles/Syringes/Lancets ,905,248 0.25 4,597 0.5
8 Buprenorphine ,899,98 0.25 27,277 0.07
82 Diltiazem ,796,95 0.24 2,667 0.0
8 Oxycodone ,794,60 0.24 47,262 0.2
84 Ciprofloxacin ,787,20 0.24 90,68 0.22
85 Telmisartan ,774,9 0.24 69,66 0.7
86 Zolpidem ,768,672 0.2 257,564 0.6
87 Captopril ,764,96 0.2 97,447 0.24
88 Insulin Aspart, Fast Acting ,758,008 0.2 0,528 0.08
89 Ezetimibe ,747,786 0.2 42,596 0.0
90 Amoxicillin ,77,99 0.2 6,989 0.89
9 Paracetamol, Combs. excl. Psycholeptics ,68,2 0.22 297,760 0.7
92 Sevelamer ,67,574 0.22 9,46 0.02
9 Insulin (Human), Comb. Intermediate/Fast Acting ,69,664 0.22 29,704 0.07
94 Aripiprazole ,64,048 0.2 8,88 0.02
95 Glyceryl Trinitrate ,60,55 0.2 52,59 0.7
96 Lactulose ,580,889 0.2 27,759 0.67
97 Terbinafine (Systemic) ,545,5 0.20 28,62 0.07
98 Insulin Detemir, Long Acting ,50,42 0.20 8,86 0.05
99 Calcipotriol, Combinations ,486,740 0.20 6,05 0.04
00 Simvastatin, Combinations ,469,975 0.9 27,52 0.07
Total e595,868,901 78.84% 21,984,647 54.02%
42101 HSE AR06 Eng.indd   76 9/20/07   6:04:01 PM
76 77
Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
 Acetylsalicylic Acid-Aspirin (Antithrombotic) 57,225 4.8 ,7,574 0.50
2 Atorvastatin 520,209 4.8 2,464,057 8.06
 Salbutamol (Inhaled) 262,868 2.2 ,,4 0.50
4 Levothyroxine Sodium 246,680 2.08 58,4 0.20
5 Amoxicillin and Enzyme Inhibitor 20,656 .72 ,957,5 0.74
6 Pravastatin 87,69 .58 8,29,895 .0
7 Diclofenac (Systemic) 86,996 .58 2,264,24 0.85
8 Bisoprolol 80,764 .52 ,96,805 0.72
9 Esomeprazole 79,6 .5 7,998,88 .0
0 Calcium, Combinations 77,2 .49 ,56,77 0.59
 Omeprazole 76,225 .48 9,75,92 .66
2 Atenolol 76,04 .48 98,56 0.7
 Amlodipine 72, .45 ,526,750 .2
4 Salmeterol and other drugs for obstructive airway diseases 60,489 .5 ,048,579 4.5
5 Ramipril 4,95 .9 2,64,424 0.89
6 Lansoprazole 4,088 .9 5,858,48 2.20
7 Prednisolone (Systemic) 9,7 .7 57, 0.2
8 Nimesulide 7,46 .6 2,22,84 0.84
9 Rosuvastatin 9,894 .0 ,582,65 .5
20 Venlafaxine 09,886 0.9 5,098,050 .92
2 Clarithromycin 09,58 0.92 2,279,206 0.86
22 Paracetamol, Combs. excl. Psycholeptics 04,86 0.88 722,79 0.27
2 Clinical Nutritional Products 02,598 0.86 4,262,980 .60
24 Perindopril 97,25 0.82 2,057,7 0.77
25 Bendroflumethiazide 96,8 0.8 5,486 0.06
26 Warfarin 9,528 0.79 26,849 0.0
27 Clopidogrel 88,206 0.74 4,89,750 .84
28 Alprazolam 86,84 0.7 5,208 0.
29 Alendronic Acid 85,64 0.72 ,0,20 .4
0 Beclometasone (Inhaled) 85,490 0.72 ,598,240 0.60
 Amoxicillin 85,86 0.72 496, 0.9
2 Pantoprazole 84,86 0.7 ,048,90 .5
 Zopiclone 8,445 0.70 920,02 0.5
4 Escitalopram 8,998 0.69 2,706,87 .02
5 Doxazosin 80,60 0.68 2,629,460 0.99
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Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
6 Citalopram 76,60 0.64 2,244,659 0.84
7 Zolpidem 7,240 0.62 54,208 0.20
8 Diazepam 7,085 0.62 44,478 0.02
9 Formoterol and other drugs for obstructive airway diseases 70,7 0.59 4,28, .55
40 Lisinopril 65,976 0.56 ,09,68 0.42
4 Tramadol 65,952 0.56 ,024,625 0.8
42 Montelukast 6,94 0.54 2,549,05 0.96
4 Glucosamine 62,80 0.5 2,004,20 0.75
44 Folic Acid 62,44 0.5 67,59 0.0
45 Bendroflumethiazide and Potassium 58,45 0.49 22,87 0.05
46 Domperidone 55,56 0.47 7,92 0.2
47 Alginic Acid 54,597 0.46 29,90 0.2
48 Allopurinol 5,884 0.45 42,770 0.6
49 Carbocisteine 5,422 0.45 0,002 0.
50 Valsartan 5,076 0.45 ,282,594 0.48
5 Paracetamol 52,940 0.45 8,787 0.0
52 Simvastatin 5,9 0.4 ,928,462 0.72
5 Mefenamic Acid 50,92 0.42 25,262 0.0
54 Drospirenone and Estrogen 49,976 0.42 47,829 0.
55 Fluoxetine 49,952 0.42 ,744,0 0.65
56 Losartan 49,82 0.42 ,9,407 0.52
57 Fluticasone (Nasal) 49,7 0.42 804,759 0.0
58 Sertraline 49,47 0.4 2,548,822 0.96
59 Diclofenac (Topical) 48,727 0.4 27,45 0.2
60 Risedronic Acid 48,726 0.4 ,777,542 0.67
6 Estradiol 48,2 0.4 445,554 0.7
62 Cefaclor 47,969 0.40 40,844 0.5
6 Paroxetine 46,82 0.9 ,54,77 0.58
64 Furosemide 45,976 0.9 6,846 0.02
65 Cetirizine 44,904 0.8 454,406 0.7
66 Betamethasone (Topical) 4,565 0.7 27,272 0.08
67 Nebivolol 4,525 0.7 656,666 0.25
68 Artificial Tears and other indifferent preparations 4,29 0.6 258,588 0.0
69 Mometasone 42,542 0.6 674,280 0.25
70 Terbinafine (Systemic) 4,962 0.5 2,465,4 0.9
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Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
7 Metoprolol 40,40 0.4 5,974 0.05
72 Valsartan and Diuretics 9,859 0.4 ,02,798 0.9
7 Candesartan 7,86 0.2 89,457 0.4
74 Olanzapine 7,6 0.2 ,624,6 .6
75 Salbutamol and other drugs for obstructive airway diseases 7,595 0.2 665,085 0.25
76 Lithium 7,89 0. 89,845 0.0
77 Codeine, Combs. excl. Psycholeptics 7,20 0. 296,502 0.
78 Mesalazine 6,97 0. 2,756,72 .0
79 Methotrexate 6,607 0. 5,96 0.06
80 Amitriptyline 6,48 0. 42,002 0.02
8 Fluticasone (Inhaled) 5,849 0.0 ,472,455 0.55
82 Flucloxacillin 5,805 0.0 7,86 0.
8 Bromazepam 5,547 0.0 9,842 0.07
84 Desloratadine ,26 0.28 75,787 0.4
85 Ostomy Appliances 2,820 0.28 2,95,899 .
86 Telmisartan 2,705 0.28 87,400 0.
87 Levonorgestrel and Estrogen (Fixed Comb. Contraceptives) 2,50 0.27 8,889 0.05
88 Cyproterone and Estrogen 2,50 0.27 29,99 0.08
89 Rabeprazole ,994 0.27 ,0,22 0.9
90 Sildenafil ,475 0.27 ,04,540 0.9
9 Ezetimibe 0,748 0.26 ,265,5 0.48
92 Tiotropium Bromide 0,77 0.26 ,56,52 0.58
9 Ciprofloxacin 0,666 0.26 690,69 0.26
94 Diltiazem 0,22 0.25 464,5 0.7
95 Fluconazole 0,8 0.25 604, 0.2
96 Antifungal Combs. (Topical) 29,9 0.25 04,975 0.04
97 Tadalafil 29,879 0.25 906,87 0.4
98 Atenolol and other Diuretics 29,7 0.25 28,68 0.
99 Raloxifene 28,676 0.24 877,2 0.
00 Doxycycline 28,62 0.24 02,099 0.
Total 8,458,399 71.25% €183,231,781 68.85%
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Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency  % of Scheme Total 
 Atorvastatin 2,464,057 8.06 520,209 4.8
2 Salmeterol and other drugs for obstructive airway diseases ,048,579 4.5 60,489 .5
 Omeprazole 9,75,92 .66 76,225 .48
4 Pravastatin 8,29,895 .0 87,69 .58
5 Esomeprazole 7,998,88 .0 79,6 .5
6 Follitropin Beta 6,64,604 2.2 6,557 0.06
7 Lansoprazole 5,858,48 2.20 4,088 .9
8 Venlafaxine 5,098,050 .92 09,886 0.9
9 Clopidogrel 4,89,750 .84 88,206 0.74
0 Clinical Nutritional Products 4,262,980 .60 02,598 0.86
 Formoterol and other drugs for obstructive airway diseases 4,28, .55 70,7 0.59
2 Olanzapine ,624,6 .6 7,6 0.2
 Rosuvastatin ,582,65 .5 9,894 .0
4 Amlodipine ,526,750 .2 72, .45
5 Pantoprazole ,048,90 .5 84,86 0.7
6 Alendronic Acid ,0,20 .4 85,64 0.72
7 Ostomy Appliances 2,95,899 . 2,820 0.28
8 Mesalazine 2,756,72 .0 6,97 0.
9 Escitalopram 2,706,87 .02 8,998 0.69
20 Doxazosin 2,629,460 0.99 80,60 0.68
2 Montelukast 2,549,05 0.96 6,94 0.54
22 Sertraline 2,548,822 0.96 49,47 0.4
2 Terbinafine (Systemic) 2,465,4 0.9 4,962 0.5
24 Ramipril 2,64,424 0.89 4,95 .9
25 Clarithromycin 2,279,206 0.86 09,58 0.92
26 Diclofenac (Systemic) 2,264,24 0.85 86,996 .58
27 Citalopram 2,244,659 0.84 76,60 0.64
28 Nimesulide 2,22,84 0.84 7,46 .6
29 Perindopril 2,057,7 0.77 97,25 0.82
0 Glucosamine 2,004,20 0.75 62,80 0.5
 Amoxicillin and Enzyme Inhibitor ,957,5 0.74 20,656 .72
2 Simvastatin ,928,462 0.72 5,9 0.4
 Bisoprolol ,96,805 0.72 80,764 .52
4 Calcipotriol, Combinations ,898,848 0.7 8,409 0.6
5 Pregabalin ,885,44 0.7 9,5 0.6
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Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency % of Scheme Total 
6 Risedronic acid ,777,542 0.67 48,726 0.4
7 IUCD with Progestogen ,77,898 0.66 ,96 0.2
8 Fluoxetine ,744,0 0.65 49,952 0.42
9 Beclometasone (Inhaled) ,598,240 0.60 85,490 0.72
40 Calcium, Combinations ,56,77 0.59 77,2 .49
4 Paroxetine ,54,77 0.58 46,82 0.9
42 Orlistat ,542,44 0.58 2,0 0.9
4 Tiotropium Bromide ,56,52 0.58 0,77 0.26
44 Fluticasone  (Inhaled) ,472,455 0.55 5,849 0.0
45 Anastrozole ,47,878 0.5 ,2 0.
46 Losartan ,9,407 0.52 49,82 0.42
47 Salbutamol (Inhaled) ,,4 0.50 262,868 2.2
48 Acetylsalicylic Acid-Aspirin (Antithrombotic) ,7,574 0.50 57,225 4.8
49 Valsartan ,282,594 0.48 5,076 0.45
50 Ezetimibe ,265,5 0.48 0,748 0.26
5 Budesonide (Inhaled) ,88,24 0.45 27,026 0.2
52 Isotretinoin ,62,00 0.44 6,8 0.4
5 Gabapentin ,56,622 0.4 20,244 0.7
54 Simvastatin, Combinations ,52,28 0.4 2,7 0.8
55 Azathioprine ,6,957 0.42 26,062 0.22
56 Lisinopril ,09,68 0.42 65,976 0.56
57 Tolterodine ,05,86 0.42 2,026 0.9
58 Risperidone ,074,47 0.40 7,057 0.4
59 Sibutramine ,058,252 0.40 6,478 0.4
60 Famciclovir ,055,90 0.40 7,789 0.07
6 Sumatriptan ,05,28 0.9 9,8 0.6
62 Sildenafil ,04,540 0.9 ,475 0.27
6 Rabeprazole ,0,22 0.9 ,994 0.27
64 Valsartan and Diuretics ,02,798 0.9 9,859 0.4
65 Quetiapine ,028,66 0.9 4,65 0.2
66 Fentanyl ,027,070 0.8 4,562 0.04
67 Tramadol ,024,625 0.8 65,952 0.56
68 Lamotrigine 995,60 0.7 2,958 0.8
69 Atenolol 98,56 0.7 76,04 .48
70 Zopiclone 920,02 0.5 8,445 0.70
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Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency % of Scheme Total 
7 Tadalafil 906,87 0.4 29,879 0.25
72 Urinary Appliances 898,720 0.4 8,087 0.07
7 Candesartan 89,457 0.4 7,86 0.2
74 Raloxifene 877,2 0. 28,676 0.24
75 Telmisartan 87,400 0. 2,705 0.28
76 Fluticasone (Nasal) 804,759 0.0 49,8 0.42
77 Ondansetron 78,077 0.29 5,885 0.05
78 Proguanil, Combinations 76,49 0.29 9,606 0.08
79 Etoricoxib 752,2 0.28 22,485 0.9
80 Tacrolimus (Topical) 748,265 0.28 0,60 0.09
8 Ranitidine 725,66 0.27 25,4 0.2
82 Paracetamol, Combs. excl. Psycholeptics 722,79 0.27 04,86 0.88
8 Tamsulosin 78,62 0.27 24,4 0.20
84 Calcipotriol 76,844 0.27 7, 0.5
85 Duloxetine 76,54 0.27 7,97 0.5
86 Zolmitriptan 694,756 0.26 6,55 0.4
87 Ciprofloxacin 690,69 0.26 0,666 0.26
88 Mometasone 674,280 0.25 42,542 0.6
89 Salbutamol and other drugs for obstructive airway diseases 665,085 0.25 7,595 0.2
90 Mirtazapine 662,64 0.25 2,962 0.8
9 Nebivolol 656,666 0.25 4,525 0.7
92 Aciclovir (Systemic) 66,82 0.24 6,880 0.06
9 Tinzaparin 62,88 0.2 ,57 0.0
94 Fluconazole 604, 0.2 0,8 0.25
95 Olmesartan Medoxomil 586,504 0.22 26,747 0.2
96 Losartan and Diuretics 584,66 0.22 2,2 0.8
97 Progesterone 58,082 0.22 6,00 0.05
98 Strontium Ranelate 577,79 0.22 2,278 0.0
99 Minocycline 577,8 0.22 27,02 0.2
00 Prednisolone (Systemic) 57, 0.2 9,7 .7
Total e214,482,084 80.59% 7,028,772 59.20%
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Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
 Diagnostic Products 29,04 .05 ,90,806 7.89
2 Acetylsalicylic Acid-Aspirin (Antithrombotic) 75,509 8. 409,8 0.62
 Metformin 64,7 7.58 575,462 0.86
4 Atorvastatin 27,86 5.90 5,86,507 7.79
5 Needles/Syringes/Lancets 5,798 5.5 ,669,594 2.5
6 Gliclazide 95,76 4.42 ,02,25 .66
7 Insulin Aspart, Fast Acting 6,704 2.94 ,766,28 5.66
8 Ramipril 62,44 2.88 ,06,00 .59
9 Valproic Acid 45,57 2.0 57,2 0.86
0 Carbamazepine 45,52 2.09 406,500 0.6
 Insulin Glargine, Long Acting 8,668 .79 2,98,895 4.48
2 Perindopril 7,6 .74 87,927 .
 Lamotrigine 6,867 .70 2,620,778 .94
4 Amlodipine 6,272 .68 778,04 .7
5 Pravastatin ,959 .57 ,487,994 2.24
6 Clinical Nutritional Products 0,78 .9 ,429,09 5.5
7 Insulin Detemir, Long Acting 25,529 .8 2,046,9 .07
8 Phenytoin 2,886 .0 68,54 0.0
9 Atenolol 2,654 .09 9,85 0.2
20 Bisoprolol 2,57 .07 252,565 0.8
2 Lisinopril 22,075 .02 90,8 0.59
22 Rosiglitazone 20,788 0.96 ,70,97 .76
2 Doxazosin 20,20 0.9 77,27 .08
24 Rosuvastatin 7,97 0.8 59,66 0.8
25 Insulin (Human), Comb. Intermediate/Fast Acting 7,90 0.8 95,72 .4
26 Levetiracetam 4,089 0.65 ,42,865 2.5
27 Metformin and Rosiglitazone ,750 0.64 727,778 .09
28 Glimepiride ,450 0.62 50,05 0.2
29 Levothyroxine Sodium ,67 0.62 0,587 0.05
0 Insulin (Human), Intermediate Acting 2,79 0.59 487,925 0.7
 Clopidogrel 2,59 0.58 702,254 .06
2 Losartan 2,46 0.57 6, 0.55
 Folic Acid ,408 0.5 2,565 0.02
4 Bendroflumethiazide 0,76 0.49 6,90 0.02
5 Valsartan 0,09 0.48 25,254 0.8
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Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
6 Furosemide 0,029 0.46 6,85 0.0
7 Phenobarbital 9,708 0.45 24,489 0.04
8 Simvastatin 9,620 0.44 68,88 0.55
9 Insulin Lispro, Fast Acting 9,090 0.42 52,66 0.79
40 Insulin Aspart, Comb. Intermediate/Fast Acting 8,906 0.4 606,59 0.9
4 Pancreatic Enzymes 7,78 0.6 885,07 .
42 Candesartan 7,490 0.5 80,78 0.27
4 Insulin (Human), Fast Acting 7,6 0. 245,079 0.7
44 Topiramate 7,046 0. 552,2 0.8
45 Levodopa and Decarboxylase Inhibitor 6,786 0. 0,568 0.20
46 Nebivolol 6,64 0. 04,759 0.6
47 Glucagon 6,59 0. 94,50 0.29
48 Warfarin 6,085 0.28 8,48 0.0
49 Glibenclamide 6,00 0.28 48,70 0.07
50 Metoprolol 5,928 0.27 2,50 0.0
5 Omeprazole 5,49 0.25 272,49 0.4
52 Telmisartan 5,27 0.25 8,877 0.2
5 Bendroflumethiazide and Potassium 5,240 0.24 ,228 0.02
54 Urinary Appliances 5,89 0.24 557,7 0.84
55 Insulin Infusion Set 5,59 0.24 684,544 .0
56 Sildenafil 5,5 0.24 6,77 0.25
57 Gabapentin 5,074 0.24 4,265 0.52
58 Irbesartan 4,92 0.2 0,67 0.20
59 Enalapril 4,879 0.2 88,69 0.
60 Valsartan and Diuretics 4,848 0.22 28,704 0.9
6 Baclofen 4,4 0.2 74,284 0.
62 Indapamide 4,42 0.20 5,202 0.05
6 Captopril 4,94 0.20 96,846 0.5
64 Perindopril and Diuretics 4,50 0.20 0,620 0.7
65 Tadalafil 4,90 0.9 26,889 0.9
66 Diltiazem 4,4 0.9 65,82 0.0
67 Lisinopril and Diuretics 4,26 0.9 80,92 0.2
68 Salbutamol (Inhaled) 4,080 0.9 5,72 0.05
69 Quinapril 4,02 0.9 66,969 0.0
70 Acetylsalicylic Acid-Aspirin (Anti-inflammatory) 4,00 0.8 5,945 0.0
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Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost E % of Scheme Total
7 Selegiline ,950 0.8 9,658 0.2
72 Vitamin A and D in Combination ,822 0.8 74,954 0.
7 Evening Primrose Oil (Naudicelle) ,80 0.8 05,687 0.6
74 Pramipexole ,7 0.7 65,76 0.98
75 Olmesartan Medoxomil ,70 0.7 8,8 0.2
76 Amoxicillin and Enzyme Inhibitor ,562 0.6 46,782 0.07
77 Lansoprazole ,5 0.6 5,500 0.2
78 Isosorbide Mononitrate ,487 0.6 47,47 0.07
79 Nifedipine ,79 0.6 50, 0.08
80 Ezetimibe ,255 0.5 4,287 0.20
8 Calcium, Combinations ,8 0.4 29,84 0.04
82 Lercanidipine ,094 0.4 48,7 0.07
8 Diazepam 2,96 0.4 9,49 0.0
84 Atenolol and other Diuretics 2,9 0.4 29,895 0.04
85 Esomeprazole 2,897 0. 25,569 0.9
86 Clobazam 2,869 0. 6,57 0.02
87 Fenofibrate 2,776 0. 60,585 0.09
88 Paracetamol 2,75 0. 9,75 0.0
89 Clonazepam 2,585 0.2 9,95 0.0
90 Oxcarbazepine 2,586 0.2 8,24 0.2
9 Dressings 2,567 0.2 80,002 0.2
92 Furosemide and Potassium-Sparing Agents 2,59 0.2 ,764 0.02
9 Glyceryl Trinitrate 2,48 0. 20,59 0.0
94 Flucloxacillin 2,47 0. 6,57 0.0
95 Tolterodine 2,48 0. 8,779 0.8
96 Eprosartan 2,42 0. 56,977 0.09
97 Omega--Triglycerides 2,97 0. 6,584 0.09
98 Digoxin 2,9 0. 2,000 0.00
99 Ropinirole 2,50 0. 00,585 0.45
00 Colistin (Parenteral) 2,05 0. 28,497 0.49
Total 1,966,209 90.81% €59,364,814 89.20%
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Table 19.6 LTI:The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency  % of Scheme Total 
 Diagnostic Products ,90,806 7.89 29,04 .05
2 Atorvastatin 5,86,507 7.79 27,86 5.90
 Insulin Aspart, Fast Acting ,766,28 5.66 6,704 2.94
4 Clinical Nutritional Products ,429,09 5.5 0,78 .9
5 Insulin Glargine, Long Acting 2,98,895 4.48 8,668 .79
6 Lamotrigine 2,620,778 .94 6,867 .70
7 Insulin Detemir, Long Acting 2,046,9 .07 25,529 .8
8 Needles/Syringes/Lancets ,669,594 2.5 5,798 5.5
9 Pravastatin ,487,994 2.24 ,959 .57
0 Levetiracetam ,42,865 2.5 4,089 0.65
 Rosiglitazone ,70,97 .76 20,788 0.96
2 Gliclazide ,02,25 .66 95,76 4.42
 Ramipril ,06,00 .59 62,44 2.88
4 Insulin (Human), Comb. Intermediate/Fast Acting 95,72 .4 7,90 0.8
5 Pancreatic Enzymes 885,07 . 7,78 0.6
6 Perindopril 87,927 . 7,6 .74
7 Amlodipine 778,04 .7 6,272 .68
8 Apomorphine 728,449 .09 98 0.04
9 Metformin and Rosiglitazone 727,778 .09 ,750 0.64
20 Doxazosin 77,27 .08 20,20 0.9
2 Clopidogrel 702,254 .06 2,59 0.58
22 Insulin Infusion Sets 684,544 .0 5,59 0.24
2 Pramipexole 65,76 0.98 ,7 0.7
24 Insulin Aspart, Comb. Intermediate/Fast Acting 606,59 0.9 8,906 0.4
25 Metformin 575,462 0.86 64,7 7.58
26 Valproic Acid 57,2 0.86 45,57 2.0
27 Urinary Appliances 557,7 0.84 5,89 0.24
28 Topiramate 552,2 0.8 7,046 0.
29 Rosuvastatin 59,66 0.8 7,97 0.8
0 Insulin Lispro, Fast Acting 52,66 0.79 9,090 0.42
 Insulin (Human), Intermediate Acting 487,925 0.7 2,79 0.59
2 Acetylsalicylic Acid-Aspirin (Antithrombotic) 409,8 0.62 75,509 8.
 Carbamazepine 406,500 0.6 45,52 2.09
4 Lisinopril 90,8 0.59 22,075 .02
5 Simvastatin 68,88 0.55 9,620 0.44
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Table 19.6 LTI:The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost Table 19.6 LTI:The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency  % of Scheme Total 
6 Losartan 6, 0.55 2,46 0.57
7 Gabapentin 4,265 0.52 5,074 0.24
8 Colistin (Parenteral) 28,497 0.49 2,05 0.
9 Nutritional/Ancillary Devices 24,585 0.49 ,86 0.09
40 Ropinirole 00,585 0.45 2,50 0.
4 Omeprazole 272,49 0.4 5,49 0.25
42 Metamfetamine 257,48 0.9 2,025 0.09
4 Valsartan 25,254 0.8 0,09 0.48
44 Bisoprolol 252,565 0.8 2,57 .07
45 Insulin (Human), Fast Acting 245,079 0.7 7,6 0.
46 Pregabalin 24,577 0.6 2,28 0.
47 Glucagon 94,50 0.29 6,59 0.
48 Candesartan 80,78 0.27 7,490 0.5
49 Sildenafil 6,77 0.25 5,5 0.24
50 Lansoprazole 5,500 0.2 ,5 0.6
5 Azithromycin 50,728 0.2 2,20 0.0
52 Glimepiride 50,05 0.22 ,450 0.62
5 Atenolol 9,85 0.2 2,654 .09
54 Selegiline 9,658 0.2 ,950 0.8
55 Orlistat 8,98 0.2 2,089 0.0
56 Telmisartan 8,877 0.2 5,27 0.25
57 Tizanidine 7,00 0.2 ,6 0.06
58 Ezetimibe 4,287 0.20 ,255 0.5
59 Irbesartan 0,67 0.20 4,92 0.2
60 Levodopa and Decarboxylase Inhibitor 0,568 0.20 6,786 0.
6 Valsartan and Diuretics 28,704 0.9 4,848 0.22
62 Tadalafil 26,889 0.9 4,90 0.9
6 Esomeprazole 25,569 0.9 2,897 0.
64 Tolterodine 8,779 0.8 2,48 0.
65 Desmopressin 7,720 0.8 ,886 0.09
66 Alimentary Tract/Metabolism, Various Products 6,006 0.7 ,562 0.07
67 Meropenem 2,700 0.7 62 0.00
68 Perindopril and Diuretics 0,620 0.7 4,50 0.20
69 Ostomy Appliances 0,54 0.7 ,0 0.05
70 Zonisamide 06,4 0.6 ,006 0.05
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Table 19.6 LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency  % of Scheme Total 
7 Evening Primrose Oil (Naudicelle) 05,687 0.6 ,80 0.8
72 Nebivolol 04,759 0.6 6,64 0.
7 Simvastatin, Combinations 0,74 0.5 ,928 0.09
74 Salmeterol and other drugs for obstructive airway diseases 0,405 0.5 ,0 0.06
75 Captopril 96,846 0.5 4,94 0.20
76 Enalapril 88,69 0. 4,879 0.2
77 Modafinil 84,48 0. 504 0.02
78 Insulin Combinations, Intermediate/Fast Acting 8,00 0.2 ,6 0.06
79 Olmesartan Medoxomil 8,8 0.2 ,70 0.7
80 Oxcarbazepine 8,24 0.2 2,586 0.2
8 Ciprofloxacin 8,092 0.2 ,52 0.07
82 Lisinopril and Diuretics 80,92 0.2 4,26 0.9
8 Dressings 80,002 0.2 2,567 0.2
84 Risperidone 76,498 0. ,255 0.06
85 Vitamin A and D in Combination 74,954 0. ,822 0.8
86 Baclofen 74,284 0. 4,4 0.2
87 Entacapone 74,206 0. 749 0.04
88 Phenytoin 68,54 0.0 2,886 .0
89 Quinapril 66,969 0.0 4,02 0.9
90 Diltiazem 65,82 0.0 4,4 0.9
9 Gemfibrozil 64,644 0.0 2,06 0.09
92 Flucloxacillin 6,57 0.0 2,47 0.
9 Pantoprazole 62,42 0.09 ,84 0.08
94 Omega--Triglycerides 6,584 0.09 2,97 0.
95 Vigabatrin 60,954 0.09 ,045 0.05
96 Fenofibrate 60,585 0.09 2,776 0.
97 Repaglinide 60,492 0.09 ,809 0.08
98 Budesonide (Inhaled) 60,77 0.09 76 0.0
99 Losartan and Diuretics 59,505 0.09 2,027 0.09
00 Cabergoline 58,509 0.09 29 0.0
Total €62,259,835 93.55% 1,871,426 86.43%
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Table 19.6 LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued Table 19.7 HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency  % of Scheme Total Ingredient Cost E  % of Scheme Total 
 Bicalutamide 2,678 8.72 4,078,758 2.4
2 Ciclosporin 9,45 7.82 2,564,056 .5
 Etanercept 8,545 7.46 20,865,56 2.45
4 Tacrolimus 6,75 6.74 5,086,286 .04
5 Erythropoietin 6,675 6.7 ,67,750 7.98
6 Mycophenolic Acid 5,49 6.09 ,79,992 2.02
7 Adalimumab 4,47 5.82 8,7,45 0.85
8 Darbepoetin alfa 2,696 5. 6,207,4 .7
9 Interferon beta-a 2,244 4.92 2,967,664 7.74
0 Leuprorelin 0,589 4.26 4,948,26 2.95
 Triptorelin 9,520 .8 ,069,08 .8
2 Interferon beta-b 8,6 .28 9,644,425 5.76
 Somatropin 6,99 2.79 4,952,82 2.96
4 Teriparatide 6,78 2.57 2,920,222 .74
5 Goserelin 6,05 2.4 2,0,455 .2
6 Pegfilgrastim 5,7 2.0 7,,82 4.8
7 Filgrastim 4,569 .84 ,05,08 .97
8 Capecitabine ,985 .60 ,042,96 0.62
9 Dornase alfa ,658 .47 ,0,474 .98
20 Glatiramer Acetate ,0 .26 ,80,522 2.27
2 Cinacalcet 2,980 .20 ,070,85 0.64
22 Imatinib 2,9 0.88 6,, .65
2 Octreotide 2,0 0.8 2,0,786 .27
24 Riluzole ,690 0.68 56,046 0.
25 Tobramycin ,506 0.6 ,22,227 .98
26 Ibandronic Acid ,80 0.56 9, 0.2
27 Temozolomide ,7 0.54 ,67,054 0.82
28 Bosentan ,208 0.49 ,77,299 2.25
29 Peginterferon alfa-2a ,70 0.47 ,22,60 0.7
0 Linezolid ,5 0.46 ,79,654 .04
 Ribavirin ,25 0.45 77,0 0.46
2 Sirolimus 972 0.9 02,297 0.8
 Nafarelin 957 0.8 5,895 0.09
4 Palivizumab 90 0.7 992,028 0.59
5 Fulvestrant 94 0.7 466,7 0.28
Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Table 19.7 HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency  % of Scheme Total Ingredient Cost E  % of Scheme Total 
6 Interferon alfa-2b 88 0. 565,878 0.4
7 Flutamide 704 0.28 97,98 0.06
8 Voriconazole 698 0.28 ,55,605 0.9
9 Erlotinib 688 0.28 ,582,79 0.94
40 Anagrelide 645 0.26 60,776 0.22
4 Clodronic Acid 622 0.25 48,08 0.09
42 Lamivudine 69 0.25 60,47 0.04
4 Lanreotide 607 0.24 598,022 0.6
44 Sildenafil 56 0.2 2,88 0.20
45 Valganciclovir 59 0.22 899,4 0.54
46 Peginterferon alfa-2b 522 0.2 254,920 0.5
47 Efalizumab 487 0.20 52,95 0.2
48 Interferon alfa-2a 46 0.9 58,49 0.09
49 Etoposide 426 0.7 4,64 0.0
50 Adefovir Dipivoxil 5 0. 85,582 0.
5 Lenograstim 0 0. 270,267 0.6
52 Anakinra 28 0. 288,475 0.7
5 Buserelin 265 0. 50,295 0.0
54 Fludarabine 245 0.0 208,026 0.2
55 Risedronic Acid 20 0.08 45,880 0.0
56 Bexarotene 2 0.05 89,777 0.2
57 Iloprost 29 0.05 775,99 0.46
58 Pegvisomant 22 0.05 44,264 0.25
59 Idarubicin 6 0.05 4,288 0.0
60 Vancomycin 97 0.04 2,244 0.0
6 Aldesleukin 5 0.02 49,74 0.0
62 Interferon gamma 4 0.0 ,82 0.0
6 Sorafenib  0.00 48,29 0.0
64 Sunitinib 9 0.00 8,5 0.02
65 Becaplermin 9 0.00 5,05 0.00
66 Epoprostenol 6 0.00 6,72 0.04
67 Deferasirox 6 0.00 4,982 0.00
68 Estramustine  0.00 20 0.00
69 Hydroxybutyric Acid 2 0.00 ,808 0.00
Total 248,641 100.00% €167,528,646 100.00%
Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Table 19.7 HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued Table 19.8 HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost 
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency  % of Scheme Total 
 Etanercept 20,865,56 2.45 8,545 7.46
2 Adalimumab 8,7,45 0.85 4,47 5.82
 Erythropoietin ,67,750 7.98 6,675 6.7
4 Interferon beta-a 2,967,664 7.74 2,244 4.92
5 Interferon beta-b 9,644,425 5.76 8,6 .28
6 Pegfilgrastim 7,,82 4.8 5,7 2.0
7 Darbepoetin alfa 6,207,4 .7 2,696 5.
8 Imatinib 6,, .65 2,9 0.88
9 Tacrolimus 5,086,286 .04 6,75 6.74
0 Somatropin 4,952,82 2.96 6,99 2.79
 Leuprorelin 4,948,26 2.95 0,589 4.26
2 Bicalutamide 4,078,758 2.4 2,678 8.72
 Glatiramer Acetate ,80,522 2.27 ,0 .26
4 Bosentan ,77,299 2.25 ,208 0.49
5 Mycophenolic Acid ,79,992 2.02 5,49 6.09
6 Tobramycin ,22,227 .98 ,506 0.6
7 Dornase alfa ,0,474 .98 ,658 .47
8 Filgrastim ,05,08 .97 4,569 .84
9 Triptorelin ,069,08 .8 9,520 .8
20 Teriparatide 2,920,222 .74 6,78 2.57
2 Ciclosporin 2,564,056 .5 9,45 7.82
22 Octreotide 2,0,786 .27 2,0 0.8
2 Goserelin 2,0,455 .2 6,05 2.4
24 Linezolid ,79,654 .04 ,5 0.46
25 Erlotinib ,582,79 0.94 688 0.28
26 Voriconazole ,55,605 0.9 698 0.28
27 Temozolomide ,67,054 0.82 ,7 0.54
28 Peginterferon alfa-2a ,22,60 0.7 ,70 0.47
29 Cinacalcet ,070,85 0.64 2,980 .20
0 Capecitabine ,042,96 0.62 ,985 .60
 Palivizumab 992,028 0.59 90 0.7
2 Valganciclovir 899,4 0.54 59 0.22
 Iloprost 775,99 0.46 29 0.05
4 Ribavirin 77,0 0.46 ,25 0.45
5 Lanreotide 598,022 0.6 607 0.24
Note: Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.
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Table 19.8 HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost E  % of Scheme Total Prescribing Frequency  % of Scheme Total 
6 Interferon alfa-2b 565,878 0.4 88 0.
7 Riluzole 56,046 0. ,690 0.68
8 Efalizumab 52,95 0.2 487 0.20
9 Fulvestrant 466,7 0.28 94 0.7
40 Pegvisomant 44,264 0.25 22 0.05
4 Ibandronic Acid 9, 0.2 ,80 0.56
42 Bexarotene 89,777 0.2 2 0.05
4 Anagrelide 60,776 0.22 645 0.26
44 Sildenafil 2,88 0.20 56 0.2
45 Sirolimus 02,297 0.8 972 0.9
46 Anakinra 288,475 0.7 28 0.
47 Lenograstim 270,267 0.6 0 0.
48 Peginterferon alfa-2b 254,920 0.5 522 0.2
49 Fludarabine 208,026 0.2 245 0.0
50 Adefovir Dipivoxil 85,582 0. 5 0.
5 Interferon alfa-2a 58,49 0.09 46 0.9
52 Nafarelin 5,895 0.09 957 0.8
5 Clodronic Acid 48,08 0.09 622 0.25
54 Flutamide 97,98 0.06 704 0.28
55 Epoprostenol 6,72 0.04 6 0.00
56 Lamivudine 60,47 0.04 69 0.25
57 Buserelin 50,295 0.0 265 0.
58 Aldesleukin 49,74 0.0 5 0.02
59 Sorafenib 48,29 0.0  0.00
60 Risedronic Acid 45,880 0.0 20 0.08
6 Etoposide 4,64 0.0 426 0.7
62 Idarubicin 4,288 0.0 6 0.05
6 Sunitinib 8,5 0.02 9 0.00
64 Vancomycin 2,244 0.0 97 0.04
65 Interferon gamma ,82 0.0 4 0.0
66 Becaplermin 5,05 0.00 9 0.00
67 Deferasirox 4,982 0.00 6 0.00
68 Hydroxybutyric Acid ,808 0.00 2 0.00
69 Estramustine 20 0.00  0.00
Total €167,528,646 100.00% 248,641 100.00%
Note: Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.
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Table 19.8 HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost continued Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
 % of Scheme 
Total 
Ingredient Cost  
E
% of Scheme 
Total 
A Alimentary Tract and Metabolism 5,104,796 12.54 119,884,799 15.86
A01 Stomatological Preparations 85,245 0.2 7,85 0.04
A02 Drugs for Acid Related Disorders 2,276,25 5.59 79,62,427 0.54
A03 Drugs for Functional Gastrointestinal Disorders 72,479 0.9 2,247,57 0.0
A04 Anti-emetics and Anti-nauseants 8,797 0.05 2,645,50 0.5
A05 Bile and Liver Therapy 0,544 0.0 528,702 0.07
A06 Laxatives 547,692 .5 4,657,005 0.6
A07 Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents 205,888 0.50 ,544,8 0.47
 
A08 Anti-obesity Preparations, excl. Diet Products 49,29 0.2 ,68,667 0.42
A09 Digestives, incl. Enzymes 9,486 0.02 900,742 0.2
A10 Drugs used in Diabetes 850,698 2.09 6,60,42 2.9
A11 Vitamins 55,78 0.4 660,460 0.09
A12 Mineral Supplements 622,654 .5 4,98,97 0.66
A14 Anabolic Agents for Systemic Use 4 0.00  0.00
B Blood and Blood Forming Organs 3,614,252 8.88 26,894,977 3.56
B01 Antithrombotic Agents ,00,597 7.45 25,579,422 .8
B02 Antihemorrhagics 0,54 0.02 28,889 0.02
B03 Anti-anemic Preparations 57,258 .4 ,86,422 0.6
B05 Blood Substitutes and Perfusion Solutions 4 0.00 244 0.00
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost  
E
% of Scheme 
Total
C  Cardiovascular System 10,212,385 25.09 185,855,300 24.59
C01  Cardiac Therapy 849,486 2.09 8,08,529 .07
C02  Antihypertensives 294,67 0.72 8,57,2 .
C03  Diuretics ,75,044 4.0 4,999,604 0.66
C04  Peripheral Vasodilators 57,997 0.4 99,55 0.
C05  Vasoprotectives 99,405 0.24 62,465 0.08
C07  Beta Blocking Agents ,644,2 4.04 ,88,568 .77
C08  Calcium Channel Blockers 984,498 2.42 6,972,272 2.25
C09  Agents Acting on the Renin-Angiotensin System 2,26,276 5.50 44,758,458 5.92
C10  Serum Lipid Reducing Agents 2,294,775 5.64 87,5,678 .58
D  Dermatologicals 1,123,056 2.76 10,939,369 1.45
D01  Antifungals for Dermatological Use 26, 0.64 ,40,02 0.45
D02  Emollients and Protectives 4,09 0. 76, 0.05
D03  Preparations for Treatment of  Wounds and Ulcers ,06 0.00 24,40 0.00
D05  Antipsoriatics 5,066 0. 2,48,957 0.
D06  Antibiotics and Chemotherapeutics for Dermatological Use 25,980 0. ,026,9 0.
D07  Corticosteroids, Dermatological Preparations 504,58 .24 2,458,05 0.
D10  Anti-Acne Preparations 4,478 0.08 589,26 0.08
D11  Other Dermatological Preparations 0,58 0.0 58,94 0.08
G  Genito Urinary System and Sex Hormones 1,424,247 3.50 28,761,176 3.81
G01  Gynecological Anti-infectives and Antiseptics 22,45 0.05 22,4 0.02
G02  Other Gynecologicals 4,787 0.04 ,4,26 0.5
G03  Sex Hormones and Modulators of the Genital System 788,55 .94 6,664,795 0.88
G04  Urologicals 598,494 .47 20,80,72 2.76
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 1,221,900 3.00 4,191,494 0.56
H01 Pituitary, Hypothalamic Hormones and Analogues ,055 0.0 688,792 0.09
H02 Corticosteroids for Systemic Use 477,70 .7 ,84,659 0.25
H03 Thyroid Therapy 726, .79 ,508,22 0.20
H04 Pancreatic Hormones 4,64 0.0 4,89 0.02
H05 Calcium Homeostasis 90 0.00 9,6 0.00
J Anti-infectives for Systemic Use 2,183,099 5.37 24,720,483 3.27
J01 Antibacterials for Systemic Use 2,02,080 5.7 2,024,26 2.78
J02 Antimycotics for Systemic Use 54,889 0. ,6,9 0.7
J04 Antimycobacterials 2,70 0.0 69,697 0.0
J05 Antivirals for Systemic Use 2,265 0.06 2,08,6 0.
J07 Vaccines 62 0.00 2,050 0.00
L Antineoplastic and Immunomodulating Agents 196,743 0.48 7,868,130 1.04
L01 Antineoplastic Agents 4,02 0.0 2,77 0.0
L02 Endocrine Therapy 82,92 0.20 5,9,20 0.78
L04 Immunosuppressive Agents 00,59 0.25 ,705,49 0.2
42101 HSE AR06 Eng.indd   95 9/20/07   6:04:09 PM
96 97
Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
M  Musculo-Skeletal System 2,662,576 6.54 47,188,008 6.25
M01  Anti-inflammatory and Antirheumatic Products ,54,87 .79 22,789,858 .02
M02  Topical Products for Joint and Muscular Pain 4,45 .0 ,66,085 0.42
M03  Muscle Relaxants 4,46 0.08 ,87,98 0.6
M04  Antigout Preparations 50,997 0.7 ,056,886 0.4
M05  Drugs for treatment of Bone Diseases 52,65 .29 8,98,28 2.50
M09  Other Drugs for Disorders of the Musculo-Skeletal System 50 0.00 68,9 0.0
N  Nervous System 7,580,958 18.63 152,976,686 20.24
N01  Anesthetics 2,2 0.0 9,507 0.00
N02  Analgesics ,755,98 4. 9,90,678 2.6
N03  Anti-epileptics 640,59 .57 9,787,572 2.62
N04  Anti-Parkinson Drugs 96,66 0.48 4,290,648 0.57
N05  Psycholeptics ,05,407 7.46 46,74,205 6.4
N06  Psychoanaleptics ,682,556 4.4 56,826,54 7.5
N07  Other Nervous System Drugs 267,69 0.66 5,786,5 0.77
P  Antiparasitic Products, Insecticides and Repellents 63,502 0.16 453,720 0.06
P01  Antiprotozoals 4,609 0.0 09,072 0.04
P02  Anthelmintics 7,84 0.02 20,784 0.00
P03  Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 4,509 0.04 2,864 0.02
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
R  Respiratory System 2,975,130 7.31 71,957,313 9.52
R01  Nasal Preparations 207,56 0.5 2,49,052 0.2
R02  Throat Preparations 8,50 0.02 9,68 0.00
R03  Drugs for Obstructive Airway Diseases 2,2,224 5.4 65,74,46 8.70
R05  Cough and Cold Preparations 29,462 0.72 ,56,52 0.20
R06  Antihistamines for Systemic Use 255,476 0.6 2,245,256 0.0
R07  Other Respiratory System Products 949 0.00 22,759 0.00
S  Sensory Organs 1,019,392 2.51 9,989,135 1.32
S01  Ophthalmologicals 98,52 2. 9,699,080 .28
S02  Otologicals 6,92 0.09 70,248 0.02
S03  Ophthalmological and Otological Preparations 4,950 0. 9,807 0.02
V  Various 1,314,694 3.23 64,038,548 8.47
V03  Other Therapeutic Products 2,022 0.0 ,99,52 0.26
V04  Diagnostic Products 0,6 0.76 2,496,696 .66
V06  Clinical Nutritional Products 449,7 . ,27,7 4.8
V07  All Other Non-Therapeutic Products 542,744 . 6,42,58 2.7
     Needles/Syringes/Lancets 4,597 0.5 ,905,248 0.25
     Ostomy Requisites 86,089 0.2 9,27, .2
     Urinary Requisites 48,555 0.2 ,800,56 0.50
     Dressings 25,402 0.06 ,054,980 0.4
     Miscellaneous 29,0 0.59 9,726 0.05
 TOTAL  40,696,730 100.00% e755,719,138 100.00%
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
A  Alimentary Tract and Metabolism 1,301,547 10.96 40,379,242 15.17
A01  Stomatological Preparations 2,55 0.20 89,579 0.0
A02  Drugs for Acid Related Disorders 7,525 5.99 28,949,590 0.88
A03  Drugs for Functional Gastrointestinal Disorders 06,448 0.89 78,2 0.27
A04  Anti-emetics and Antinauseants 8,80 0.07 960,529 0.6
A05  Bile and Liver Therapy 5,78 0.05 55,574 0.
A06  Laxatives 6,528 0.54 545,86 0.2
A07  Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents 96,925 0.82 ,560,25 .4
A08  Anti-obesity Preparations, excl. Diet Products 40,4 0.4 2,658,574 .00
A09  Digestives, incl. Enzymes ,552 0.0 79,495 0.0
A10  Drugs used in Diabetes 8,97 0. 54,750 0.20
A11  Vitamins 5,576 0. 26,495 0.0
A12  Mineral Supplements 88,544 .59 ,654,609 0.62
A14  Anabolic Agents for Systemic Use 40 0.00 994 0.00
A16  Other Alimentary Tract and Metabolism Products  0.00 780 0.00
B  Blood and Blood Forming Organs 865,427 7.29 7,648,502 2.87
B01  Antithrombotic Agents 762,59 6.42 7,4,977 2.76
B02  Antihemorrhagics 4,575 0.04 60,54 0.02
B03  Anti-anemic Preparations 98,2 0.8 244,074 0.09
B05  Blood Substitutes and Perfusion Solutions 2 0.00 297 0.00
Note: The above costs are inclusive of the monthly payment of €85 payable to the Pharmacy by an individual or family.
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
C  Cardiovascular System 3,054,650 25.73 70,619,231 26.53
C01  Cardiac Therapy 02,720 0.87 ,466,966 0.55
C02  Antihypertensives 84,6 0.7 2,676,088 .0
C03  Diuretics 278,477 2.5 965,725 0.6
C04  Peripheral Vasodilators ,767 0.0 74,609 0.0
C05  Vasoprotectives 40,28 0.4 28,085 0.09
C07  Beta Blocking Agents 5,595 4.49 4,747,679 .78
C08  Calcium Channel Blockers 264,052 2.22 4,857,99 .8
C09  Agents Acting on the Renin-Angiotensin System 769,08 6.48 6,79,097 6.28
C10  Serum Lipid Reducing Agents 978,242 8.24 8,872,99 4.60
D  Dermatologicals 477,403 4.02 10,473,084 3.94
D01  Antifungals for Dermatological Use 4,00 . ,78,58 .27
D02  Emollients and Protectives 28,674 0.24 99,076 0.04
D03  Preparations for Treatment of  Wounds and Ulcers 402 0.00 47,969 0.02
D04  Antipruritics, incl. Antihistamines, Anesthetics, etc. 825 0.0 2,58 0.0
D05  Antipsoriatics 44,42 0.7 ,046,2 .5
D06  Antibiotics and Chemotherapeutics for Dermatological Use 4,825 0.5 567,9 0.2
D07  Corticosteroids, Dermatological Preparations 68,208 .42 928,259 0.5
D08  Antiseptics and Disinfectants 4 0.00 9 0.00
D10  Anti-Acne Preparations 46,40 0.9 ,54,52 0.58
D11  Other Dermatological Preparations 2,699 0. 829,795 0.
G  Genito Urinary System and Sex Hormones 572,973 4.83 18,877,963 7.09
G01  Gynecological Anti-infectives and Antiseptics 8,99 0.07 46,875 0.02
G02  Other Gynecologicals 8,40 0.5 ,908,89 0.72
G03  Sex Hormones and Modulators of the Genital System 86,58 .26 ,00,80 4.24
G04  Urologicals 59,826 .5 5,62,468 2.
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 428,707 3.61 1,800,764 0.68
H01  Pituitary, Hypothalamic Hormones and Analogues 7,80 0.07 5,67 0.9
H02  Corticosteroids for Systemic Use 62,524 .7 70,5 0.27
H03  Thyroid Therapy 258,69 2.7 577,2 0.22
H04  Pancreatic Hormones 6 0.00 4,02 0.00
H05  Calcium Homeostasis 75 0.00 2,848 0.00
J  Anti-infectives for Systemic Use 778,735 6.55 12,044,160 4.53
J01  Antibacterials for Systemic Use 720,02 6.07 8,77,979 .0
J02  Antimycotics for Systemic Use 6,05 0.0 984,558 0.7
J04  Antimycobacterials ,748 0.0 49,284 0.02
J05  Antivirals for Systemic Use 20,78 0.7 2,25,799 0.84
J07  Vaccines 76 0.00 540 0.00
L  Antineoplastic and Immunomodulating Agents 96,164 0.81 3,988,924 1.50
L01  Antineoplastic Agents 4,745 0.04 44,900 0.05
L02  Endocrine Therapy 26,288 0.22 2,28,754 0.86
L04  Immunosuppressive Agents 65, 0.55 ,560,270 0.59
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
M Musculo-Skeletal System 878,140 7.40 16,753,522 6.29
M01 Anti-inflammatory and Antirheumatic Products 56,006 4.74 9,9,47 .4
M02 Topical Products for Joint and Muscular Pain 8,08 0.70 66,65 0.25
M03 Muscle Relaxants 4,08 0.04 47,222 0.05
M04 Antigout Preparations 54,702 0.46 448,28 0.7
M05 Drugs for treatment of Bone Diseases 72,690 .46 6,05,67 2.7
M09 Other Drugs for Disorders of the Musculo-Skeletal System 26 0.00 5,445 0.02
N Nervous System 1,729,353 14.57 40,617,532 15.26
N01 Anesthetics 869 0.0 0,245 0.04
N02 Analgesics 68,24 .0 6,05,684 2.27
N03 Anti-epileptics 5,50 0.97 4,766,82 .79
N04 Anti-Parkinson Drugs 5,59 0. 452,56 0.7
N05 Psycholeptics 626,09 5.27 9,204,26 .46
N06 Psychoanaleptics 569,67 4.80 9,294,96 7.25
N07 Other Nervous System Drugs ,76 0.29 744,078 0.28
P Antiparasitic Products, Insecticides and Repellents 35,503 0.30 901,704 0.34
P01 Antiprotozoals 2,889 0.28 88,804 0.
P02 Anthelmintics ,09 0.0 ,474 0.00
P03 Ectoparasiticides, incl. Scabicides, Insecticides and Repellents ,52 0.0 6,426 0.0
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Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
R  Respiratory System 1,208,575 10.18 30,452,666 11.44
R01  Nasal Preparations 47,289 .24 ,975,79 0.74
R02  Throat Preparations 2,797 0.02 6,82 0.00
R03  Drugs for Obstructive Airway Diseases 87,50 7.4 26,847,2 0.09
R05  Cough and Cold Preparations 60,258 0.5 ,405 0.2
R06  Antihistamines for Systemic Use 26,809 .07 ,290,777 0.49
R07  Other Respiratory System Products 72 0.00 ,52 0.00
S  Sensory Organs 237,379 2.00 2,143,967 0.81
S01  Ophthalmologicals 98,84 .67 2,08,775 0.76
S02  Otologicals ,94 0.2 65,2 0.0
S03  Ophthalmological and Otological Preparations 24,65 0.2 60,07 0.02
V  Various 207,661 1.75 9,446,945 3.55
V03 Other Therapeutic Products ,879 0.02 05,76 0.
V04  Diagnostic Products 4,00 0.2 548,72 0.2
V06  Clinical Nutritional Products 02,598 0.86 4,262,979 .60
V07  All Other Non-Therapeutic Products 89,54 0.75 4,0,28 .6
     Ostomy Appliances 2,820 0.28 2,95,899 .
     Needles/Syringes/Lancets 7,257 0.4 90,86 0.0
     Dressings 9,882 0.08 255,867 0.0
     Urinary Appliances 8,087 0.07 898,720 0.4
     Miscellaneous 2,08 0.8 2,869 0.05
 TOTAL  11,872,217 100.00% €266,148,206 100.00%
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Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
A  Alimentary Tract and Metabolism 566,237 26.15 18,118,402 27.22
A01  Stomatological Preparations 790 0.04 ,876 0.0
A02  Drugs for Acid Related Disorders 6,2 0.76 668,65 .00
A03  Drugs for Functional Gastrointestinal Disorders 2,282 0. ,689 0.05
A04  Anti-emetics and Antinauseants 99 0.04 45,295 0.07
A05  Bile and Liver Therapy 848 0.04 50,20 0.08
A06  Laxatives 7,208 0. 7,656 0.
A07  Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents ,086 0.05 25,845 0.04
A08  Anti-obesity Preparations, excl. Diet Products 2,82 0. 86,4 0.28
A09  Digestives, incl. Enzymes 7,80 0.6 89,67 .4
A10  Drugs used in Diabetes 505,67 2.4 5,626,94 2.48
A11  Vitamins 4,545 0.67 248,972 0.7
A12  Mineral Supplements 4,405 0.20 42,72 0.06
A13  Tonics 2 0.00 2 0.00
A16  Other Alimentary Tract and Metabolism Products ,797 0.08 222,80 0.
B  Blood and Blood Forming Organs 210,478 9.72 1,218,465 1.83
B01  Antithrombotic Agents 95,4 9.0 ,64,960 .75
B02  Antihemorrhagics 2 0.0 4,8 0.0
B03  Anti-anemic Preparations 4,45 0.66 24,60 0.04
B05  Blood Substitutes and Perfusion Solutions 40 0.02 24,586 0.0
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Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
C  Cardiovascular System 596,770 27.56 15,083,653 22.66
C01  Cardiac Therapy 0,897 0.50 27,222 0.9
C02  Antihypertensives 20,98 0.97 74,7 .2
C03  Diuretics 7,62 .72 59,460 0.24
C04  Peripheral Vasodilators 70 0.0 6,260 0.02
C05  Vasoprotectives 80 0.0 ,59 0.00
C07  Beta Blocking Agents 68,4 .6 66,202 0.96
C08  Calcium Channel Blockers 49,4 2.28 977,989 .47
C09  Agents Acting on the Renin-Angiotensin System 204,507 9.44 4,47,520 6.5
C10  Serum Lipid Reducing Agents 204,55 9.45 8,074,08 2.
D  Dermatologicals 7,962 0.37 98,618 0.15
D01  Antifungals for Dermatological Use 2,4 0. 7,292 0.06
D02  Emollients and Protectives ,900 0.09 4,697 0.02
D03  Preparations for Treatment of Wounds and Ulcers 28 0.00 ,99 0.00
D04  Antipruritics, incl. Antihistamines, Anesthetics,etc. 99 0.00 2,25 0.00
D05  Antipsoriatics 28 0.0 9,7 0.0
D06  Antibiotics and Chemotherapeutics for Dermatological Use 559 0.0 4,278 0.0
D07  Corticosteroids, Dermatological Preparations ,566 0.07 8,72 0.02
D08  Antiseptics and Disinfectants 54 0.0 2,879 0.00
D10  Anti-Acne Preparations 52 0.0 2,4 0.00
D11  Other Dermatological Preparations 428 0.02 5,059 0.0
G  Genito Urinary System and Sex Hormones 20,830 0.96 695,649 1.05
G01  Gynecological Anti-infectives and Antiseptics 48 0.0 6,60 0.0
G02  Other Gynecologicals 98 0.00 ,775 0.02
G03  Sex Hormones and Modulators of the Genital System 2,99 0.0 ,470 0.05
G04  Urologicals 8,85 0.85 6,774 0.95
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Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
H  Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 25,999 1.20 399,977 0.60
H01  Pituitary, Hypothalamic Hormones and Analogues ,9 0.09 4,76 0.22
H02  Corticosteroids for Systemic Use ,499 0.6 26,99 0.04
H03  Thyroid Therapy ,976 0.65 2,64 0.05
H04  Pancreatic Hormones 6,594 0.0 94,5 0.29
H05  Calcium Homeostasis 7 0.00 2,0 0.00
J  Anti-infectives for Systemic Use 20,420 0.94 1,069,175 1.61
J01  Antibacterials for Systemic Use 9,495 0.90 ,02,05 .54
J02  Antimycotics for Systemic Use 584 0.0 22,22 0.0
J04  Antimycobacterials 06 0.00 5,045 0.0
J05  Antivirals for Systemic Use 208 0.0 9,965 0.0
J07  Vaccines 27 0.00 89 0.00
L  Antineoplastic and Immunomodulating Agents 1,388 0.06 58,213 0.09
L01  Antineoplastic Agents 29 0.0 22,92 0.0
L02  Endocrine Therapy 4 0.0 ,645 0.02
L04  Immunosuppressive Agents 96 0.04 2,656 0.04
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Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
M  Musculo-Skeletal System 17,339 0.80 407,705 0.61
M01  Anti-inflammatory and Antirheumatic Products 6,07 0.28 9,259 0.4
M02  Topical Products for Joint and Muscular Pain 629 0.0 5,52 0.0
M03  Muscle Relaxants 5,96 0.27 27,697 0.2
M04  Antigout Preparations 2,20 0. 8,978 0.0
M05  Drugs for treatment of Bone Diseases ,986 0.09 72,5 0.
M09  Other Drugs for Disorders of the Musculo-Skeletal System 424 0.02 ,899 0.00
N  Nervous System 267,515 12.35 10,031,807 15.07
N01  Anesthetics 256 0.0 9,86 0.0
N02  Analgesics 0,677 0.49 04,085 0.6
N03  Anti-epileptics 200,50 9.26 6,6,50 9.9
N04  Anti-Parkinson Drugs 2,094 .07 2,85,564 .28
N05  Psycholeptics 6,867 0.78 44,27 0.52
N06  Psychoanaleptics 4,776 0.68 709,0 .06
N07  Other Nervous System Drugs ,5 0.06 57,972 0.09
P  Antiparasitic Products, Insecticides and Repellents 153 0.01 1,264 0.00
P01  Antiprotozoals 2 0.0 ,07 0.00
P02  Anthelmintics 6 0.00 2 0.00
P03  Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 5 0.00 79 0.00
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06 07
Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
R  Respiratory System 14,464 0.67 357,439 0.54
R01  Nasal Preparations ,644 0.08 22,66 0.04
R02  Throat Preparations 29 0.00 76 0.00
R03  Drugs for Obstructive Airway Diseases 0,25 0.47 ,826 0.47
R05  Cough and Cold Preparations 826 0.04 5,44 0.0
R06  Antihistamines for Systemic Use ,72 0.08 5,928 0.02
S  Sensory Organs 7,026 0.33 98,748 0.15
S01  Ophthalmologicals 6,702 0. 97,554 0.5
S02  Otologicals 24 0.0 598 0.00
S03  Ophthalmological and Otological Preparations 200 0.0 596 0.00
V  Various 408,719 18.88 18,914,285 28.42
V03  Other Therapeutic Products 277 0.0 46,6 0.07
V04  Diagnostic Products 29,04 .05 ,90,806 7.89
V06  Clinical Nutritional Products 0,78 .9 ,429,09 5.5
V07  All Other Non-Therapeutic Products: 8,960 6.4 ,54,827 5.
      Needles/Syringes/Lancets/Swabs 20,957 5.59 2,54,8 .54
      Dressings 2,567 0.2 80,002 0.2
      Urinary Appliances 5,89 0.24 557,7 0.84
      Nutritional/Ancillary Devices ,86 0.09 24,585 0.49
      Ostomy Appliances ,0 0.05 0,54 0.6
      Miscellaneous 7,254 0.4 08,07 0.6
 TOTAL  2,165,300 100.00% €66,553,400 100.00%
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Table 20.3 HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
A Alimentary Tract and Metabolism 97 0.04 21,244 0.01
A07A Intestinal Anti-infectives 97 0.04 2,244 0.0
B Blood and Blood Forming Organs 30,151 12.12 20,774,038 12.40
B0 Antithrombotic Agents 780 0. ,99,47 0.72
B0 Anti-anemic Preparations 29,7 .8 9,574,89 .68
C Cardiovascular System 1,769 0.72 4,105,688 2.45
C02 Antihypertensives ,769 0.72 4,05,688 2.45
D Dermatologicals 9 0.00 5,051 0.00
D0A Cicatrizants 9 0.00 5,05 0.00
Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Table 20.3 HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 19,996 8.04 12,238,405 7.30
H0 Pituitary and Hypothalamic Hormones and Analogues 0,68 4.28 8,247,48 4.92
H05 Calcium Homeostasis 9,58 .76 ,99,057 2.8
J  Anti-infectives for Systemic Use 6,903 2.77 9,523,697 5.69
J0 Antibacterials for Systemic Use 2,657 .07 5,06,88 .02
J02 Antimycotics for Systemic Use 698 0.28 ,55,605 0.9
J05 Antivirals for Systemic Use 2,68 .05 ,98,8 .5
J06 Immune Sera and Immunoglobulins 90 0.7 992,028 0.59
L Antineoplastic and Immunomodulating Agents 182,148 73.27 116,396,713 69.48
L0 Antineoplastic Agents 9,4 .68 0,875,077 6.49
L02 Endocrine Therapy 49,72 20.00 4,742,475 8.80
L0 Immunostimulants 7,87 4.96 9,587,54 2.6
L04 Immunosuppressive Agents 86,095 4.6 5,92,007 0.56
Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Table 20.3 HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost E
% of Scheme 
Total
M Musculo-Skeletal System 2,212 0.89 585,499 0.35
M05 Drugs for treatment of Bone Diseases 2,22 0.89 585,499 0.5
N Nervous System 1,692 0.68 562,854 0.34
N07XX Other Nervous System Drugs ,692 0.68 562,854 0.4
R Respiratory System 3,658 1.47 3,310,475 1.98
R05CB Mucolytics (Inhaled) ,658 .47 ,0,475 .98
V Various 6 0.00 4,982 0.00
V0AC Iron Chelating Agents 6 0.00 4,982 0.00
 TOTAL  248,641 100.00% €167,528,646 100.00%
Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Table 21 GMS: Average Payment to Doctors in Panel Ranges
Health 
Service  
Executive
Average Panel Ranges in 2006
0-100
         e
101-250
         e
251-500
         e
501-1,000
         e
1,001-1,500
         e
1,501-2,000
         e
2,001 and Over
         e  
East Coast Area 20,50 (5) 84,999 (4) 55,089 (54) 240,92 (6) 6,084 (5) - -
South Western 
Area 28,289 (6) 56,04 (2) 05,094 (47) 20,990 (88) 00,595 (44) 65,565 (7) 9,840 ()
Northern Area 26,558 (7) 6,627 (22) 27,525 (40) 27,650 (67) 299,677 (5) 44,656 (9) 560,958 (2)
Midland ,5 (5) 48,97 (8) 2,66 (8) 24,05 (45) 8,57 (26) 59,54 () -
Mid-Western ,5 (5) 62,9 (9) 28,624 (4) 22,62 (76) 0,978 (20) 88,864 (7) -
North Eastern 7,788 () 57,80 (6) 06,76 (28) 2,06 (86) 282,79 (2) 6,7 (4) -
North Western 4,48 (5) 97,60 (6) ,800 (2) 25,686 (52) 25,952 (4) 40,845 () -
South Eastern 7,295 (9) 58,659 (2) 7,774 (5) 29,679 (6) 28,605 (8) 45,27 (5) -
Southern 22,056 (4) 59,80 (48) 6,066 (7) 225,270 (45) 6,48 () 460,44 (4) 40,75 ()
Western 29,204 () 62,648 (9) 20,08 (56) 225,667 (00) 9,47 (7) 454,82 () -
National 2006 e23,529 (88) e65,239 (197) e129,032 (415) e220,019 (836) e317,033 (295) e404,237 (49) e454,698 (6)
National 2005 €25,556 (42) €68,250 (248) €9,55 (46) €244,750 (82) €4,24 (252) €44,76 (4) €476,42 (5)
Note:  (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.
 (ii) The number of Doctors in each range is shown in brackets.
 (iii) The average payment to Doctors in each panel range is the gross payments divided by the number of Doctors in that range.
 (iv) Doctors payment is exclusive of superannuation paid to retired DMOs.
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Table 21.1 GMS: Number of Doctors in Payment Ranges
Health 
Service 
Executive
Up to 
€30,000
€30,001 -  
€60,000
 €60,001 - 
 €90,000
€90,001-
€120,000
€120,001 - 
€150,000
€150,001-
€180,000
€180,001-
€210,000
€210,001-
€240,000
€240,001-
€270,000
€270,001-
€370,000
€370,001-
€470,000
€470,001 
and Over
East Coast 
Area 2 (9)   ()  2 (2)  2 (7)  5 (4)  6 (5)  7 ()  0 ()  8 (0)  22 ()  4 (5)  - ()  
South 
Western 
Area
 (29)  28 (20)  22 (8)   (5)  29 (2)  8 (2)  2 ()  27 (9)   (9)  40 (4)  4 (5)   ()  
Northern 
Area 5 (0)  5 ()  7 (9)  2 (5)  2 (7)   ()  5 (6)  27 (22)   ()   (2)  8 ()  5 (6)  
Midland 6 (6)  5 (4)   (4)  6 (4)  5 (4)  8 (0)   (0)   (8)  5 (0)  26 (2)  5 (0)  - (-)
Mid-
Western 8 (5)  7 (8)  5 (9)  6 (2)  24 (7)  7 (2)  6 (4)  5 ()  4 (8)  0 (0)  7 (8)   (2)  
North 
Eastern  (6)  8 (6)  9 (6)  9 (6)  6 (5)  6 (8)  25 (6)  9 (24)  8 (4)  2 (27)  5 (6)   ()  
North 
Western 4 (6)   (5)  5 (6)  0 (8)  8 (8)   (8)   (9)   (0)  8 ()  5 (5)  8 (5)   (5)  
South 
Eastern 9 (8)  7 (9)  9 (8)  0 (2)  7 (4)   (9)  2 (9)  25 (2)  28 (28)  42 (5)   (6)   (5)  
Southern 2 (25)  28 (20)  0 (2)  2 (25)  6 (2)  7 (4)  6 (0)  2 (24)   (6)  47 (5)  2 (5)   (6)  
Western 9 (5)  6 (8)  2 (2)  20 (8)  7 (6)  5 (8)  20 (22)   (2)  0 (8)  52 (4)  8 (8)   (7)  
National 77 (139) 128 (126) 156 (156) 149 (132) 170 (151) 182 (159) 188 (160) 210 (177) 178 (179) 346 (375) 82 (119) 20 (36)  
Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.
 (ii) Above table relates to the payments listed in Table 3.
 (iii) Doctors payment is exclusive of superannuation paid to retired DMOs.
2006 (2005 in brackets)
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Table 22 GMS: Number of Pharmacists in Dispensing Fee Ranges
Note: Pharmacies that entered or left the Scheme during the year are not included in the above table.
Health 
Service 
Executive
Up to 
€20,000
€20,001-
€40,000
€40,001-
€60,000
€60,001-
€80,000
€80,001-
€100,000
€100,001-
€120,000
€120,001-
€140,000
€140,001-
€160,000
€160,001-
€180,000
€180,001-
€200,000
€200,001-
€220,000
€220,001-
€240,000
€240,001 
and over
East Coast 
Area 4 (5)  ()  (7) 20 (9) 9 (0) 6 () 4 (9) 8 () 2 (6) 8 (4) - (2)  () 4 (2)
South 
Western 
Area
2 (7) 7 (22) 2 (6) 25 (26) 9 (20) 6 () 2 (4) 0 (8) 9 (8) 6 (9) 0 (5) 7 (4) 4 ()
Northern 
Area  (2) 2 (9) 9 (9) 9 (2) 9 (2) 9 (9) 0 (5) 9 (9) 6 () 4 (7) 5 () 4 (5) 4 (0)
Midland 2 (2) 5 (5) 7 (4) 6 (4) 5 () 6 (8) 2 (0) 6 (0) 8 (6) 6 ()  () 2 () 0 (4)
Mid-
Western 7 (2) 0 (2) 4 ()  (5) 25 (8)  (0) 0 (9)  (9) 8 (9) 0 (6)  (2) 2 () 6 (5)
North 
Eastern 6 (2) 8 (8) 8 (7) 4 (5) 6 (4) 9 (5) 4 (2) 7 (0) 9 (4) 5 (4)  (5) 5 (-) 5 (5)
North 
Western 6 (4)  (2) 8 (6) 7 () 9 (9) 7 (7) 7 (5) 5 (6)  () 5 (5)  (2)  () 0 (8)
South 
Eastern 5 (6) 8 (5)  (7) 20 (6) 4 () 4 (6) 6 (9) 2 (8) 9 (2) 8 (8) 0 (4) 5 (4) 5 ()
Southern 6 (7) 20 () 22 (8) 0 (4) 27 (2) 26 (26) 8 (2) 20 (5) 2 () 0 () 8 (4) 5 ()  ()
Western 7 (5) 9 () 9 (9) 9 (4) 4 (20) 20 (2)  (2) 7 (7) 9 (0) 0 (9) 9 (6)  (4) 8 (7)
National 77 (62) 103 (100) 132 (116) 171 (175) 167 (149) 146 (135) 124 (126) 97 (85) 75 (72) 72 (68) 52 (34) 39 (28) 89 (68)
2006 (2005 in brackets)
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Table 23 DP: Number of Eligible Persons and Number and Cost of Pharmacists Claims
Note:  *As at 31st December 2006.
Health Service 
Executive
*Number 
of Persons 
Covered
 Unique 
Number of 
Claimants
Number of 
Items
Cost per Item 
E
Gross Cost
E
Net Cost per 
Claimant  
E 
Paid by HSE 
E 
 Eastern Areas 54,984 206,75 4,597,267 8.52 77,02,429 562.70 6,7,65 
Midland 95,227 9,09 749,8 5.20 26,9,659 428.6 6,722,99 
Mid-Western 60,867 54,504 ,0,75 6.0 6,77,4 422.84 2,046,697 
North Eastern 7,8 56,495 ,06,509 5.48 7,665,424 45.26 2,460,72 
North Western 64,47 22,74 40,705 7.79 5,520,47 446.74 9,906,0 
South Eastern 57,480 62,99 ,274,099 5.26 44,99,987 442.58 27,855,8 
Southern 254,70 00,090 ,824,097 8.00 69,,494 48.7 4,856,55 
Western 40,84 55,879 94,4 7.42 5,295,77 92.68 2,942,62 
National 2006 1,525,657 597,835 11,872,217 €37.31 €442,923,858 €473.56 €283,108,115
National 2005 ,478,650 526,052 0,58,689 €6.67 €88,02,077 €464.76 €244,485,98
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Table 23.1 DP: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges
Note: (i) Pharmacies that entered or left the Scheme during the year are not included in the above table.
 (ii) The above figures do not include the monthly co-payment of e85 payable to the Pharmacy by an individual or family.
2006 (2005 in brackets)
Health 
Service 
Executive
Up to 
€20,000
€20,001 - 
€40,000
€40,001-
€60,000
€60,001-
€80,000
€80,001-
€100,000
€100,001-
€120,000
€120,001-
€140,000
€140,001-
€160,000
€160,001-
€180,000
€180,001-
€200,000
€200,001-
€220,000
€220,001-
€240,000
€240,001 
and over
East Coast 
Area 9 (9) 5 (2) 24 (26) 7 (2) 6 (20) 0 (8) 0 (7) 2 (4) 2 ()  (-) 2 (5) 2 (-) 2 ()
South 
Western 
Area
2 (2) 6 (2) 2 (2) 22 (25) 20 (2)  ()  (6) 6 (2)  (0) 8 () 2 (2) 2 (-) 9 (7)
Northern 
Area 6 (7) 24 (25) 2 (7)  (2) 6 (9) 8 (20) 4 (0) 9 ()  (2) 2 (6)  (5) 4 (2) 8 (4)
Midland 8 (4) 4 () 6 () 2 (0) 7 (8) 5 (7) 6 (5) 4 (2)  (-) - (2)  () 2 (-) -
Mid-
Western 20 (4) 25 (29) 26 (2) 2 (25) 6 (4) 8 (5) 4 (4) 5 () 2 () 2 (-)  () - -
North 
Eastern  (8) 25 (29) 0 (20) 5 (5) 0 (6) 7 (0) 7 () 4 (5) 5 ()  ()  ()  (-)  ()
North 
Western 7 (5) 7 (22)  (5) 4 (8)  (4)  (2) 2 (2) - - - ()  (-) - -
South 
Eastern 2 (5) 24 (27) 0 () 27 (20) 7 (4) 8 ()  (8)  (2) 4 (-) - - - (2) 2 (-)
Southern 4 (4) 52 (5) 5 (42) 26 (9) 28 (4) 7 () 0 (8) 5 ()  ()  (2) 4 (2)  (2) 4 ()
Western 26 (28) 9 (0) 25 (2) 7 (6) 9 (0) 5 (0) 9 (5) 4 (2) - ()  () -  (-) -
 National 167 (145) 271 (272) 261 (233) 186 (193) 142 (111) 92 (97) 84 (58) 42 (36) 33 (23) 18 (16) 15 (17) 13 (6) 26 (14)
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Table 24 LTI: Number of Eligible Persons and Number and Cost of Pharmacists Claims
Note:  *As at 31st December 2006.
Health Service Executive *Number of 
Eligible Persons
Unique Number 
of Claimants
Number of 
Items
Cost per Item 
E
Total  
Cost 
E
Cost per 
Claimant
E
Eastern Areas 54,859 22,568 92,052 54.4 50,75,65 2,248.2
Midland 5,888 ,082 28,57 52.0 6,686,599 2,69.56
Mid-Western 7,42 4,06 5,966 48. 7,44,77 ,8.60
North Eastern 8,622 4,759 95,75 5.64 0,50,05 2,206.56
North Western 5,96 ,02 28,89 5.72 6,99,72 2,289.02
South Eastern 0,852 5,582 26,47 50.72 ,99,855 2,48.67
Southern 7,507 6,262 25,280 54.0 ,572,52 2,67.44
Western 5,220 ,74 8,86 54.99 7,60,20 2,0.8
National 2006 106,307 53,082 2,165,300 e53.32 e115,461,340 e2,175.15
National 2005 99,280 5,006 ,929, e52.2 e00,546,64 e,896.89
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Table 24.1 LTI: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges
Note: Pharmacies that entered or left the Scheme during the year are not included in the above table.
2006 (2005 in brackets)
Health Service 
Executive
Up to €10,000 €10,001 - €20,000 €20,001- €30,000 €30,001- €40,000 €40,001- €50,000 €50,001 - €60,000 €60,001 and over
East Coast Area  (2) 28 (25)  (8) 8 () 2 (4)  (7) 20 (6)
South Western 
Area
25 (22) 9 (9) 26 (24) 25 (2) 2 (20) 5 () 0 (24)
Northern Area 2 (2) 25 (22)  (28) 7 (2) 6 (2) 6 (2) 25 (6)
Midland 0 () 25 () 2 (2) 4 (4) 7 (7) 2 (4) 8 (4)
Mid-Western 4 (5) 45 (47) 29 (2) 9 (7) 6 (4) 4 ()  (4)
North Eastern 22 (8) 28 (27) 25 (8) 4 (20) 2 (6) 6 (5) 2 (7)
North Western 4 (2) 7 (5)  (7) 7 () 9 () 4 (6) 7 (2)
South Eastern 28 (24)  (6) 5 () 24 (9) 5 (8) 6 (6) 8 (4)
Southern 54 (5) 7 (7) 47 (7) 6 (9) 4 (9) 6 (5) 5 (2)
Western 47 (44) 4 (9) 2 (2) 2 (5) 5 ()  () 2 (2)
National 266 (250) 344 (334) 252 (231) 166 (164) 117 (95) 73 (58) 120 (81)
42101 HSE AR06 Eng.indd   117 9/20/07   6:04:17 PM
8 9
Table 25 EEA: Number and Cost of Pharmacists Claims
Health Service Executive Number of Items Cost per Item  
e
Total Cost  
e
East Coast Area ,94 22.49 76,6 
South Western Area 5,267 2.78 25,248 
Northern Area 2,855 24.08 68,75 
Midland ,727 2.44 87,44 
Mid-Western 0,049 2.58 26,909 
North Eastern 5,896 24.04 4,78 
North Western ,467 24.09 276,94 
South Eastern 0,295 24.40 25,77 
Southern 20,427 2.7 484,687 
Western 5,65 2.79 65,545 
National 2006 88,742 €23.82 €2,113,911
National 2005 8,965 €22.9 €,879,609
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Table 26 DTS: Number of Treatments
Health Service Executive Above the Line Below the Line Total
Eastern Areas 274,054 25,705 299,759 
Midland 5,46 6,704 58,050 
Mid-Western 87,444 ,54 98,798 
North Eastern 84,87 0,20 94,47 
North Western 72,26 5,452 77,75 
South Eastern 7,457 5,0 2,767 
Southern 8,470 8,408 20,878 
Western 6,928 5,607 2,55 
National 2006 987,149 108,770 1,095,919 
National 2005 962,96 06,466 ,069,402 
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Table 26.1 DTS: Number of Dentists in Payment Ranges
Note: Dentists who entered or left the Scheme during the year are not included in the above table.
Health 
Service 
Executive
 Up to 
€10,000 
 €10,001-
€20,000 
 €20,001-
€30,000 
 €30,001-
€40,000 
 €40,001-
€50,000 
 €50,001-
€60,000 
 €60,001-
€70,000 
 €70,001-
€80,000 
 €80,001-
€90,000 
 €90,001-
€100,000 
 €100,001-
€110,000 
 €110,001-
€120,000 
 €120,001 
and over 
Eastern 
Areas 0 (4) 9 (9) 2 (40) 26 (28) 24 (7) 9 (8) 5 (5) 9 (2) 20 (4)  () 7 (0) 5 (4)  (7)
Midland 5 (4) 2 (4)  (4)  () 6 (6) 4 (4) 6 (5) 4 (4)  (2) - (2) 4 (4)  ()  ()
Mid-
Western 6 (5) 9 (7) 6 (8)  (0) 4 ()  (2) 7 (4) 4 (4)  (2)  (2)  () 4 () 6 (9)
North 
Eastern  () 6 (4) 6 (8) 0 (0) 8 (9) 6 (8) 7 (5) 5 (8)  ()  (6) 4 (4) 2 (-) 6 ()
North 
Western  () - 5 () 2 () 2 () 2 (4) 2 () 2 (2) 4 (5)  (2) 5 (2)  (2) 6 (9)
South 
Eastern 7 (9)  (5) 0 ()  (4) 0 () 8 (2)  (0) 5 (5) 0 (7) 8 (8)  () 2 (2) 9 (8)
Southern 2 (9)  (27) 40 (7) 25 (26) 25 (25) 4 (0) 24 (2) 4 (4) 2 () 5 () 2 (8)  (-) 6 (9)
Western 9 (8) 0 (5) 7 (8) 4 () 7 (0) 7 () 0 (8) 7 (9) 7 (0) 5 (7) 2 () 7 () 2 (4)
National 106 (114) 102 (91) 107 (111) 106 (103) 96 (92) 71 (71) 84 (71) 60 (67) 60 (46) 38 (49) 28 (35) 27 (15) 61 (72)
2006 (2005 in brackets)
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Table 27 HSE-COS: Number of Treatments and Cost of Claims
Health Service Executive Number of  Treatments Cost of Claims
E
Eastern Areas 4,442 4,980,99
Midland 29,75 ,0,709
Mid-Western 44,56 ,6,79
North Eastern 5,802 ,289,8
North Western 6,48 ,27,90
South Eastern 66,457 2,7,466
Southern 72,09 2,644,6
Western 45,669 ,645,584
National 2006 464,623 e16,927,104
National 2005 47,5 e5,8,940
Note: Optometrists/Ophthalmologists were also paid in respect of: Health (Amendment) Act 1996 €51,154; Optical services for Teenagers €105,252; Optical services for Children €919,093.
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Table 27.1 HSE-COS: Number of Optometrists/Ophthalmologists in Payment Ranges
Note: Optometrists/Ophthalmologists who entered or left the Scheme during the year are not included in the above table.
Health 
Service 
Executive
 Up to 
€10,000 
 €10,001-
€20,000 
 €20,001-
€30,000 
 €30,001-
€40,000 
 €40,001-
€50,000 
 €50,001-
€60,000 
 €60,001-
€70,000 
 €70,001-
€80,000 
 €80,001-
€90,000 
 €90,001-
€100,000 
 €100,001-
€110,000 
 €110,001-
€120,000 
 €120,001 
and over 
Eastern 
Areas 45 (48) 7 (4) 6 () 4 () 6 (8)  (5) 5 ()  () - ()  (-)  (-) - (2)  ()
Midland 4 (2) 5 (6)  () 5 (6)  ()  () - -  (-) - - -  ()
Mid-
Western 5 () 7 (6) 4 ()  ()  (2) 2 (-) - - - () -  (-) - 2 (2)
North 
Eastern 7 (7)  (0) 4 () 2 (2)  ()  ()  () -  (-) - - - -
North 
Western 5 (6) 5 () 4 (4) 7 (2)  (2)  ()  (2) - - - ()  (-) - -
South 
Eastern 2 (5)  (6)  (4)  ()  (5) 7 (6) 2 (2)  () - ()  ()  () -  (-)
Southern 5 (6) 2 (7) 5 (0) 9 (7) 6 (5) 2 ()  () - - -  (-) - () 2 ()
Western 2 (8) 8 (9) 7 (8) 6 (4)  () - - ()  (-) - - () - -  (-)
National 144 (145) 117 (91) 46 (46) 47 (38) 24 (29) 19 (15) 10 (8) 5 (2) 2 (3) 2 (3) 5 (1) - (3) 10 (5)
2006 (2005 in brackets)
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Table 28 GMS: Investment in General Practice Development
Note: The above are payments from the Indicative Drug Target Savings.
Health Service Executive 2006
E
2005
E
Eastern Areas 2,8,46 ,999,647 
Midland 86,585 262,648 
Mid-Western 400,42 572,4 
North Eastern 527,24 409,79 
North Western 2,492,60 2,68,2 
South Eastern ,9,556 ,895,60 
Southern 888,24 2,85,906 
Western ,94,506 ,258,08 
National €10,062,393 €11,932,845
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